学术周报 · IF≥10

心血管科领域文献阅读汇编

2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
80
临床研究
56
基础研究
24
IF≥20
19
IF 10-20
61
子领域
27
期刊种类
26
数据日期
2026-10-31

★本周 Top 10 高影响力文献

#论文期刊IF
1MCT1-dependent mitochondrial lactate import sustains cardiac metabolism.NatureIF 56.1
2Great debate: a dual biomarker strategy improves the triage of patients with suspected acute coronar...European heart journalIF 45.3
3Cortisol in cardio-kidney-metabolic disease.European heart journalIF 45.3
4Safety of low lipoprotein(a) levels: the FOURIER trial.European heart journalIF 45.3
5Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease w...European heart journalIF 45.3
6Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Cr...CirculationIF 41.3
7Natural Missplicing Events Amplified by an Elusive Deep-Intronic MYBPC3 Variant Cause Hypertrophic C...CirculationIF 41.3
8LDLR Variant Classification Through Activity-Normalized Prime Editing Screening.CirculationIF 41.3
9Effectiveness of Nurse-Coordinated, Digital-Supported Collaborative Care Model in Reducing Hospital ...CirculationIF 41.3
10Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE...CirculationIF 41.3

Ŧ期刊分布统计

期刊篇数IF
European journal of heart failure16IF 10.3
European journal of preventive cardiology9IF 10.0
Stroke7IF 11.1
Circulation7IF 41.3
Cardiovascular research6IF 12.5
JAMA cardiology5IF 15.2
European heart journal4IF 45.3
Circulation research4IF 18.0
Nature cardiovascular research3IF 12.6
Molecular biomedicine3IF 13.0

1心力衰竭 (22篇)

临床研究 (17篇)

JAMA cardiology IF 15.2 2026-10-30 PMID: 42961411
Concern for ototoxicity hinders loop diuretic (LD) dosing in heart failure (HF); given the mechanism by which LDs affect the ear, high-dose LDs should produce transient, not permanent, hearing changes. To measure the association of LD dose with permanent and temporary ototoxicity. Cohort 1 received a randomized sequence of LD doses (bumetanide, 1.25-10 mg) across study visits with serial audiometry assessments. Cohort 2 received serial LD up to furosemide 500-mg doses during a HF hospitalization with audiometry at baseline and prior to discharge. Cohort 3 retrospectively characterized clinically diagnosed ototoxicity in HF hospitalizations was defined using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Cohorts 1 and 2 were single center, while cohort 3 was multicenter. Cohort 1 studied outpatient participants with stable HF, while cohort 2 (n = 40) and cohort 3 studied hospitalized patients with acute HF. Intravenous LD. The primary outcomes were clinically diagnosed ototoxicity and hearing changes via audiometry. Cohort 1 contained 50 participants, cohort 2 contained 40 participants, and cohort 3 contained 22 656 participants. In cohort 1, mean (SD) participant age was 63.2 (10.4) years, and 21 of 50 participants (42%) were women. In cohorts 1 and 2, clinically diagnosed ototoxicity was not observed. In cohort 1, at peak diuretic concentration, worsening hearing shifts were infrequent (24 ears of 400 doses [6%]) but were more common with higher doses (odds ratio [OR], 1.99; 95% CI, 1.21-3.28 per doubling dose; P = .007). Within hours, hearing shifts largely resolved and were absent in 98% of measurements (393 ears of 400 doses). No significant association between LD dose and hearing shifts was present at any time aside from peak LD concentration. In cohort 2, hearing shifts were not different across groups divided by the median daily LD dose and were not associated with LD dose (OR, 1.19; 95% CI, 0.71-1.98 per doubling dose; P = .52). In cohort 3, 608 HF hospitalizations (2.7%) had clinically diagnosed ototoxicity. In multivariable analyses, peak dose of 160 mg furosemide equivalents or greater (OR, 0.83; 95% CI, 0.52-1.31; P = .43) and 400 mg furosemide equivalents or greater (OR, 1.28; 95% CI, 0.71-2.31; P = .41) were not associated with greater clinically diagnosed ototoxicity risk relative to less than 160 mg. In this analysis of 2 small HF cohorts, short-term exposure to high-dose LD was not associated with permanent ototoxicity, although concomitant ototoxin use was excluded. Future studies are needed to understand the risk of ototoxicity with repeated LD exposure and in broader HF populations. ClinicalTrials.gov Identifiers: NCT04481919 and NCT05323487.
中文摘要:对耳毒性的担忧限制了心力衰竭患者袢利尿剂的剂量调整;鉴于袢利尿剂影响耳部的机制,高剂量袢利尿剂应引起短暂而非永久的听力改变。研究旨在评估袢利尿剂剂量与永久性和暂时性耳毒性之间的关联。队列1在研究访视期间按随机顺序接受不同剂量袢利尿剂(布美他尼1.25-10 mg),并连续进行听力测定。队列2在心力衰竭住院期间连续接受袢利尿剂直至呋塞米500 mg剂量,并在基线及出院前进行听力测定。队列3回顾性分析心力衰竭住院中临床诊断的耳毒性,采用国际疾病统计分类第十版(ICD-10)编码定义。队列1和队列2为单中心,队列3为多中心。队列1研究病情稳定的心力衰竭门诊参与者,队列2(n=40)和队列3研究急性心力衰竭住院患者。干预为静脉袢利尿剂。主要结局为临床诊断的耳毒性和听力测定所示的听力变化。队列1有50名参与者,队列2有40名参与者,队列3有22656名参与者。队列1参与者平均(SD)年龄为63.2(10.4)岁,50名参与者中21名(42%)为女性。队列1和队列2中未观察到他临床诊断的耳毒性。队列1中,在利尿剂浓度峰值时,听力恶化移位不常见(400次剂量中24耳[6%]),但较高剂量时更常见(每倍剂量比值比[OR]1.99;95%CI 1.21-3.28;P=0.007)。数小时内听力移位大多恢复,98%的测量中不存在(400次剂量中393耳)。除袢利尿剂浓度峰值外,任何时间点均未见袢利尿剂剂量与听力移位存在显著关联。队列2中,按每日袢利尿剂剂量中位数分组后各组听力移位无差异,且与袢利尿剂剂量无关(每倍剂量OR 1.19;95%CI 0.71-1.98;P=0.52)。队列3中,608次心力衰竭住院(2.7%)存在临床诊断的耳毒性。多变量分析中,与低于160 mg相比,呋塞米等效剂量峰值160 mg或以上(OR 0.83;95%CI 0.52-1.31;P=0.43)和400 mg或以上(OR 1.28;95%CI 0.71-2.31;P=0.41)与更高的临床诊断耳毒性风险无关。在这项对2个小型心力衰竭队列的分析中,短期暴露于高剂量袢利尿剂与永久性耳毒性无关,但排除了同时使用其他耳毒性药物者。未来研究需要了解重复暴露于袢利尿剂以及更广泛心力衰竭人群中的耳毒性风险。ClinicalTrials.gov标识符:NCT04481919和NCT05323487。
JAMA cardiology IF 15.2 2026-10-30 PMID: 42961405
Rural-urban disparities in heart failure (HF) care delivery and outcomes are well documented. However, it remains unclear if differences in outcomes after HF hospitalization are primarily driven by patient rural residence, hospital resources, or both. To evaluate associations of patient and hospital rurality with quality of care and postdischarge outcomes after hospitalization for HF with reduced ejection fraction (HFrEF). This was a retrospective cohort study of Medicare beneficiaries in US hospitals with HFrEF with an index hospitalization from January 1, 2013, to December 31, 2021. Included were Medicare beneficiaries discharged alive after an index hospitalization for HFrEF. Participants were classified as rural patients hospitalized in rural hospitals (rural-rural), rural patients in urban hospitals (rural-urban), urban patients in urban hospitals (urban-urban), and urban patients in rural hospitals (urban-rural). Study data were analyzed from July to September 2026. Patient rural residence and hospital rurality. Primary outcome was 90-day all-cause mortality after hospitalization. Secondary outcomes included inpatient cardiology consultation, 90-day postdischarge guideline-directed medical therapy (GDMT) use based on prescription fills, and HF readmission at 30 days, 90 days, and 1 year. Among 735 460 beneficiaries (median [IQR] age, 77 [70-85] years; 415 077 male [56.4%]), 69 061 (9.4%) were rural-rural, 65 510 (8.9%) rural-urban, 582 947 (79.3%) urban-urban, and 17 942 (2.4%) urban-rural. Compared with rural patients treated in rural hospitals, rural patients treated in urban hospitals were more likely to receive inpatient cardiology consultation (odds ratio [OR], 2.02; 95% CI, 1.84-2.22) and initiation of several GDMT classes, including β-blockers (OR, 1.20; 95% CI, 1.16-1.25), ARNIs (OR, 1.23; 95% CI, 1.13-1.34), MRAs (OR, 1.23; 95% CI, 1.15-1.31), and SGLT2Is (OR, 1.48; 95% CI, 1.32-1.67). They also had lower rates of HF readmission and mortality at all time points (HF readmission 1-year: OR, 0.85; 95% CI, 0.82-0.88; mortality 1-year: OR, 0.91; 95% CI, 0.89-0.94) than rural-rural patients. Compared with urban patients hospitalized at urban hospitals, rural patients hospitalized at urban hospitals more often received inpatient cardiology consultation (OR, 1.38; 95% CI, 1.31-1.44), whereas postdischarge GDMT differences were modest (absolute difference in GDMT score 0.09 points; 95% CI, 0.05-0.14). Rural patients also had lower HF readmission (1-year OR, 0.81; 95% CI, 0.79-0.82) but higher 30- and 90-day mortality than urban patients (30-day OR, 1.10; 95% CI, 1.06-1.14; 90-day OR, 1.05; 95% CI, 1.02-1.08). Results suggest that hospital rurality was associated with lower odds of GDMT use and higher rates of all-cause mortality, whereas rural residence was associated with mortality differences despite treatment in urban hospitals. Interventions addressing both inpatient resource disparities and postdischarge transitions of care may reduce rural-urban inequities in HF outcomes.
中文摘要:心力衰竭照护和结局中的城乡差异已有充分记录。不过,心力衰竭住院后结局差异主要由患者农村居住地、医院资源还是两者共同驱动,仍不清楚。为评估患者与医院农村属性同射血分数降低型心力衰竭(HFrEF)住院后照护质量及出院后结局的关联,研究开展了一项回顾性队列研究,纳入2013年1月1日至2021年12月31日期间在美国医院因HFrEF指数住院的Medicare受益人,纳入对象为HFrEF指数住院后存活出院的Medicare受益人。参与者分为农村患者在农村医院住院(农村-农村)、农村患者在城市医院住院(农村-城市)、城市患者在城市医院住院(城市-城市)和城市患者在农村医院住院(城市-农村)。研究数据于2026年7月至9月分析。暴露为患者农村居住地和医院农村属性。主要结局为住院后90天全因死亡。次要结局包括住院期间心内科会诊、基于处方配药的出院后90天指南导向药物治疗(GDMT)使用,以及30天、90天和1年心力衰竭再住院。在735460名受益人(年龄中位数[IQR]77[70-85]岁;415077名男性[56.4%])中,69061名(9.4%)为农村-农村,65510名(8.9%)为农村-城市,582947名(79.3%)为城市-城市,17942名(2.4%)为城市-农村。与在农村医院治疗的农村患者相比,在城市医院治疗的农村患者更可能接受住院期间心内科会诊(比值比[OR]2.02;95%CI 1.84-2.22),并启动多类GDMT,包括β受体阻滞剂(OR 1.20;95%CI 1.16-1.25)、ARNI(OR 1.23;95%CI 1.13-1.34)、MRA(OR 1.23;95%CI 1.15-1.31)和SGLT2抑制剂(OR 1.48;95%CI 1.32-1.67)。他们在所有时间点的心力衰竭再住院率和死亡率也低于农村-农村患者(1年心力衰竭再住院:OR 0.85;95%CI 0.82-0.88;1年死亡率:OR 0.91;95%CI 0.89-0.94)。与在城市医院住院的城市患者相比,在城市医院住院的农村患者更常接受住院期间心内科会诊(OR 1.38;95%CI 1.31-1.44),出院后GDMT差异较小(GDMT评分绝对差0.09分;95%CI 0.05-0.14)。农村患者的心力衰竭再住院率也较低(1年OR 0.81;95%CI 0.79-0.82),但30天和90天死亡率高于城市患者(30天OR 1.10;95%CI 1.06-1.14;90天OR 1.05;95%CI 1.02-1.08)。结果提示,医院农村属性与较低的GDMT使用几率和较高的全因死亡率相关,而患者农村居住地与死亡率差异相关,即使治疗发生在城市医院也是如此。针对住院资源差异和出院后照护衔接的干预措施可能减少心力衰竭结局中的城乡不平等。
Drugs IF 14.7 2026-10-29 PMID: 42955666
The comparative efficacy and safety of the new drugs (including sodium-glucose cotransporter-2 inhibitors [SGLT-2Is], glucagon-like peptide-1 receptor agonists [GLP-1RAs], non-steroidal mineralocorticoid receptor antagonists [nsMRAs], and soluble guanylate cyclase stimulators [sGCs]) for heart failure with mildly reduced or preserved (HFmrEF/HFpEF) ejection fraction remains largely unclear. We conducted a systematic review and network meta-analysis to evaluate their comparative effects on HFmrEF/HFpEF, aiming to provide evidence-based guidance for treatment selection. MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials were comprehensively searched. We included randomized controlled trials that compared nsMRA, sGC, SGLT-2I, and GLP-1RA with placebo for patients with HFmrEF/HFpEF. Primary efficacy outcomes were cardiovascular (CV) death, hospitalization for heart failure (HF hospitalization), and all-cause mortality, while primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs). The main analysis was conducted to compare the effects on HFmrEF/HFpEF between individual drugs. A frequentist network meta-analysis with random-effects models was used to calculate risk ratios (RRs) for dichotomous outcomes and standardized mean differences (SMDs) for continuous outcomes. A total of 20 randomized controlled trials (RCTs, including 10 drugs from 35 publications) were included for analyses, but none provided head-to-head direct comparisons. No significant differences among all the individual drugs were found in risks of CV death or all-cause mortality. Compared with exenatide, low or moderate certainty evidence showed that dapagliflozin (RR 0.57, 95% CI 0.36-0.91), empagliflozin (RR 0.54, 95% CI 0.34-0.86), and semaglutide (RR 0.43, 95% CI 0.20-0.91) were related to decreased risk of HF hospitalization. No significant differences in the risk of SAEs were found among the individual drugs. Compared with empagliflozin, very low certainty evidence showed that tirzepatide (RR 1.17, 95% CI 1.04-1.32) was related to increased risk of AEs. When comparing the four drug classes (nsMRA, sGC, SGLT-2I, and GLP-1RA), no significant differences in efficacy outcomes were found, while SGLT-2I (RR 0.87, 95% CI 0.78-0.96) was associated with a decreased risk of AEs compared with GLP-1RA. No significant differences among the individual SGLT-2I, GLP-1RA, nsMRA, and sGC drugs were found in risks of CV death, all-cause mortality or SAEs in patients with HFmrEF/HFpEF. Further evidence is needed to support these comparative effects and update guidance on medication choice for HFmrEF/HFpEF. PROSPERO identifier number CRD420251143542.
中文摘要:新型药物(包括钠-葡萄糖协同转运蛋白2抑制剂SGLT-2I、胰高血糖素样肽-1受体激动剂GLP-1RA、非甾体盐皮质激素受体拮抗剂nsMRA和可溶性鸟苷酸环化酶刺激剂sGC)对射血分数轻度降低或保留的心力衰竭(HFmrEF/HFpEF)的比较疗效与安全性仍不清楚。我们开展系统评价和网络荟萃分析,评估这些药物对HFmrEF/HFpEF的比较效应,为治疗选择提供循证依据。全面检索MEDLINE、EMBASE、Web of Science和Cochrane Central Register of Controlled Trials。纳入比较nsMRA、sGC、SGLT-2I和GLP-1RA与安慰剂用于HFmrEF/HFpEF患者的随机对照试验。主要疗效结局为心血管(CV)死亡、心力衰竭住院(HF住院)和全因死亡,主要安全性结局为不良事件(AE)和严重不良事件(SAE)。主要分析比较单个药物对HFmrEF/HFpEF的影响。采用频率学派网络荟萃分析及随机效应模型计算二分类结局的风险比(RR)和连续结局的标准均数差(SMD)。共纳入20项随机对照试验(RCT,来自35篇文献的10种药物)进行分析,但均无头对头直接比较。所有单个药物在心血管死亡或全因死亡风险方面未发现显著差异。与艾塞那肽相比,低或中等确定性证据显示达格列净(RR 0.57,95%CI 0.36-0.91)、恩格列净(RR 0.54,95%CI 0.34-0.86)和司美格鲁肽(RR 0.43,95%CI 0.20-0.91)与心力衰竭住院风险降低相关。单个药物间SAE风险未发现显著差异。与恩格列净相比,极低确定性证据显示替尔泊肽(RR 1.17,95%CI 1.04-1.32)与AE风险增加相关。比较四类药物(nsMRA、sGC、SGLT-2I和GLP-1RA)时,疗效结局未发现显著差异;与GLP-1RA相比,SGLT-2I(RR 0.87,95%CI 0.78-0.96)与AE风险降低相关。HFmrEF/HFpEF患者中,单个SGLT-2I、GLP-1RA、nsMRA和sGC药物之间在心血管死亡、全因死亡或SAE风险方面未发现显著差异。需要进一步证据支持这些比较效应并更新HFmrEF/HFpEF用药选择指南。PROSPERO注册号CRD420251143542。
European journal of preventive cardiology IF 10.0 2026-10-29 PMID: 42954724
To characterize the pattern of chronotropic incompetence (CI) response to exercise in patients with heart failure (HF) across distinct phenotypes of the left ventricular ejection fraction and to explore the extent to which heart rate (HR) response should be prioritized as a therapeutic target within personalized HF management strategies. Patients with HF with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), and healthy controls underwent incremental exercise testing with simultaneous gas exchange and echocardiography assessments. Stroke volume (SV), HR, cardiac output (CO), and arteriovenous oxygen difference [C(a-v)O2] were assessed from rest to peak exercise. Graphical analyses explored relationships amongst determinants of oxygen uptake (V̇O2). Both HF phenotypes exhibited CI and a blunted increase in CO during exercise compared with controls. Peak HR was similarly reduced by 20% in HFpEF and 23% in HFrEF. HFpEF, however, exhibited a steeper HR-VO2 relationship. HFrEF demonstrated a greater compensatory increase in peripheral O2 extraction, with peak C(a-v)O2 73% higher than controls and 21% higher than HFpEF. In contrast, HFpEF showed limited ability to augment C(a-v)O2 and presented the lowest relative peak V̇O2 (-39% vs. controls and -16% vs. HFrEF), despite similar peak V̇O2%pred between HF phenotypes. CI can contribute to exercise intolerance in both HF phenotypes, with distinct compensatory mechanisms. An integrated cardiopulmonary exercise testing-echocardiography approach may support identifying phenotype-specific physiological profiles that might address therapeutic strategies targeting CI, SV reserve, and peripheral O2 utilization to improve functional capacity in HF. Addressing the kinetics of HR slope and ΔHR metrics seems relevant to implement knowledge on the fundamental CI contribution in HF phenotypes.
中文摘要:旨在描述不同左心室射血分数表型的心力衰竭患者运动时变时性功能不全(CI)的反应模式,并探讨在个体化心衰管理策略中将心率反应优先作为治疗靶点的程度。射血分数保留的心衰(HFpEF)、射血分数降低的心衰(HFrEF)患者与健康对照接受递增运动试验,同时进行气体交换和超声心动图评估。从静息至峰值运动评估每搏量、心率、心输出量和动静脉氧差。采用图形分析探讨摄氧量决定因素之间的关系。两种心衰表型均表现出CI,且运动时心输出量增加较对照减弱。峰值心率在HFpEF和HFrEF中分别降低20%和23%。HFpEF的心率-摄氧量关系更陡。HFrEF外周氧摄取代偿性增加更明显,峰值动静脉氧差较对照高73%,较HFpEF高21%。HFpEF增加动静脉氧差的能力有限,相对峰值摄氧量最低(较对照低39%,较HFrEF低16%),尽管两种心衰表型的峰值摄氧量占预计值百分比相近。CI可导致两种心衰表型的运动不耐受,但代偿机制不同。心肺运动试验-超声心动图整合方法可能有助于识别表型特异的生理特征,从而针对CI、每搏量储备和外周氧利用制定治疗策略,以改善心衰患者功能能力。关注心率斜率动力学和ΔHR指标似乎有助于深化对CI在心衰表型中基础贡献的认识。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42485618
Advanced heart failure (AdvHF) remains a major clinical challenge, yet contemporary epidemiological real-world data on AdvHF patients are limited. The aim was to assess 20-year trends in clinical characteristics, outcomes, and use of left ventricular assist devices (LVAD) and heart transplantation (HTx) in patients with AdvHF and reduced ejection fraction (AdvHFrEF) in Sweden. Between 2003 and 2022, 5323 patients (median age 76 [IQR 68-82], 23% females) included in the Swedish HF Registry met adapted ESC-HFA criteria for AdvHF (NYHA III-IV, EF <30%, ≥1 HF hospitalization ≤6 months). Of these, 29% were eligible for AdvHF therapies (median age 63 [IQR 57-67] years, 18% females) according to the following additional criteria: ≤70 years old, no dialysis within ≤5 years, no active cancer within ≤3 years.Unadjusted temporal trends in 1-year outcomes (all-cause, CV and non-CV death, HTx, and LVAD implantation) were presented as estimated annual percent change (eAPC). 1-year all-cause mortality declined significantly in the overall cohort (eAPC -3.8; 95%CI -5.3 to -2.2) as well as in patients eligible for AdvHF therapies (eAPC -3.2; 95%CI -6.3 to -0.1) over the study period. These improvements were largely driven by reductions in CV mortality (overall cohort: eAPC -4.3; 95%CI -6.0 to -2.6; eligible cohort: eAPC -5.6, 95%CI -9.4 to -1.7). Use of LVAD significantly increased over the study period, while HTx showed a modest but non-significant rise. In a large nationwide cohort, all-cause and CV-mortality among AdvHFrEF patients markedly declined over the past 20 years, potentially reflecting improvements in treatments. Despite progress, significant opportunities remain to improve access to and adoption of advanced therapies.
中文摘要:晚期心力衰竭仍是重大临床挑战,但针对晚期心力衰竭患者的当代真实世界流行病学数据有限。研究目的是评估瑞典射血分数降低的晚期心力衰竭患者在20年间临床特征、结局以及左心室辅助装置和心脏移植使用情况的变化趋势。2003年至2022年,瑞典心力衰竭登记中5323例患者(中位年龄76岁,四分位距68-82岁,女性23%)符合改编的ESC-HFA晚期心力衰竭标准,即NYHA III-IV级、EF低于30%、6个月内至少1次心力衰竭住院。其中29%符合晚期心力衰竭治疗候选条件(中位年龄63岁,四分位距57-67岁,女性18%),附加条件为年龄不超过70岁、5年内未透析、3年内无活动性癌症。1年结局(全因死亡、心血管死亡、非心血管死亡、心脏移植和左心室辅助装置植入)的未校正时间趋势以估计年百分比变化表示。研究期间,总体队列1年全因死亡率显著下降(eAPC -3.8;95%CI -5.3至-2.2),符合晚期心力衰竭治疗条件的患者同样下降(eAPC -3.2;95%CI -6.3至-0.1)。这些改善主要来自心血管死亡率下降(总体队列eAPC -4.3;95%CI -6.0至-2.6;符合条件队列eAPC -5.6;95%CI -9.4至-1.7)。左心室辅助装置使用在研究期间显著增加,心脏移植呈小幅但未达显著的上升。在一个大型全国性队列中,射血分数降低的晚期心力衰竭患者全因死亡率和心血管死亡率在过去20年明显下降,可能反映治疗改善。尽管取得进展,在改善晚期治疗的可及性和采用方面仍有显著空间。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42484006
Recent clinical trials have underscored the importance of early initiation of heart failure (HF) guideline-directed medical therapy (GDMT), with growing emphasis on rapid sequencing, particularly after hospitalization for acute HF (AHF). Despite the proven short-term benefit of this approach, few patients receive this therapy at discharge. In patients with AHF, we evaluated whether treatment at discharge with dual sodium-glucose co-transporter-2 inhibitors (SGLT2i)-mineralocorticoid receptor antagonist (MRA) therapy or four-class GDMT was associated with short-term mortality and incremental risk reduction. We analysed two prospective registries of AHF: the China HF-CAP (n = 441 320; main cohort) and the Swedish HF Registry (SwedeHF) (n = 2367; external validation cohort). We assessed the association between discharge prescription of dual therapy SGLT2i and MRA versus neither, and four-class GDMT vs none, with 90-day cardiovascular (CV) and all-cause mortalities, further stratified by baseline serum potassium levels and left ventricular ejection fraction (LVEF) categories. In the main cohort, for dual SGLT2i and MRA therapy (n = 71 154) vs neither (n = 81 793) therapy, adjusted odds of 90-day CV and all-cause death were 0.320 [0.283-0.361] and 0.504 [0.472-0.539], respectively. In the external validation cohort, results were directionally consistent. Association between dual SGLT2i and MRA therapy and short-term survival was consistent irrespective of hyperkalaemia and across HF phenotypes. Further, in the main cohort, adjusted odds of 90-day CV death of four-class GDMT (n = 36 301) were 0.122 (0.106-0.14) vs no therapy (n = 18 374). After AHF, early initiation of dual SGLT2i and MRA therapy was associated with lower short-term mortality, irrespective of LVEF or potassium levels. Four-class GDMT conferred the lowest risk, emphasizing the importance of timely implementation after AHF.
中文摘要:近期临床试验强调心力衰竭指南导向药物治疗早期启动的重要性,快速序贯治疗尤其受到重视,急性心衰住院后更为突出。尽管该策略短期获益已获证实,出院时接受治疗者仍少。在急性心衰患者中,评估出院时双联SGLT2i-MRA或四联GDMT与短期死亡及逐级风险降低的关系。分析两个前瞻性急性心衰注册研究:中国HF-CAP(n=441320;主队列)和瑞典心衰注册SwedeHF(n=2367;外部验证队列)。评估出院处方双联SGLT2i与MRA对比两者均无、四联GDMT对比无治疗与90天心血管死亡和全因死亡的关联,并按基线血钾水平和LVEF类别分层。主队列中,双联SGLT2i与MRA(n=71154)对比两者均无(n=81793),校正后90天心血管死亡和全因死亡OR分别为0.320[0.283-0.361]和0.504[0.472-0.539]。外部验证队列结果方向一致。双联SGLT2i与MRA治疗和短期生存的关联在高钾血症及不同心衰表型中一致。主队列中,四联GDMT(n=36301)对比无治疗(n=18374)的校正后90天心血管死亡OR为0.122(0.106-0.14)。急性心衰后,早期启动双联SGLT2i与MRA治疗与较低短期死亡相关,不受LVEF或血钾水平影响。四联GDMT风险最低,凸显急性心衰后及时实施的重要性。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42462167
To assess the cost-effectiveness of guideline-directed medical treatments for heart failure with reduced ejection fraction (HFrEF) by performing a network meta-analysis (NMA) of randomized controlled trials (RCTs) feeding a subsequent cost-effectiveness analysis. A random-effects NMA of RCTs was conducted. The primary analysis included only RCTs evaluating drugs in clinical settings as recommended in the 2021 European Society of Cardiology HF guidelines. Main efficacy outcomes included all-cause mortality (ACM) and total HF hospitalizations (HFH). A decision tree-Markov model was populated with NMA-derived efficacy estimates, quality-of-life data, and costs from United Kingdom (UK, main analysis), as well as Sweden and United States (US) (scenario analyses) healthcare perspectives. A total of 47 RCTs (75 978 patients) were included. The risk of ACM and total HFH decreased with increasing number of pharmacological treatments. In the main (UK) analysis, the greatest benefit was observed with a quadruple therapy including angiotensin receptor-neprilysin inhibitor (ARNI) + β-blocker (BB) + mineralocorticoid receptor antagonist (MRA) + sodium-glucose cotransporter 2 inhibitors (SGLT2i), which resulted as the most cost-effective strategy (12.31 quality-adjusted life-years; net monetary benefit of £338 460; UK perspective). Findings were consistent in Sweden and USA. Quadruple therapy with ARNI + BB + MRA + SGLT2i had the highest probability of being the most cost-effective strategy. Our findings might inform future health economic policies and reimbursement decisions, while also considering affordability, budget impact, and implementation feasibility.
中文摘要:通过随机对照试验的网络荟萃分析并衔接后续成本效果分析,评估射血分数降低的心力衰竭指南导向药物治疗的成本效果。研究开展随机效应网络荟萃分析,主分析仅纳入在临床环境中评估2021年欧洲心脏病学会心力衰竭指南推荐药物的随机对照试验,主要疗效结局为全因死亡和心力衰竭总住院。决策树-Markov模型采用网络荟萃分析所得疗效估计、生活质量数据和成本,主分析采用英国医疗体系视角,情景分析采用瑞典和美国视角。共纳入47项随机对照试验、75978例患者。随着药物治疗数量增加,全因死亡和心力衰竭总住院风险下降。英国主分析中,获益最大的是血管紧张素受体-脑啡肽酶抑制剂联合β受体阻滞剂、盐皮质激素受体拮抗剂和钠-葡萄糖协同转运蛋白2抑制剂的四联治疗,该方案最具成本效果,获得12.31个质量调整生命年,净货币收益为338460英镑。瑞典和美国分析结果一致。上述四联治疗成为最具成本效果策略的概率最高。研究结果可为未来卫生经济政策和报销决策提供参考,同时需考虑可负担性、预算影响和实施可行性。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42440133
Left ventricular assist device (LVAD) implantation is an established therapy for advanced heart failure, either as bridge-to-transplantation (BTT) or destination therapy (DT). The Italian National Transplant Center supported the development of the Italian multicentre registry for mechanically assisted circulatory support (ITAMACS). We report the first analysis of the ITAMACS registry, focusing on durable intracorporeal LVADs. All durable LVAD implantations performed in Italy between January 2010 and December 2021 were collected, including follow-up data, and submitted by participating centres to a centralized database. Demographic characteristics, procedural variables, and clinical outcomes were analysed. Survival was assessed using Kaplan-Meier analysis, and Cox proportional hazards models were used to identify independent predictors of long-term mortality. A total of 1061 patients from 12 centres underwent durable LVAD implantation. BTT was the indication in 40.5% and DT in 38.8% of cases; 14.8% of patients were in INTERMACS class 1, and 16.3% underwent minimally invasive implantation. Overall survival at 1, 3, and 5 years was 73%, 54%, and 42%, respectively. On multivariable analysis, older age (hazard ratio [HR] 1.02, 95% confidence interval [CI] 1.01-1.04) and redo surgery (HR 1.25, 95% CI 1.02-1.55) were associated with higher mortality, whereas INTERMACS class >1 (HR 0.66, 95% CI 0.50-0.87) and BTT indication (HR 0.63, 95% CI 0.48-0.83) were protective. ITAMACS is the first national registry reporting real-world outcomes of durable LVAD therapy in Italy. These data provide an overview of national practice and may support optimization of LVAD programs and patient care.
中文摘要:左心室辅助装置(LVAD)植入是晚期心力衰竭的成熟治疗选择,可作为移植前过渡(BTT)或终点治疗(DT)。意大利国家移植中心支持建立意大利机械辅助循环支持多中心登记研究(ITAMACS)。我们报告ITAMACS登记研究的首次分析,聚焦耐久性体内LVAD。纳入2010年1月至2021年12月在意大利实施的所有耐久性LVAD植入,包括随访数据,由参与中心提交至集中数据库。分析人口学特征、手术变量和临床结局。采用Kaplan-Meier分析评估生存,Cox比例风险模型识别长期死亡的独立预测因素。12个中心共1061例患者接受耐久性LVAD植入。BTT为适应证者占40.5%,DT占38.8%;14.8%患者为INTERMACS 1级,16.3%接受微创植入。1、3、5年总生存率分别为73%、54%、42%。多变量分析中,年龄较大(风险比[HR] 1.02,95%置信区间[CI] 1.01-1.04)和再次手术(HR 1.25,95% CI 1.02-1.55)与较高死亡率相关,而INTERMACS分级>1(HR 0.66,95% CI 0.50-0.87)和BTT适应证(HR 0.63,95% CI 0.48-0.83)为保护因素。ITAMACS是首个报告意大利耐久性LVAD治疗真实世界结局的国家登记研究。这些数据提供全国实践概览,或可支持LVAD项目和治疗照护的优化。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42430197
The role of the nurse in the heart failure (HF) multi-disciplinary team (MDT) has become well-established, with clear evidence of improved patient outcomes and recommended by professional guidelines. Recognizing the change in the HF landscape since the publication of the first Heart Failure Association (HFA) of the European Society of Cardiology (ESC) HF nurse curriculum in 2016, and the expanding role of HF nurses of in the HF MDT, the HFA in collaboration with the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC prioritized this update to the curriculum. Standardized training programmes for HF nurses improve the quality of care provided to patients with HF and their caregivers. Recognizing the variability of education background and clinical autonomy across Europe and beyond, this curriculum is designed in a flexible way to be able to be adapted and adjusted based on individual country regulations and forms. Endorsement of this curriculum from national professional bodies or Nursing Councils would ensure uniformity and enhance the profession's contribution to HF care. The updated specialist HF nurse curriculum provides the basis for the advanced level of knowledge, skills and attitudes required for the appropriate expansion of the role of the HF nurse that can be adapted across Europe and beyond, while complying with professional legislation of different healthcare systems and supporting nurses who move between countries.
中文摘要:护士在心力衰竭多学科团队中的作用已得到确立,有明确证据显示可改善患者结局,并获专业指南推荐。鉴于自2016年欧洲心脏病学会心力衰竭协会发布首版心衰护士课程以来心衰领域格局发生变化,且心衰护士在多学科团队中的角色不断扩展,欧洲心脏病学会心力衰竭协会与欧洲心脏病学会心血管护理及相关专业人员协会合作,将更新该课程列为优先事项。针对心衰护士的标准化培训项目可提高对心衰患者及其照护者所提供照护的质量。考虑到欧洲及其他地区教育背景和临床自主性的差异,本课程采用灵活设计,可根据各国法规和形式进行调整。由国家专业机构或护理委员会认可该课程,可确保一致性并提升该专业对心衰照护的贡献。更新后的心衰专科护士课程为心衰护士角色适当扩展所需的高级知识、技能和态度提供了基础,可在欧洲及其他地区适用,同时符合不同医疗体系的专业法规,并支持护士在国家间流动。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42106971
Heart failure (HF) is a common sequela of type 2 diabetes (diabetes), and models have been developed for its prediction. We aimed to synthesize the available evidence by performing a systematic review and meta-analysis of models predicting incident HF and HF hospitalization (HFH) in individuals with diabetes. We searched MEDLINE and EMBASE for multivariable models predicting HF or HFH in patients with diabetes from inception to 2 December 2025. Discrimination metrics from models validated in ≥3 cohorts were pooled using Bayesian meta-analysis. Heterogeneity was assessed using 95% prediction intervals (PI), and risk of bias with PROBAST. In total, 65 studies describing 56 HF and 44 HFH prediction models were included. Following exclusion of studies at high risk of bias, two HF models (RECODe (0.711, 95% CI 0.651-0.767) and DMRS (0.758, 95% CI 0.684-0.827)) and two HFH models (WATCH-DM 2022 (r) (0.705, 95% CI, 0.624-0.795), WATCH-DM 2022(i) (0.718, 95% CI 0.587-0.850)) had acceptable prediction performance, while one HFH model had good performance (DM-CURE (0.837, 95% CI 0.757-0.913). Of these, none reported a prediction horizon of less than ten years. For all models, regardless of risk of bias, none were prospectively tested, and only three underwent clinical utility analysis. While some HF and HFH models in diabetes show acceptable/good long-term discriminative performance, the scarcity of utility analyses and prospective testing limits translation to clinical settings. Prospective evaluation of these models is required to establish clinical utility.
中文摘要:心力衰竭是2型糖尿病常见后遗症,已有模型用于其预测。我们通过系统综述和荟萃分析,汇总预测糖尿病患者新发心衰和心衰住院(HFH)模型的现有证据。检索MEDLINE和EMBASE中从建库至2025年12月2日、用于预测糖尿病患者心衰或HFH的多变量模型。对在至少3个队列中验证的模型的区分度指标采用贝叶斯荟萃分析合并。用95%预测区间(PI)评估异质性,用PROBAST评估偏倚风险。共纳入65项研究,描述56个心衰预测模型和44个HFH预测模型。排除高偏倚风险研究后,两个心衰模型(RECODe,0.711,95% CI 0.651-0.767;DMRS,0.758,95% CI 0.684-0.827)和两个HFH模型(WATCH-DM 2022(r),0.705,95% CI 0.624-0.795;WATCH-DM 2022(i),0.718,95% CI 0.587-0.850)具有可接受的预测性能,一个HFH模型性能良好(DM-CURE,0.837,95% CI 0.757-0.913)。这些模型均未报告少于十年的预测时界。所有模型无论偏倚风险如何,均未进行前瞻性检验,仅三个模型进行了临床效用分析。糖尿病中的部分心衰和HFH模型显示出可接受或良好的长期区分性能,但效用分析和前瞻性检验稀缺,限制了向临床环境的转化。需要对这些模型进行前瞻性评估以确定临床效用。
European journal of heart failure IF 10.3 2026-10-28 PMID: 41789668
This review evaluates the role of heart failure (HF) registries in the Nordic countries-Sweden, Denmark, Norway, and Iceland-in the implementation of the European Society of Cardiology's guidelines for guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF). It critically examines how these registries facilitate clinical practice and enhance patient outcomes through their design, data collection methods, and the evaluation of key metrics related to GDMT implementation over time. We highlight the nurse-led models adopted by these registries, which emphasize quality benchmarks and feature real-time feedback mechanisms regarding the application of GDMT. Between 2021 and 2024, registry population-weighted estimates revealed significant increases in the utilization of key therapies: mineralocorticoid receptor antagonists rose from 51% to 72%, sodium-glucose co-transporter-2 inhibitors from 20% to 81%, and sacubitril/valsartan from 22% to 32%. The use of beta-blockers and renin-angiotensin-system inhibitors remained consistently high at 91% and 94%, respectively. These shifts were linked to better treatment outcomes. The findings underscore that HF registries play a crucial role in enhancing care quality through established drug therapies for HFrEF, offering a model for integrating data-driven methodologies into HF management. Future utilization and expansion of these registries are vital for tackling healthcare disparities and refining treatment strategies for HF patients.
中文摘要:本综述评估北欧国家(瑞典、丹麦、挪威和冰岛)的心力衰竭登记注册在落实欧洲心脏病学会射血分数降低的心力衰竭指南指导药物治疗指南中的作用。文章批判性考察这些注册体系如何通过其设计、数据收集方式以及对指南指导药物治疗实施关键指标随时间变化的评价,推动临床实践并改善患者结局。我们重点介绍这些注册体系采用的护士主导模式,该模式强调质量基准,并对指南指导药物治疗的应用提供实时反馈机制。2021年至2024年间,注册人群加权估计显示关键疗法的使用率显著上升:盐皮质激素受体拮抗剂从51%升至72%,钠-葡萄糖共转运蛋白2抑制剂从20%升至81%,沙库巴曲/缬沙坦从22%升至32%。β受体阻滞剂和肾素-血管紧张素系统抑制剂的使用率分别稳定在91%和94%的高位。这些变化与更好的治疗结局相关。研究结果凸显心力衰竭注册体系通过射血分数降低的心力衰竭的成熟药物治疗提升照护质量的关键作用,为将数据驱动方法整合进心力衰竭管理提供了范本。未来对这些注册体系的利用与扩展,对于应对医疗差异、优化心力衰竭患者的治疗策略至关重要。
European journal of heart failure IF 10.3 2026-10-28 PMID: 41771117
Cardiogenic shock (CS) is often treated with catecholamines titrated to an adequate target mean arterial pressure (MAP) while minimizing adverse effects. We aim to assess the optimal catecholamine dose/MAP balance in heart failure-associated CS (HF-CS). Patients with HF-CS were retrospectively enrolled from 16 tertiary centres in 5 European countries (2016-2021; NCT03313687). Dosage was quantified by inotropic scores (epinephrine, norepinephrine, and dobutamine). Associations of baseline and seven-day summarized dosage with intensive care unit (ICU) discharge (mixed-effects logistic regression) and 30-day mortality (Cox regression) were analysed. Potential catecholamine/MAP target ratios for optimized outcomes were assessed in models adjusted for age, sex, pH, lactate and prior resuscitation, stratified by centre. N = 704 patients: median age 63 years, 74% male, 34% post-resuscitation, median lactate 5.2 mmol/l. Of these, 53% were discharged from ICU, 48% died within 30 days. Higher inotropic scores independently predicted a lower probability of ICU discharge (baseline score: OR 0.78 [95%-CI 0.69-0.88]; summarized score: OR 0.46 [0.38-0.56]; both P < .001) and higher risk of 30-day mortality (baseline score: HR 1.27 [1.15-1.40], summarized score HR 1.83 [1.60-2.09]; both P < .001). A score/MAP ratio <0.403 µg/kg/min/mmHg was associated with higher ICU discharge odds (ceiling effect); a < 0.426 µg/kg/min/mmHg with lower 30-day mortality hazards (no ceiling effect). Lowering catecholamine doses by accepting reduced MAP targets was linked to better outcomes. In HF-CS, higher catecholamine support independently associates with worse outcomes. Accepting lower blood pressure targets to reduce catecholamine dosage may improve outcomes. Validation in randomized controlled trials is urgently needed.
中文摘要:心源性休克(CS)常用儿茶酚胺类药物滴定至合适的平均动脉压(MAP)目标,同时尽量减少不良反应。本研究旨在评估心力衰竭相关心源性休克(HF-CS)中儿茶酚胺剂量与MAP的最佳平衡。研究回顾性纳入5个欧洲国家16家三级中心2016至2021年的HF-CS患者(NCT03313687)。剂量以正性肌力评分量化(肾上腺素、去去甲肾上腺素和多巴胺……),需要准确:肾上腺素、去甲肾上腺素和dobutamine(多巴酚丁胺)。基线与7天汇总剂量与重症监护病房(ICU)转出(混合效应logistic回归)及30天死亡(Cox回归)的关联被分析。以年龄、性别、pH、乳酸及既往复苏调整并按中心分层的模型评估可能实现结局优化的儿茶酚胺/MAP目标比值。共704例患者:中位年龄63岁,男性74%,复苏后34%,中位乳酸5.2 mmol/l。其中53%转出ICU,48%在30天内死亡。较高的正性肌力评分独立预测较低的ICU转出概率(基线评分:OR 0.78[95%CI 0.69-0.88];汇总评分:OR 0.46[0.38-0.56];均P<.001),并预测较高的30天死亡风险(基线评分:HR 1.27[1.15-1.40],汇总评分HR 1.83[1.60-2.09];均P<.001)。评分/MAP比值<0.403 µg/kg/min/mmHg与更高的ICU转出比值比相关(存在天花板效应);<0.426 µg/kg/min/mmHg与更低的30天死亡风险相关(无天花板效应)。通过接受较低的MAP目标来降低儿茶酚胺剂量与更好的结局相关。在HF-CS中,较高的儿茶酚胺支持独立地与更差的结局相关。接受较低的血压目标以减少儿茶酚胺剂量可能改善结局。亟需在随机对照试验中验证。
European journal of heart failure IF 10.3 2026-10-28 PMID: 41771063
Given the emerging role of transcatheter valve repair in HFrEF patients with moderate/severe secondary mitral regurgitation (MR), we evaluated the prevalence and outcomes related to MR in the GALACTIC-HF trial. The randomized GALACTIC-HF trial compared the efficacy and safety of omecamtiv mecarbil to placebo in 8232 patients with HFrEF, with a primary composite outcome of a first HF event or cardiovascular death. Of 7998 patients (97.2%) with baseline data on MR, 5782 (72.3%) had no MR, 970 (12.1%) had mild MR, and 1221 (15.3%) had moderate MR (only 25 had severe MR). Patients with moderate MR had a higher risk of the primary outcome than those without MR (adjusted HR 1.11; 95% CI 1.01-1.23); risk was not higher in patients with mild MR. The association between moderate MR and the primary outcome was most prominent in patients with less severe HF (milder NYHA class, higher LVEF, and lower N-terminal pro-B-type natriuretic peptide) compared to more severe HF. In adjusted analyses, MR was not associated with mortality, and the results of all analyses remained consistent after including patients with severe MR. The beneficial treatment effect of omecamtiv mecarbil versus placebo on clinical outcomes was not modified by MR. Over 80% of patients with moderate/severe MR fulfilled the broad inclusion criteria for COAPT and RESHAPE-HF2. In GALACTIC-HF, almost 15% of patients with heart failure and reduced ejection fraction had moderate MR, which was associated with a higher risk of the primary outcome.
中文摘要:经导管瓣膜修复在合并中重度继发性二尖瓣反流的射血分数降低的心力衰竭患者中作用逐渐受到关注,本研究基于GALACTIC-HF试验评估二尖瓣反流的患病率及其相关结局。随机对照GALACTIC-HF试验在8232例射血分数降低的心力衰竭患者中比较omecamtiv mecarbil与安慰剂的疗效和安全性,主要复合终点为首次心力衰竭事件或心血管死亡。7998例(97.2%)患者有基线二尖瓣反流数据,其中5782例(72.3%)无二尖瓣反流,970例(12.1%)为轻度,1221例(15.3%)为中度,仅25例为重度。中度二尖瓣反流患者发生主要终点的风险高于无二尖瓣反流者(校正HR 1.11;95%CI 1.01-1.23),轻度二尖瓣反流患者风险未升高。中度二尖瓣反流与主要终点的关联在心力衰竭程度较轻的患者中更明显(NYHA分级更轻、LVEF更高、N末端B型利钠肽原更低),在心力衰竭更重的患者中相对较弱。校正分析中,二尖瓣反流与死亡率无关,纳入重度二尖瓣反流患者后所有分析结果保持一致。omecamtiv mecarbil相较安慰剂对临床结局的有益治疗效应未受二尖瓣反流影响。中度或重度二尖瓣反流患者中超过80%符合COAPT和RESHAPE-HF2的宽泛纳入标准。在GALACTIC-HF中,近15%的射血分数降低的心力衰竭患者存在中度二尖瓣反流,并与主要终点风险升高相关。
European journal of preventive cardiology IF 10.0 2026-10-27 PMID: 42945405
Cardiometabolic diseases increasingly manifest as interconnected dysfunction across the heart, vasculature, kidneys, liver, and metabolic system. The global rise in obesity, insulin resistance, and diabetes, together with therapies benefiting multiple organs, has reshaped the epidemiology and understanding of cardiometabolic disease, exposing the limitations of organ-specific or single-stage approaches. The cardioVascular-kidney-liver-metabolic (CVKLM) framework is a multidimensional staging system in which cardiac, vascular, kidney, liver, and metabolic involvement are graded independently from absent to advanced. Analogous to tumour-node-metastasis staging, it provides a standardized language describing disease severity within each organ and its distribution across organs. Rather than replacing existing classifications, CVKLM integrates universal heart failure stages, validated vascular risk assessment, KDIGO chronic kidney disease stratification, contemporary metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced liver disease criteria, and current definitions of diabetes and clinical obesity. Unlike hierarchical frameworks assigning a single overall stage, CVKLM preserves organ-specific information and records coexisting abnormalities across domains. Intended for clinical and research phenotyping and staging rather than as a validated global risk score, it may facilitate systematic recognition of concomitant organ disease, support existing organ-specific diagnostic, referral, and treatment pathways, and provide a standardized taxonomy for observational studies and clinical trials. The prognostic significance of CVKLM profiles, their incremental value beyond established risk tools, and their clinical utility remain to be established. By integrating these domains within a common architecture, CVKLM offers a pragmatic framework spanning the full spectrum of cardiometabolic disease, from preclinical involvement to advanced multiorgan failure.
中文摘要:心血管代谢疾病日益表现为心脏、血管、肾脏、肝脏和代谢系统之间相互关联的功能障碍。全球肥胖、胰岛素抵抗和糖尿病增加,以及可惠及多个器官的治疗手段,改变了心血管代谢疾病的流行病学与认识,也暴露出按单个器官或单一分期方法的局限。心血管-肾脏-肝脏-代谢(CVKLM)框架是一种多维分期系统,其中心脏、血管、肾脏、肝脏和代谢受累分别从无到晚期独立分级。它类似肿瘤-淋巴结-转移分期,提供标准化语言来描述各器官内的疾病严重程度及跨器官分布。CVKLM并非替代现有分类,而是整合通用心力衰竭分期、经验证的血管风险评估、KDIGO慢性肾脏病分层、当代代谢功能障碍相关脂肪性肝病(MASLD)及晚期肝病标准,以及当前糖尿病和临床肥胖定义。与赋予单一总体分期的层级框架不同,CVKLM保留器官特异性信息,并记录不同领域并存的异常。该框架用于临床和研究中的表型划分与分期,而非作为经验证的全局风险评分,可能有助于系统识别合并器官疾病,支持现有器官特异性诊断、转诊和治疗路径,并为观察性研究和临床试验提供标准化分类体系。CVKLM分型的预后意义、其超越现有风险工具的增量价值及临床效用仍有待确定。通过将上述领域整合到共同架构中,CVKLM提供了一个覆盖心血管代谢疾病全谱的实用框架,从临床前受累到晚期多器官衰竭。
Circulation IF 41.3 2026-10-27 PMID: 42932419
The totality of evidence indicates that the mechanisms underlying the increase in pulmonary vascular resistance in patients with combined postcapillary and precapillary pulmonary hypertension (CpcPH) associated with heart failure with preserved ejection fraction (HFpEF) differ meaningfully from those responsible for the increase in pulmonary vascular resistance in patients with pulmonary arterial hypertension. CpcPH-HFpEF is a complex disorder involving the pulmonary veins, left atrium, and pulmonary arterioles, but recent evidence has highlighted a potentially central role for pulmonary venous and left atrial (LA) dysfunction. Epicardial adipose tissue occupies anatomical proximity to both structures, allowing derivative secretory products to influence their structure and function. The most well-characterized proinflammatory adipokine released from an expanded epicardial fat mass is activin A, which causes fibrosis and cardiomyocyte stiffness and senescence in underlying tissues by signaling through activin type II receptor signal transduction. Such signaling regulates pulmonary venular responses to mechanical stretch, and circulating activin A is elevated in patients with HFpEF who have enlarged LA chambers, pulmonary venous hypertension and increased pulmonary vascular resistance. The adipokine hypothesis of HFpEF identified activin A and activin type II receptor signaling as key adipokine mediators in the pathogenesis of HFpEF. Experimentally, activin A signaling promotes the development of both atrial myopathy and HFpEF, and activin type II receptor ligand traps alleviate HFpEF and ameliorate both the pulmonary vascular and left heart abnormalities in experimental models in which CpcPH-HFpEF is induced by obesity. These collective observations led to the prospective hypothesis that adipokine modulation by sotatercept would mediate benefits on the left heart in patients with CpcPH-HFpEF. These expectations were validated when the CADENCE trial showed that sotatercept decreased both pulmonary artery wedge pressures and left atrial volume index in patients with CpcPH-HFpEF, which are effects that could not explained by a decrease in pulmonary vascular resistance. Activin A released from an expanded epicardial adipose tissue promotes both pulmonary venous and left atrial remodeling and fibrosis in vivo, which (in turn) are effects that can be attenuated by an activin A decoy. The efficacy of sotatercept to slow the progression of CpcPH-HFpEF is now being tested in a phase III outcomes trial.
中文摘要:现有总体证据表明,射血分数保留的心力衰竭(HFpEF)相关的同时存在毛细血管后和毛细血管前肺动脉高压(CpcPH)患者肺血管阻力升高的机制,与肺动脉高压患者肺血管阻力升高的机制存在实质差异。CpcPH-HFpEF是累及肺静脉、左心房和肺小动脉的复杂疾病,近期证据提示肺静脉和左心房(LA)功能障碍可能起核心作用。心外膜脂肪组织在解剖上邻近这两种结构,其分泌产物可影响这些结构及功能。从扩大的心外膜脂肪团块释放、特征最明确的促炎脂肪因子是激活素A,它通过激活素II型受体信号转导,引起下方组织纤维化以及心肌细胞僵硬和衰老。该信号调节肺小静脉对机械牵张的反应;在左心房扩大、肺静脉高压和肺血管阻力升高的HFpEF患者中,循环激活素A水平升高。HFpEF的脂肪因子假说将激活素A及激活素II型受体信号确定为HFpEF发病过程中的关键脂肪因子介质。实验研究表明,激活素A信号促进心房肌病和HFpEF的发展;在肥胖诱导CpcPH-HFpEF的实验模型中,激活素II型受体配体陷阱可缓解HFpEF,并改善肺血管和左心异常。这些观察共同引出前瞻性假设:在CpcPH-HFpEF患者中,通过sotatercept调节脂肪因子可对左心产生获益。CADENCE试验显示sotatercept降低CpcPH-HFpEF患者的肺动脉楔压和左心房容积指数,这些效应无法用肺血管阻力下降解释,从而验证了上述预期。扩大的心外膜脂肪组织释放的激活素A在体内促进肺静脉和左心房重构及纤维化,而这些效应可被激活素A诱饵受体减弱。sotatercept延缓CpcPH-HFpEF进展的疗效目前正在一项III期结局试验中接受检验。
Circulation IF 41.3 2026-10-27 PMID: 42668439
Heart failure with reduced ejection fraction causes high mortality and recurrent hospitalizations in India. We evaluated the effectiveness of the collaborative care model in improving days alive and out of the hospital and overall survival. We conducted a parallel-group, cluster-randomized controlled trial involving 1507 adults with heart failure with reduced ejection fraction across 22 centers in India (CTRI/2021/11/037797). Centers were randomized 1:1 to the intervention or usual care. Participants were followed up for 2 years. The intervention included risk stratification, lifestyle and pharmacological optimization, and a nurse-coordinated, mobile health-supported disease management program with self-care education, active follow-up, and continuous outpatient monitoring throughout the study period. The primary outcome was days alive and out of the hospital, and all-cause mortality was assessed as a secondary outcome. Days alive and out of the hospital was analyzed with a one-inflated β model. All-cause mortality was analyzed with Cox proportional hazards models adjusted for the clustered study design. Among 1507 participants (752 usual care; 755 intervention), the mean age was 61.9 years, and 77.6% were men. All participants except one completed 24 months of follow-up. Most participants (70%) had low educational attainment; 57.3% lived in rural areas; and ischemic heart disease was the predominant cause (77.4%). Baseline characteristics were comparable between the intervention and usual care groups. In the one-inflated β model, the probability of surviving up to 730 days without hospitalization was 34.7% (95% CI, 31.2%-38.1%) in the usual care group and 46.5% (95% CI, 42.6%-49.9%) in the intervention group. Participants in the intervention group had 78% higher odds of achieving a percent days alive and out of the hospital of exactly 1 (730/730 days) compared with those in the usual care group (odds ratio, 1.78 [95% CI, 1.42-2.23]). There were 201 deaths (26.73%) in the usual care group compared with 163 deaths (21.59%) in the intervention group (risk ratio, 0.80 [95% CI, 0.67-0.97]). In the multivariable Cox proportional hazards model, the intervention group had a 22% lower mortality risk than the usual care group (hazard ratio, 0.78 [95% CI, 0.63-0.95]; P=0.028). A nurse-coordinated, mobile health-supported collaborative care model for heart failure with reduced ejection fraction in India increased the number of days alive and out of hospital, raised the absolute probability of remaining out of hospital by 11.8 percentage points, and reduced all-cause mortality by 22%. URL: www.ctri.nic.in; Unique identifier: CTRI/2021/11/037797.
中文摘要:射血分数降低的心力衰竭在印度造成高死亡率和反复住院。该试验评估协作照护模式对存活且未住院天数和总生存期的改善效果。研究为平行组、整群随机对照试验,纳入印度22个中心的1507例射血分数降低的心力衰竭成人(CTRI/2021/11/037797)。各中心按1:1随机分配至干预组或常规照护组,参与者随访2年。干预包括风险分层、生活方式与药物优化,以及由护士协调、移动健康支持的疾病管理方案,内容涵盖自我照护教育、主动随访和整个研究期间的持续门诊监测。主要结局为存活且未住院天数,全因死亡作为次要结局评估。存活且未住院天数采用一膨胀β模型分析;全因死亡采用按整群研究设计校正的Cox比例风险模型分析。1507例参与者中,常规照护组752例,干预组755例,平均年龄61.9岁,77.6%为男性。除1例以外,所有参与者均完成24个月随访。70%的参与者受教育程度较低,57.3%居住在农村,缺血性心脏病为主要病因(77.4%)。干预组与常规照护组基线特征可比。一膨胀β模型显示,常规照护组存活至730天且未住院的概率为34.7%(95% CI,31.2%-38.1%),干预组为46.5%(95% CI,42.6%-49.9%)。与常规照护组相比,干预组达到存活且未住院天数百分比恰为1(730/730天)的比值高78%(比值比,1.78[95% CI,1.42-2.23])。常规照护组死亡201例(26.73%),干预组死亡163例(21.59%)(风险比,0.80[95% CI,0.67-0.97])。多变量Cox比例风险模型显示,干预组死亡风险较常规照护组低22%(风险比,0.78[95% CI,0.63-0.95];P=0.028)。在印度,针对射血分数降低的心力衰竭采用护士协调、移动健康支持的协作照护模式,增加了存活且未住院天数,使保持未住院的绝对概率提高11.8个百分点,并使全因死亡率降低22%。网址:www.ctri.nic.in;唯一标识:CTRI/2021/11/037797。
European journal of preventive cardiology IF 10.0 2026-10-26 PMID: 42932779
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are agents originally developed as glucose-lowering drugs but now widely used to improve cardiorenal outcomes, including in patients with heart failure and chronic kidney disease regardless of diabetes status. However, their exact mode of action remains unclear. Here, we investigated the association of loss-of-function (LoF) and other rare coding variants in the SLC5A2 gene, as a genetic model of altered SGLT2 function, with 13 cardiometabolic and renal traits and clinical outcomes. A total of 442 570 European ancestry participants from the UK Biobank with exome sequence and phenotype data were included. We applied SAIGE-GENE+ for gene-based and single-variant association tests in the full study population and in individuals with heart failure, renal failure, and type 2 diabetes (T2D). A total of 52 LoF variants in SLC5A2 were identified. Rare variants in SLC5A2 were associated with decreased uric acid (PCauchy = 4.98 × 10-13) and with increased haematocrit (PCauchy = 1.67 × 10-5), haemoglobin (PCauchy = 1.60 × 10-5), and estimated glomerular filtration rate (PCauchy = 9.88 × 10-4). One frameshift variant (rs267607067) was significantly associated with increased haemoglobin (β = 0.33 [95% CI 0.15-0.51]; P-value = 2.40 × 10-4) and another (rs768095044) with decreased uric acid (β = -0.31 [95% CI -0.49 to -0.13]; P-value = 4.22 × 10-4). In patients with T2D, the rare variants within SLC5A2 were also associated with a lower probability of having heart failure (PCauchy = 4.00 × 10-4). Rare genetic variants in SLC5A2 were associated with increased haemoglobin and decreased uric acid. These variants were also associated with a lower probability of heart failure among participants with T2D, providing tentative genetic support for a cardioprotective effect of SGLT2 inhibition.
中文摘要:钠-葡萄糖共转运蛋白2(SGLT2)抑制剂最初作为降糖药开发,如今已广泛用于改善心肾结局,包括心力衰竭与慢性肾脏病患者,无论其糖尿病状态如何。但其确切作用方式仍不清楚。本研究以SLC5A2基因功能缺失(LoF)变异及其他罕见编码变异作为SGLT2功能改变的遗传模型,分析其与13项心脏代谢及肾脏表型和临床结局的关联。研究纳入英国生物银行(UK Biobank)中具有外显子组测序与表型数据的442 570名欧洲血统参与者。在全研究人群以及心力衰竭、肾功能衰竭和2型糖尿病(T2D)个体中,采用SAIGE-GENE+进行基于基因和单变异的关联检验。共识别出SLC5A2的52个LoF变异。SLC5A2罕见变异与尿酸降低(PCauchy = 4.98 × 10-13)相关,并与红细胞压积(PCauchy = 1.67 × 10-5)、血红蛋白(PCauchy = 1.60 × 10-5)及估算肾小球滤过率(PCauchy = 9.88 × 10-4)升高相关。一个移码变异(rs267607067)与血红蛋白升高显著相关(β = 0.33 [95% CI 0.15-0.51];P值 = 2.40 × 10-4),另一个变异(rs768095044)与尿酸降低相关(β = -0.31 [95% CI -0.49 至 -0.13];P值 = 4.22 × 10-4)。在T2D患者中,SLC5A2内的罕见变异还与较低的心力衰竭患病概率相关(PCauchy = 4.00 × 10-4)。SLC5A2罕见遗传变异与血红蛋白升高和尿酸降低相关。这些变异在T2D参与者中亦与较低的心力衰竭概率相关,为SGLT2抑制的心脏保护作用提供了初步遗传学支持。

基础研究 (5篇)

Cardiovascular research IF 12.5 2026-10-30 PMID: 42958931
Cardiomyocyte senescence is a hallmark of cardiac aging and closely associated with diastolic dysfunction and heart failure in older adults. Strategies to effectively delay or reverse cardiomyocyte senescence in the aged heart remain limited. We investigated whether NAD+ replenishment regulates cardiomyocyte senescence and cardiac function in aging. Ventricular NAD+ metabolism, senescence markers, and cardiac function were assessed in young and aged mice of both sexes. Aged male mice exhibited reduced cardiac NAD+ levels due to impaired biosynthesis, limited mitochondrial mobilization, and increased consumption, leading to suppressed SIRT1 and SIRT6 activity and accumulation of senescent cardiomyocytes. These changes were accompanied by diastolic dysfunction, myocardial hypertrophy, and fibrosis. In cultured cardiomyocytes, NAD+ depletion induced cellular senescence, which was reversed by supplementation with the NAD+ precursors nicotinamide riboside (NR) and dihydronicotinamide riboside (NRH). In aged male mice, two months of NR or NRH treatment suppressed senescence markers, improved diastolic function, and reduced hypertrophy and fibrosis. Mechanistically, both NR and NRH activated SIRT1 and suppressed cell cycle arrest markers. NRH induced more robust SIRT1 activation, which deacetylated SIRT6, promoting its binding to histones and enhancing DNA damage repair. In contrast, aged female mice exhibited diastolic dysfunction without significant decline in cardiac NAD+ levels and did not respond to NR or NRH treatment. NAD+ is a critical regulator of cardiomyocyte senescence in aging male hearts. NAD+ replenishment, particularly with NRH, reverses senescence-associated cardiac dysfunction through coordinated activation of SIRT1 and SIRT6. The sex-specific differences observed highlight distinct mechanisms underlying cardiac aging and emphasize the importance of considering biological sex in the development of NAD+-based therapeutic strategies.
中文摘要:心肌细胞衰老是心脏衰老的标志,与老年人舒张功能障碍和心力衰竭密切相关。有效延缓或逆转衰老心脏中心肌细胞衰老的策略仍有限。研究探讨了补充NAD+是否调控衰老过程中的心肌细胞衰老和心脏功能。在年轻和老年雌雄小鼠中评估了心室NAD+代谢、衰老标志物和心脏功能。老年雄性小鼠因生物合成受损、线粒体动员受限和消耗增加而出现心脏NAD+水平下降,导致SIRT1和SIRT6活性受抑及衰老心肌细胞积聚。这些变化伴随舒张功能障碍、心肌肥厚和纤维化。在培养的心肌细胞中,NAD+耗竭诱导细胞衰老,补充NAD+前体烟酰胺核糖(NR)和二氢烟酰胺核糖(NRH)可逆转该过程。老年雄性小鼠接受NR或NRH治疗两个月后,衰老标志物受抑,舒张功能改善,肥厚和纤维化减轻。机制上,NR和NRH均激活SIRT1并抑制细胞周期停滞标志物。NRH引起更强的SIRT1激活,使SIRT6去乙酰化,促进其与组蛋白结合并增强DNA损伤修复。老年雌性小鼠表现为舒张功能障碍,但心脏NAD+水平未见显著下降,且对NR或NRH治疗无反应。NAD+是衰老雄性心脏中心肌细胞衰老的关键调节因子。补充NAD+,尤其使用NRH,可通过协同激活SIRT1和SIRT6逆转衰老相关心脏功能障碍。观察到的性别差异提示心脏衰老机制不同,并强调在开发基于NAD+的治疗策略时考虑生物学性别的重要性。
Nature IF 56.1 2026-10-28 PMID: 42951956
The heart possesses a dynamic capacity to oxidize a variety of fuels, including glucose and lactate, to meet its energetic demands under diverse dietary, exertion and injury stressors1. Oxidation of carbohydrate substrates is thought to converge on the cytosolic generation of pyruvate, which is transported by the mitochondrial pyruvate carrier (MPC) for entry into the tricarboxylic acid cycle2. Here we find that glucose-derived carbon is oxidized in mouse myocardium even when the MPC is genetically ablated. Using genetic and pharmacological tools, we demonstrate that lactate monocarboxylate transporter 1 (MCT1, encoded by Slc16a1) is required for the oxidation of glucose carbon by MPC-deficient myocardium. We further observe that MCT1, traditionally localized to the plasma membrane, also resides in the inner mitochondrial membrane of mouse and human cardiomyocytes. Together with matrix-localized LDHB, MCT1 enables mitochondrial lactate conversion to pyruvate and NADH, directly fueling the electron transport chain. Loss of MCT1 impairs lactate oxidation, disrupts metabolic flexibility and accelerates the development of heart failure with increased mortality after hyperactivation of the neurohormonal axis or ischemia-reperfusion injury. Thus, the existence of a parallel lactate-based pathway for carbohydrate oxidation can sustain cardiac energetics and maintain myocardial structure and function under diverse stress conditions.
中文摘要:心脏具有动态氧化葡萄糖、乳酸等多种燃料的能力,以满足不同饮食、运动和损伤应激下的能量需求。碳水化合物底物氧化被认为汇聚于胞质丙酮酸生成,并由线粒体丙酮酸载体(MPC)转运进入三羧酸循环。本研究发现,即使MPC被基因敲除,小鼠心肌仍能氧化葡萄糖来源碳。利用遗传和药理学工具,证明乳酸单羧酸转运体1(MCT1,由Slc16a1编码)是MPC缺陷心肌氧化葡萄糖碳所必需。进一步观察到,传统定位于质膜的MCT1也存在于小鼠和人心肌细胞线粒体内膜。与基质定位的LDHB一起,MCT1使线粒体乳酸转化为丙酮酸和NADH,直接为电子传递链供能。MCT1缺失损害乳酸氧化,破坏代谢灵活性,并在神经激素轴过度激活或缺血再灌注损伤后加速心力衰竭发展、增加死亡率。因此,一条并行的基于乳酸的碳水化合物氧化途径可维持心脏能量学,并在多种应激条件下保持心肌结构和功能。
Circulation research IF 18.0 2026-10-28 PMID: 42948903
Heart failure with preserved ejection fraction (HFpEF) is a major clinical challenge characterized by diastolic dysfunction. Left ventricular stiffening and inflammation are hallmarks of HFpEF, yet the contribution of ECM (extracellular matrix) stiffness and the immune-stromal mechanisms driving ECM stiffening in cardiometabolic HFpEF remain poorly understood. We used the murine 2-hit model of cardiometabolic HFpEF, in which the combination of high-fat diet and hypertension induced by L-nitro-arginine-methyl ester causes diastolic dysfunction. We evaluated diastolic function by echocardiography and ECM mechanics by uniaxial tensile testing of decellularized cardiac tissue. Functional in vivo studies included genetic depletion of T cells, IFNγ (interferon-γ) knockout mice, and pharmacological lysyl oxidase inhibition. We combined cocultures of CD4+ T cells and cardiac fibroblasts with mechanical testing of cardiac ECM and molecular biology to elucidate cellular and molecular mechanisms. Left ventricular ECM stiffness strongly correlated with impaired diastolic function in experimental cardiometabolic HFpEF. Cardiac CD4+ T-cell infiltration was required for ECM stiffening and upregulation of lysyl oxidase enzymes in cardiac fibroblast. We discovered that CD4+ T-cell-derived IFNγ was required to induce LOXL3 in cardiac fibroblast, which increased ECM stiffness in vitro. Mechanistically, we demonstrate that a signaling axis involving IFNγ, PI3K (phosphoinositide 3-kinase), AKT, and HIF1α (hypoxia-inducible factor-1α) drives LOXL3 expression and subsequent collagen crosslinking. Genetic or pharmacological disruption of this IFNγ-HIF1α-LOXL3 axis attenuated adverse ECM remodeling and improved diastolic function. CD4+ T cells promote pathological ECM stiffening in cardiometabolic HFpEF through IFNγ-mediated, cardiac fibroblast LOXL3-dependent ECM crosslinking. Targeting this immune-stromal pathway may offer a novel therapeutic strategy for HFpEF.
中文摘要:射血分数保留的心力衰竭(HFpEF)是伴舒张功能障碍的重大临床挑战。左心室僵硬和炎症是HFpEF的标志,但细胞外基质(ECM)僵硬在心脏代谢性HFpEF中的作用及其驱动ECM僵硬的免疫-间质机制仍知之甚少。我们采用心脏代谢性HFpEF小鼠双打击模型,其中高脂饮食联合L-硝基精氨酸甲酯诱导的高血压导致舒张功能障碍。通过超声心动图评估舒张功能,并对去细胞心脏组织进行单轴拉伸测试评估ECM力学。体内功能研究包括遗传性T细胞清除、IFNγ(干扰素-γ)基因敲除小鼠和赖氨酰氧化酶药理抑制。我们将CD4+ T细胞与心脏成纤维细胞共培养,结合心脏ECM力学测试和分子生物学,阐明细胞与分子机制。在实验性心脏代谢性HFpEF中,左心室ECM刚度与舒张功能受损强相关。心脏CD4+ T细胞浸润是ECM僵硬和心脏成纤维细胞赖氨酰氧化酶上调所必需的。我们发现,CD4+ T细胞来源的IFNγ是诱导心脏成纤维细胞LOXL3所必需的,而LOXL3在体外增加ECM刚度。机制上,我们证明涉及IFNγ、PI3K(磷脂酰肌醇3-激酶)、AKT和HIF1α(缺氧诱导因子-1α)的信号轴驱动LOXL3表达及随后的胶原交联。遗传或药理阻断该IFNγ-HIF1α-LOXL3轴可减轻不良ECM重塑并改善舒张功能。CD4+ T细胞通过IFNγ介导、心脏成纤维细胞LOXL3依赖的ECM交联促进心脏代谢性HFpEF的病理性ECM僵硬。靶向这一免疫-间质通路可能为HFpEF提供新的治疗策略。
Circulation IF 41.3 2026-10-26 PMID: 42934204
No therapies exist to reverse right ventricular failure (RVF), and the molecular mechanisms that drive RVF remain understudied. We recently reported that the developmentally restricted noncanonical WNT receptor ROR2 (receptor tyrosine kinase-like orphan receptor 2) is upregulated in human RVF in proportion to severity of disease. Here we test the mechanistic role of ROR2 in RVF pathogenesis. ROR2 was overexpressed or knocked down in neonatal rat ventricular myocytes and then characterized using confocal microscopy, RNA sequencing, proteomics, proteostatic functional assays, and pacing to assess contractile properties. The impact of cardiac ROR2 expression was evaluated in mice by AAV9-mediated overexpression and by AAV9-mediated delivery of short hairpin RNA to knockdown ROR2 in a pulmonary artery banded pressure overload model of RVF. ROR2-modified mice were evaluated by echocardiography, histology, and right ventricle protein synthesis and proteasome capacity. In neonatal rat ventricular myocytes, we find that ROR2 profoundly dysregulates the coordination between protein translation and folding. This imbalance leads to excess protein clearance by the ubiquitin proteasome system with dramatic impacts on sarcomere and cytoskeletal structure and function. Inhibiting the ubiquitin proteasome system or restoring chaperone expression is sufficient to partially rescue ROR2-induced structural and contractile deficits in cardiomyocytes. In mice, forced cardiac ROR2 expression is sufficient to disrupt proteostasis and drive RVF, whereas conversely Ror2 knockdown partially rescues proteostasis and right ventricle structure and function in a pressure overload model of RVF. In sum, ROR2 is a key driver of RVF pathogenesis through proteostatic disruption and thus provides a promising target to treat RVF.
中文摘要:目前没有能够逆转右心室衰竭(RVF)的治疗方法,驱动RVF的分子机制仍研究不足。我们近期报道,发育阶段受限的非经典WNT受体ROR2(受体酪氨酸激酶样孤儿受体2)在人类RVF中表达上调,且上调程度与疾病严重度成比例。本研究检验ROR2在RVF发病机制中的作用。我们在新生大鼠心室肌细胞中过表达或敲低ROR2,随后用共聚焦显微镜、RNA测序、蛋白质组学、蛋白稳态功能实验以及起搏评估收缩特性进行表征。通过AAV9介导的过表达以及AAV9介导的短发夹RNA递送敲低ROR2,在肺动脉结扎压力超负荷RVF模型中评估心脏ROR2表达的影响。对ROR2修饰小鼠进行超声心动图、组织学以及右心室蛋白合成和蛋白酶体能力评估。在新生大鼠心室肌细胞中,我们发现ROR2显著扰乱蛋白翻译与折叠之间的协调。这种失衡导致泛素蛋白酶体系统过度清除蛋白,对肌节和细胞骨架的结构与功能产生显著影响。抑制泛素蛋白酶体系统或恢复分子伴侣表达足以部分挽救ROR2诱导的心肌细胞结构和收缩缺陷。在小鼠中,强制心脏表达ROR2足以破坏蛋白稳态并驱动RVF;相反,在压力超负荷RVF模型中敲低Ror2可部分挽救蛋白稳态以及右心室结构和功能。总之,ROR2通过破坏蛋白稳态成为RVF发病机制的关键驱动因素,因而提供了治疗RVF的有前景靶点。
Circulation research IF 18.0 2026-10-26 PMID: 42929140
Pulmonary hypertension due to left heart disease (PH-LHD) is a common complication of myocardial infarction (MI) and heart failure (HF). Myeloid inflammation is a major hallmark of both the local cardiac and systemic post-MI response, with resident and recruited monocyte-derived macrophages orchestrating each step of the ensuing inflammatory cascade, from clearance of dead cardiomyocytes to scar tissue formation. Similarly, myeloid inflammation is a key feature of the PH lung, driving remodeling of small pulmonary vessels. We thus hypothesized that MI-induced systemic myeloid inflammation contributes directly to the development of PH-LHD. We assessed expression of inflammatory adhesion molecules, as markers of vascular inflammatory activation and myeloid cell recruitment pathways, in patients with pulmonary arterial hypertension, PH-LHD, as well as in a PH-LHD rat model. We then induced MI and subsequent HF in 8- to 10-week-old female C57BL/6J mice via permanent ligation of the left anterior descending coronary artery. HF mice were then treated with a CCR2 (C-C chemokine receptor 2) antagonist to block monocyte recruitment and the development of PH-LHD was assessed at 6 weeks post-MI by a combination of invasive hemodynamics, flow cytometry, echocardiography, and lung histology. Expression of key inflammatory adhesion molecules, including VCAM1 and SELE, was increased in PH-LHD lungs from humans and rats. Following early post-MI development of HF with reduced ejection fraction, mice exhibited increased numbers of circulating monocytes, lung monocytes, and lung interstitial macrophages, as well as PH-LHD by 6 weeks, characterized by right ventricular hypertrophy, elevated right ventricular pressures, and lung vascular remodeling of small-to-medium-sized pulmonary vessels. Administration of the selective CCR2 antagonist RS102895 from day 10 post-MI to reduce monocyte tissue recruitment attenuated lung vascular remodeling, right ventricular systolic and diastolic pressures, right ventricular hypertrophy, and lung adhesion molecule expression at 6 weeks, compared with vehicle-treated controls, without improving the underlying left-sided HF. This proof-of-concept study demonstrates a causal role for CCR2-dependent myeloid cell recruitment in the progression from MI-induced HF to secondary pulmonary vascular disease.
中文摘要:左心疾病相关肺动脉高压(PH-LHD)是心肌梗死(MI)和心力衰竭(HF)的常见并发症。髓系炎症是MI后局部心脏和全身反应的主要标志,驻留和募集的单核细胞来源巨噬细胞协调后续炎症级联的每一步,从清除死亡心肌细胞到瘢痕组织形成。同样,髓系炎症是PH肺的关键特征,驱动小肺血管重构。我们因此假设MI诱导的全身髓系炎症直接促进PH-LHD发生。我们在肺动脉高压、PH-LHD患者以及PH-LHD大鼠模型中评估炎症黏附分子表达,作为血管炎症激活和髓系细胞募集通路的标志物。随后通过永久结扎左前降支冠状动脉,在8至10周龄雌性C57BL/6J小鼠中诱导MI及后续HF。HF小鼠接受CCR2(C-C趋化因子受体2)拮抗剂治疗以阻断单核细胞募集,并在MI后6周通过侵入性血流动力学、流式细胞术、超声心动图和肺组织学联合评估PH-LHD发展。来自人和大鼠的PH-LHD肺中,包括VCAM1和SELE在内的关键炎症黏附分子表达增加。MI后早期发生射血分数降低的心力衰竭后,小鼠在6周时表现为循环单核细胞、肺单核细胞和肺间质巨噬细胞数量增加,并出现PH-LHD,特征为右心室肥厚、右心室压力升高以及中小型肺血管的肺血管重构。从MI后第10天开始给予选择性CCR2拮抗剂RS102895以减少单核细胞组织募集,与溶媒对照相比,在6周时减轻肺血管重构、右心室收缩压和舒张压、右心室肥厚及肺黏附分子表达,但未改善潜在的左心衰竭。这项概念验证研究证明CCR2依赖性髓系细胞募集在MI诱导的HF向继发性肺血管疾病进展中具有因果作用。

2脑卒中/脑血管病 (12篇)

临床研究 (8篇)

Stroke IF 11.1 2026-10-30 PMID: 42961033
Patients with medium or distal vessel occlusion stroke are heterogeneous. Randomized trials show no net benefit of endovascular treatment (EVT) over best medical treatment (BMT) alone, which may mask heterogeneity of treatment effect. We used an externally developed machine learning model to predict excellent early neurological outcome (EENO) with BMT alone and examined whether the effect of EVT differed across predicted risk. A Tabular Prior-Data Fitted Network (TabPFN) model was trained to predict EENO (24-hour National Institutes of Health Stroke Scale [NIHSS] score of 0-2) in patients with medium or distal vessel occlusion treated with BMT alone in a local Bernese Stroke Registry. This model was applied to patients from the DISTAL randomized trial (55 centers and 11 countries), who were randomized to EVT plus BMT or BMT alone. We tested for interaction between predicted EENO and treatment allocation on the primary outcome (90-day modified Rankin Scale shift), repeating this using admission NIHSS alone. In the development cohort (n=257, 42% female, and mean age 70.4±14.8 years), 54% achieved EENO. In the DISTAL cohort (270 BMT alone, 269 EVT plus BMT, 44% female, and mean age 74.9±12.0 years), the model showed moderate external discrimination (area under the receiver operating characteristic curve 0.73). A significant interaction was found between predicted EENO and treatment effect (Pinteraction=0.012): in 152 patients predicted to achieve EENO, EVT was associated with worse 90-day modified Rankin Scale score (common odds ratio, 0.48 [95% CI, 0.27-0.84]), whereas no treatment effect was seen in 387 patients predicted not to achieve EENO (common odds ratio 1.13 [95% CI, 0.79-1.60]). A model using admission NIHSS alone showed comparable discrimination (area under the receiver operating characteristic curve 0.71) and a common odds ratio for EVT of 0.47 (95% CI, 0.25-0.89) in patients with an NIHSS score of ≤4 and a common odds ratio of 1.05 (95% CI, 0.75-1.47) in patients with an NIHSS score of >4 (Pinteraction=0.029). EVT was harmful in patients with medium or distal vessel occlusion predicted to achieve EENO with BMT alone, and an NIHSS-alone model performed comparably to the multivariable model. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05029414.
中文摘要:中等或远端血管闭塞卒中患者具有异质性。随机试验显示血管内治疗(EVT)相较单纯最佳药物治疗(BMT)无净获益,这可能掩盖治疗效应的异质性。我们使用外部开发的机器学习模型预测单纯BMT下的优良早期神经功能结局(EENO),并检验EVT效应是否随预测风险不同而变化。在本地伯尔尼卒中登记中,使用表格先验数据拟合网络(TabPFN)模型预测接受单纯BMT的中等或远端血管闭塞患者的EENO(24小时美国国立卫生研究院卒中量表[NIHSS]评分0-2分)。该模型应用于DISTAL随机试验(55个中心、11个国家)中随机接受EVT加BMT或单纯BMT的患者。我们检验预测EENO与治疗分配对主要结局(90天改良Rankin量表移位)的交互作用,并用入院NIHSS单独重复该分析。在开发队列(n=257,42%女性,平均年龄70.4±14.8岁)中,54%达到EENO。在DISTAL队列(单纯BMT 270例,EVT加BMT 269例,44%女性,平均年龄74.9±12.0岁)中,模型显示中等外部区分度(受试者工作特征曲线下面积0.73)。预测EENO与治疗效应之间存在显著交互作用(交互作用P=0.012):在预测可达到EENO的152例患者中,EVT与较差的90天改良Rankin量表评分相关(共同比值比0.48[95%CI,0.27-0.84]),而在预测不能达到EENO的387例患者中未见治疗效应(共同比值比1.13[95%CI,0.79-1.60])。仅使用入院NIHSS的模型显示可比区分度(受试者工作特征曲线下面积0.71),在NIHSS评分≤4分的患者中EVT的共同比值比为0.47(95%CI,0.25-0.89),在NIHSS评分>4分的患者中为1.05(95%CI,0.75-1.47)(交互作用P=0.029)。在预测单纯BMT可达到EENO的中等或远端血管闭塞患者中,EVT有害,仅用NIHSS的模型与多变量模型表现相当。URL: https://www.clinicaltrials.gov;唯一标识符:NCT05029414。
Stroke IF 11.1 2026-10-30 PMID: 42960430
The ABCD2 score is widely used to stratify stroke risk after transient neurological events. We aimed to evaluate the association between the ABCD2 score and the risk of subsequent ischemic stroke among patients with diffusion-weighted imaging (DWI)-positive (DWI+) or DWI-negative (DWI-) findings for the index event. We pooled individual participant data from 3 multicenter cohorts including patients presenting with transient or minor neurological events. Patients presenting with transient neurological symptoms, a normal neurological examination, and available DWI for the index event were included. Associations between the ABCD2 score and 90-day ischemic stroke risk were analyzed separately in the DWI+ and DWI- groups using logistic regression models adjusted for sex, atrial fibrillation, and study source. Among 2014 patients (1143 [56.8%] men; median age 67 years), the median ABCD2 score was 4 (interquartile range, 3-5), and 504 (25.0%) were DWI+. Ischemic stroke occurred within 90 days in 20 patients (4.0%) in the DWI+ group and 33 (2.2%) in the DWI- group. The ABCD2 score was associated with stroke risk in the DWI- group (per 1-point increase, odds ratio, 1.36 [95% CI, 1.04-1.79]), but this relationship was not significant in the DWI+ group (per 1-point increase, odds ratio, 1.08 [95% CI, 0.76-1.53]). When stratified ABCD2 score into 0 to 3, 4 to 5, and 6 to 7, the predicted 90-day stroke risks were 3.2%, 3.9%, and 4.5% in the DWI+ group (per 1-category increase, odds ratio, 1.23 [95% CI, 0.63-2.40]) and 1.0%, 2.3%, and 4.1% in the DWI- group (per 1-category increase, odds ratio, 1.88 [95% CI, 1.11-3.20]), respectively. The ABCD2 score was associated with 90-day stroke risk among patients with DWI- findings. Patients with both a low ABCD2 score and DWI- findings had a particularly low risk of subsequent stroke, which may inform risk stratification and clinical decision-making after transient neurological events.
中文摘要:ABCD2评分广泛用于短暂神经事件后卒中风险分层。我们旨在评估ABCD2评分与索引事件弥散加权成像(DWI)阳性(DWI+)或阴性(DWI-)患者后续缺血性卒中风险之间的关系。汇总3个多中心队列的个体参与者数据,纳入表现为短暂或轻微神经事件的患者。纳入标准为短暂神经症状、神经系统查体正常且索引事件有可用DWI。分别在DWI+和DWI-组中,采用校正性别、心房颤动和研究来源的logistic回归模型分析ABCD2评分与90天缺血性卒中风险的关系。2014例患者(1143例[56.8%]男性;中位年龄67岁)中,ABCD2评分中位数为4(四分位距3-5),504例(25.0%)为DWI+。90天内缺血性卒中发生于DWI+组20例(4.0%)和DWI-组33例(2.2%)。ABCD2评分与DWI-组卒中风险相关(每增加1分,比值比1.36[95%CI,1.04-1.79]),但该关系在DWI+组不显著(每增加1分,比值比1.08[95%CI,0.76-1.53])。将ABCD2评分分为0-3、4-5和6-7后,DWI+组预测90天卒中风险分别为3.2%、3.9%和4.5%(每增加1个类别,比值比1.23[95%CI,0.63-2.40]),DWI-组分别为1.0%、2.3%和4.1%(每增加1个类别,比值比1.88[95%CI,1.11-3.20])。ABCD2评分与DWI-患者的90天卒中风险相关。ABCD2评分低且DWI-的患者后续卒中风险尤其低,这可能有助于短暂神经事件后的风险分层和临床决策。
Stroke IF 11.1 2026-10-29 PMID: 42953960
Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy. This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days. Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35-3.21]; P=0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29-2.44]; P=0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05-2.77]; P=0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34-1.22]; P=0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group. Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05624190.
中文摘要:近期试验显示,机械取栓成功再通后联合动脉内溶栓可能有助于获得优良结局,但结果并不一致。本研究按取栓后扩大脑梗死溶栓分级(eTICI)对患者分层,考察动脉内溶栓的疗效与安全性。这是ANGEL-TNK试验(急性大血管闭塞机械取栓成功再通后动脉内重组人TNK-tPA溶栓;多中心、随机、开放标签、终点盲法)的预设二次分析。入组前循环大血管闭塞患者,在达到eTICI 2b50至3级再灌注后按1:1随机接受动脉内替奈普酶(TNK,0.125 mg/kg)或标准内科管理。主要结局为90天改良Rankin量表评分0至1分的比例。安全性结局包括48小时内症状性颅内出血和任何颅内出血,以及90天内死亡。253例入组患者中,164例属eTICI 2b50至67组,89例属eTICI 2c至3组。在eTICI 2b50至67患者中,血管内治疗(EVT)后动脉内TNK与90天改良Rankin量表评分0至1分比例更高相关(39例[44.8%]对15例[19.5%];相对危险度2.08[95% CI,1.35-3.21];P=0.001),在eTICI 2c至3患者中未见此关联(12例[30.8%]对19例[38.0%];相对危险度0.84[95% CI,0.29-2.44];P=0.749)。eTICI 2c至3组中,动脉内TNK使48小时内任何颅内出血增加(13例[33.3%]对10例[20.0%];相对危险度1.70[95% CI,1.05-2.77];P=0.032),eTICI 2b50至67组则无此差异(18例[20.7%]对25例[32.5%];相对危险度0.65[95% CI,0.34-1.22];P=0.176)。两组48小时内症状性颅内出血及90天内死亡均未见差异。EVT后动脉内TNK可为eTICI 2b50至67患者带来90天改良Rankin量表评分0至1分的优良结局获益,eTICI 2c至3患者则无此获益;后者任何颅内出血风险升高,但症状性颅内出血与死亡风险未增加。网址:https://www.clinicaltrials.gov;唯一标识号:NCT05624190。
Stroke IF 11.1 2026-10-29 PMID: 42953937
Patients with atrial fibrillation who experience ischemic stroke despite oral anticoagulation (breakthrough stroke) remain at high risk of recurrent vascular events and death. Although inflammation has been associated with thromboembolic risk, its prognostic role in breakthrough stroke remains unclear. We investigated whether a composite inflammatory burden index was associated with adverse outcomes after breakthrough ischemic stroke. We conducted a multicenter retrospective cohort study of consecutive patients with breakthrough ischemic stroke from the ASPERA-R registry. Inflammatory burden was assessed using admission neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and C-reactive protein. Biomarkers were log-transformed, standardized using Z scores, and combined into a composite inflammatory burden index. Patients were classified as having high (upper tertile) or lower inflammatory burden (lower 2 tertiles). Outcomes included new 90-day ischemic events (recurrent ischemic stroke, transient ischemic attack, or systemic embolism), 24-hour hemorrhagic transformation, and 90-day moderate-to-severe bleeding, intracranial hemorrhage, and mortality. Inverse probability of treatment weighting accounted for center, demographics, vascular risk factors and comorbidities, anticoagulation, competing stroke causes, baseline National Institutes of Health Stroke Scale, prestroke modified Rankin Scale, and time to blood collection. Among 1649 patients enrolled in ASPERA-R, 671 patients from 14 centers had complete biomarker data (median age, 80.1 years [interquartile range, 73.5-85.5]; 52.3% female). Of these, 223 (33.2%) had high inflammatory burden, and 448 (66.8%) had lower inflammatory burden. After weighting, high inflammatory burden was associated with increased risks of ischemic events at 90 days (hazard ratio, 1.53 [95% CI, 1.02-2.30]), all-cause mortality (hazard ratio, 1.70 [95% CI, 1.17-2.47]), moderate-to-severe bleeding (hazard ratio, 2.92 [95% CI, 1.04-8.17]), and hemorrhagic transformation at 24 hours (odds ratio, 2.18 [95% CI, 1.43-3.33]). In breakthrough ischemic stroke, high inflammatory burden was associated with increased risks of recurrent ischemic events, mortality, hemorrhagic transformation, and major bleeding. A composite of routinely available inflammatory biomarkers may help identify patients with higher residual vascular risk.
中文摘要:在接受口服抗凝治疗仍发生缺血性卒中的心房颤动患者(突破性卒中)中,复发血管事件和死亡风险仍然较高。炎症与血栓栓塞风险相关,但其在突破性卒中中的预后作用尚不明确。我们探讨复合炎症负荷指数是否与突破性缺血性卒中后的不良结局相关。研究基于ASPERA-R登记,纳入连续突破性缺血性卒中患者,开展多中心回顾性队列研究。炎症负荷采用入院时中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、系统性免疫炎症指数和C反应蛋白评估。生物标志物经对数转换、Z评分标准化后合成为复合炎症负荷指数。患者分为高炎症负荷组(上三分位)和较低炎症负荷组(下两个三分位)。结局包括90天新发缺血事件(复发性缺血性卒中、短暂性脑缺血发作或系统性栓塞)、24小时出血转化,以及90天中重度出血、颅内出血和死亡。采用逆概率治疗加权校正中心、人口学特征、血管危险因素和合并症、抗凝治疗、竞争性卒中病因、基线美国国立卫生研究院卒中量表评分、卒中前改良Rankin量表评分及采血时间。ASPERA-R登记的1649例患者中,14个中心的671例具有完整生物标志物数据(中位年龄80.1岁[四分位间距73.5-85.5];女性52.3%)。其中223例(33.2%)为高炎症负荷,448例(66.8%)为较低炎症负荷。加权后,高炎症负荷与90天缺血事件风险增加相关(风险比1.53[95% CI 1.02-2.30])、全因死亡(风险比1.70[95% CI 1.17-2.47])、中重度出血(风险比2.92[95% CI 1.04-8.17])及24小时出血转化(比值比2.18[95% CI 1.43-3.33])风险增加相关。在突破性缺血性卒中中,高炎症负荷与复发性缺血事件、死亡、出血转化和大出血风险增加相关。由常规可获得的炎症生物标志物构成的复合指标可能有助于识别残余血管风险较高的患者。
Stroke IF 11.1 2026-10-29 PMID: 42953922
The aim of this study was to investigate the association between PAR-1 (protease-activated receptor-1) gene F2R polymorphisms and the efficacy of clopidogrel therapy initiated within a time window extended to 72 hours for mild ischemic stroke or transient ischemic attack with intracranial or extracranial atherosclerosis. This was a secondary analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), a randomized clinical trial conducted at 222 centers across China between September 2018 and October 2022. Four single-nucleotide polymorphisms (F2R [IVSn-14 A/T, rs168753], CYP2C19*2 [681G>A, rs4244285], CYP2C19*3 [636G>A, rs4986893], and CYP2C19*17 [-806C>T, rs12248560]) were genotyped among 5791 patients treated with clopidogrel plus aspirin (n=2894) or aspirin alone (n=2897). The primary efficacy outcome was new stroke, and the safety outcome was moderate-to-severe bleeding within 90 days. Cox proportional hazards models were used to estimate the interaction between treatment assignment and F2R polymorphisms for the primary outcomes. Among 5791 patients, 1698 (29.3%) were AA homozygotes, and 4093 (70.7%) were the T-allele carriers (AT/TT) for F2R IVSn-14 polymorphisms. Compared with aspirin alone, clopidogrel-aspirin reduced the rate of new stroke in patients with AT/TT genotype (7.1% versus 9.2%; hazard ratio [HR], 0.77 [95% CI, 0.62-0.95]; P=0.02) but not in carriers of the AA genotype (7.7% versus 8.1%; HR, 0.95 [95% CI, 0.67-1.33]; P=0.75; P=0.30 for interaction). For the safety outcome, the risk of moderate-to-severe bleeding between the clopidogrel plus aspirin group and aspirin group was not significant in patients with AT/TT genotype (HR, 1.91 [95% CI, 0.85-4.29]; P=0.12) or AA genotype (HR, 1.97 [95% CI, 0.59-6.55]; P=0.27; P=0.97 for interaction). Moreover, the presence of CYP2C19 loss-of-function allele carrier status did not alter the effect of the F2R polymorphisms on clinical outcomes, although a marginally reduced risk of stroke with clopidogrel-aspirin versus aspirin alone was observed only among carriers of at least 1 F2R IVSn-14 T allele without CYP2C19 loss-of-function allele (HR, 0.73 [95% CI, 0.52-1.01]; P=0.06). With the treatment initiated within a time window extended to 72 hours after mild ischemic stroke or transient ischemic attack onset, we found that clopidogrel plus aspirin may reduce the occurrence of new stroke specifically in F2R IVSn-14 T-allele carriers. This finding suggests that the clopidogrel-aspirin treatment may appear more beneficial among carriers of the F2R IVSn-14 T allele. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.
中文摘要:本研究旨在探讨PAR-1(蛋白酶激活受体-1)基因F2R多态性与氯吡格雷治疗的关系及疗效;该治疗用于伴有颅内或颅外动脉粥样硬化的轻型缺血性卒中或短暂性脑缺血发作,并在发病后延长至72小时的时间窗内启动。该研究为INSPIRES试验(急性高风险颅内或颅外动脉粥样硬化强化他汀与抗血小板治疗)的二次分析;该随机临床试验于2018年9月至2022年10月在中国222个中心开展。研究对5791例接受氯吡格雷联合阿司匹林(n=2894)或单用阿司匹林(n=2897)治疗的患者进行了4个单核苷酸多态性的基因分型:F2R IVSn-14 A/T(rs168753)、CYP2C19*2 681G>A(rs4244285)、CYP2C19*3 636G>A(rs4986893)和CYP2C19*17 -806C>T(rs12248560)。主要疗效结局为新发卒中,安全性结局为90天内中重度出血。采用Cox比例风险模型估计治疗分组与F2R多态性对主要结局的交互作用。5791例患者中,F2R IVSn-14多态性AA纯合子1698例(29.3%),T等位基因携带者(AT/TT)4093例(70.7%)。与单用阿司匹林相比,氯吡格雷联合阿司匹林降低了AT/TT基因型患者的新发卒中发生率(7.1%比9.2%;风险比[HR] 0.77 [95% CI 0.62-0.95];P=0.02);AA基因型携带者中未见降低(7.7%比8.1%;HR 0.95 [95% CI 0.67-1.33];P=0.75;交互作用P=0.30)。安全性结局方面,AT/TT基因型患者中氯吡格雷联合阿司匹林组与阿司匹林组的中重度出血风险差异无统计学意义(HR 1.91 [95% CI 0.85-4.29];P=0.12);AA基因型患者中该差异同样无统计学意义(HR 1.97 [95% CI 0.59-6.55];P=0.27;交互作用P=0.97)。CYP2C19功能缺失等位基因携带状态并未改变F2R多态性对临床结局的影响;仅在携带至少1个F2R IVSn-14 T等位基因且不携带CYP2C19功能缺失等位基因的患者中,观察到氯吡格雷联合阿司匹林较单用阿司匹林有边缘性降低卒中风险(HR 0.73 [95% CI 0.52-1.01];P=0.06)。在轻型缺血性卒中或短暂性脑缺血发作发病后时间窗延长至72小时内启动治疗的情况下,氯吡格雷联合阿司匹林可能仅在F2R IVSn-14 T等位基因携带者中减少新发卒中的发生。该结果提示,氯吡格雷联合阿司匹林治疗在F2R IVSn-14 T等位基因携带者中可能获益更多。URL: https://www.clinicaltrials.gov;唯一标识符:NCT03635749。
Blood IF 23.9 2026-10-26 PMID: 42932254
In this pragmatic long-term follow-up of the SPRINT randomized trial cohort, rates of recurrent stroke and all-cause mortality did not differ significantly by an initial fixed low- versus moderate-dose of hydroxyurea over 4.9 years, with events clustering in the first year.
中文摘要:在SPRINT随机试验队列的实用性长期随访中,初始固定低剂量与中等剂量羟基脲治疗4.9年期间,复发性卒中发生率和全因死亡率无显著差异,事件集中发生在第一年。
JAMA neurology IF 23.6 2026-10-26 PMID: 42931749
For US patients presenting to the emergency department (ED) with transient ischemic attack (TIA), guidelines recommend resource-intensive multimodal evaluation to optimize secondary stroke prevention. These resources are not available in all EDs, and national patterns of ED TIA care are not well described. To evaluate national trends in ED TIA care, including discharge practices, imaging use, and associated costs, and to assess patient- and hospital-level factors associated with these patterns. This was a retrospective repeated cross-sectional study of ED visits using the 2013-2021 National Emergency Department Sample of the Healthcare Cost and Utilization Project, a weighted, nationally representative annual sample of ED visits in the US. TIA and stroke encounters during the study period were identified among patients aged 18 years or older by a first-listed International Classification of Diseases, Ninth Revision or Tenth Revision code for TIA or stroke diagnosis. Analyses were performed from October 2024 to April 2026. Calendar year. ED discharge; imaging use among discharged TIA encounters; and inflation-adjusted ED cost per discharged encounter. This study included 2 151 408 (95% CI, 2 107 855-2 194 960) weighted ED visits for TIA (1 194 630 [55.5%] female; mean [SEM] age, 69.8 [0.05] years). Adjusted models found the predicted probability of discharge increased from 45% (95% CI, 43%-46%) in 2013 to 66% (95% CI, 64%-68%) in 2021 (P < .001 for trend). During this time, mean ED charges increased from $1746 (95% CI, $1662-$1830) to $2755 (95% CI, $2674-$2836) per encounter (P < .001 for trend). Imaging use among discharged TIA encounters increased substantially, including computed tomography angiography (predicted probability, 4% [95% CI, 3%-4%] in 2013 vs 45% [95% CI, 42%-47%] in 2021; P < .001 for trend) and magnetic resonance imaging (predicted probability, 17% [95% CI, 16%-19%] in 2013 vs 53% [95% CI, 50%-55%] in 2021; P < .001 for trend). Rate of discharge was higher in rural encounters than in urban encounters for all years studied, and the rate of magnetic resonance imaging use was lower. This cross-sectional study demonstrates a shift in TIA care over time that suggests increased use of the ED to expedite evaluation for TIA that previously occurred during a brief hospitalization. This approach has consequences in terms of cost and ED throughput and may not be as feasible in rural hospitals as it is in urban hospitals.
中文摘要:在美国,因短暂性脑缺血发作(TIA)到急诊科就诊的患者,指南推荐采用资源密集型的多模式评估,以优化卒中二级预防。这些资源并非所有急诊科都具备,全国范围内急诊科TIA诊疗模式也缺乏充分描述。研究旨在评估急诊科TIA诊疗的全国趋势,包括离院实践、影像使用和相关费用,并分析与这些模式相关的患者层面和医院层面因素。研究为回顾性重复横断面研究,使用2013—2021年医疗费用与利用项目全国急诊科样本中的急诊就诊数据,该样本为美国急诊就诊的加权、全国代表性年度样本。研究期间TIA和卒中就诊通过18岁及以上患者首位列出的国际疾病分类第九版或第十版TIA或卒中诊断编码识别。分析时间为2024年10月至2026年4月。暴露变量为日历年。结局包括急诊离院;离院TIA就诊中的影像使用;每次离院就诊经通胀调整的急诊费用。研究纳入2 151 408次加权TIA急诊就诊(95%CI,2 107 855-2 194 960),其中女性1 194 630次(55.5%),平均(SEM)年龄69.8(0.05)岁。调整模型显示,离院预测概率从2013年的45%(95%CI,43%-46%)升至2021年的66%(95%CI,64%-68%)(趋势P<.001)。同期每次就诊平均急诊费用从1746美元(95%CI,1662-1830美元)升至2755美元(95%CI,2674-2836美元)(趋势P<.001)。离院TIA就诊中的影像使用大幅增加,包括CT血管成像(预测概率,2013年4%[95%CI,3%-4%] vs 2021年45%[95%CI,42%-47%];趋势P<.001)和磁共振成像(预测概率,2013年17%[95%CI,16%-19%] vs 2021年53%[95%CI,50%-55%];趋势P<.001)。研究各年份农村就诊的离院率均高于城市就诊,磁共振成像使用率则较低。这项横断面研究显示TIA诊疗随时间发生转变,提示急诊科更多用于加快TIA评估,而这类评估过去常在短暂住院期间完成。该方式在费用和急诊流转方面带来后果,在农村医院可能不如城市医院可行。
Acta neuropathologica IF 10.3 2026-10-24 PMID: 42925335
Although hypertension is the leading modifiable risk factor for cerebrovascular disease, less is known about the relation of late-life change in blood pressure (BP) and cerebrovascular pathology beyond brain infarcts. Our previous work found sex-specific associations between declining systolic BP (SBP) and cognitive decline in late-life, suggesting that cerebrovascular pathology may be an upstream contributor to these sex differences. However, postmortem studies have not examined whether BP change differentially relates to vascular brain pathology in men and women, despite well-established sex differences in BP trajectories and cerebrovascular pathology. We examined associations between change in late-life BP and postmortem cerebrovascular (arteriolosclerosis, atherosclerosis, and cerebral amyloid angiopathy) pathology from 2033 community-dwelling older adults (mean baseline age = 79.7 [SD = 7.1] years; 69% women) from four longitudinal cohort studies with brain autopsy (mean age-at-death = 89.8 [6.6] years). Person-specific late-life BP slopes estimated from annual clinical evaluations over an average of 9.1 [5.7] years were entered in ordinal regressions adjusted for age-at-death, sex, antihypertensive medication use, and BP slope × sex, age-at-death × sex, and BP slope × age-at-death interactions. Faster SBP decline was associated with greater severity of arteriolosclerosis (OR = 1.24, 95%CI 1.08-1.42) and atherosclerosis (OR = 1.41, 95%CI 1.22-1.63). A sex × SBP slope interaction (p = 0.01) revealed a stronger association of SBP decline with arteriolosclerosis severity in women than men. This longitudinal, clinical-pathologic study of older decedents showed sex differences in the association of declining SBP in late-life with severity of arteriolosclerosis, extending prior associations with cognitive decline to cerebrovascular pathology, and suggests potential for longitudinal BP monitoring for precision medicine approaches in cerebrovascular disease risk stratification.
中文摘要:高血压是脑血管病最主要的可干预危险因素,但晚年血压变化与脑梗死以外的脑血管病理之间的关系仍不清楚。我们此前发现,晚年收缩压下降与认知下降存在性别特异性关联,提示脑血管病理可能是这些性别差异的上游因素。尽管血压轨迹和脑血管病理的性别差异已较明确,尸检研究尚未检验男性和女性中血压变化是否与脑血管病理存在不同关联。本研究纳入四项纵向队列中含脑尸检的2033名社区居住老年人(基线平均年龄79.7岁,SD 7.1;女性69%),分析晚年血压变化与尸检脑血管病理(小动脉硬化、动脉粥样硬化和脑淀粉样血管病)的关联,死亡时平均年龄89.8岁(SD 6.6)。基于平均9.1年(SD 5.7)年度临床评估估算个体晚年血压斜率,纳入序数回归,并校正死亡年龄、性别、降压药使用以及血压斜率×性别、死亡年龄×性别、血压斜率×死亡年龄交互项。收缩压下降较快与小动脉硬化(OR=1.24,95%CI 1.08-1.42)和动脉粥样硬化(OR=1.41,95%CI 1.22-1.63)更严重相关。性别×收缩压斜率交互作用(p=0.01)显示,女性中收缩压下降与小动脉硬化严重程度的关联强于男性。这项针对老年死者的纵向临床-病理研究显示,晚年收缩压下降与小动脉硬化严重程度的关联存在性别差异,将既往与认知下降的关联扩展至脑血管病理,并提示纵向血压监测在脑血管病风险分层精准医学中的潜在价值。

基础研究 (4篇)

Acta biomaterialia IF 10.4 2026-10-30 PMID: 42962843
Proper cerebral artery function is essential for maintaining the brain's microenvironment. The multilayered organization of cellular and extracellular matrix (ECM) constituents enables large cerebral arteries to accommodate pulse pressure and ensure both effective blood distribution and protection of the microcirculation. However, aging and disease induce compositional and structural remodeling in cerebral arteries, such as the middle cerebral artery (MCA), which can alter biomechanical properties and increase susceptibility to cerebrovascular conditions including atherosclerosis and aneurysms, both major contributors to stroke. Understanding how age-related changes in arterial structure and composition influence biomechanical behavior is critical for improving prediction of cerebrovascular risk. In this study, we characterized the age-dependent elastic and viscoelastic properties of human MCAs and related these changes to ECM structure and composition using imaging and biochemical assays. Our results demonstrate that aging is associated with increased stiffness and stress relaxation in MCAs. Biochemical analyses revealed age-related increases in collagen and glycosaminoglycan (GAG) content, both of which correlated with altered mechanical properties. Histological staining further showed denser collagen organization within the adventitia and elevated GAG presence, consistent with mechanical and biochemical findings. Additionally, multiphoton imaging under mechanical loading provided insight into layer-specific collagen reorganization in the adventitia. Collectively, these findings elucidate key age-dependent alterations in the structure-function relationship of human cerebral arteries and provide a mechanistic basis for increased cerebrovascular risk with aging. STATEMENT OF SIGNIFICANCE: Age-related remodeling of the extracellular matrix is a fundamental driver of tissue dysfunction, yet its effects on human cerebral artery mechanics remain poorly understood. In this study, we combine biomechanical testing, biochemical assays, histology, and multiphoton microscopy to characterize structural and functional remodeling of human middle cerebral arteries across a broad age range. We demonstrate that aging is associated with increased arterial stiffness and viscoelastic relaxation, accompanied by elevated collagen and glycosaminoglycan content. By directly linking extracellular matrix composition and organization to biomechanical function, this work provides new insights into the mechanisms governing cerebrovascular aging. These findings establish an important structure function framework for understanding vascular tissue remodeling and have broader implications for age related vascular dysfunction, mechanobiology, and biomaterials research.
中文摘要:脑动脉功能正常对维持脑微环境至关重要。细胞与细胞外基质(ECM)成分的多层组织使大型脑动脉能够承受脉压,并保证有效血液分布与微循环保护。衰老和疾病会诱导脑动脉(如大脑中动脉,MCA)发生成分和结构重塑,改变生物力学特性并增加动脉粥样硬化和动脉瘤等脑血管病的易感性,二者均为卒中的重要原因。理解动脉结构和成分的年龄相关变化如何影响生物力学行为,对改进脑血管风险预测至关重要。本研究表征人MCA的年龄依赖性弹性和黏弹性特性,并用影像学和生化检测将这些变化与ECM结构和成分相联系。结果显示,衰老与MCA刚度增加和应力松弛增强相关。生化分析显示胶原和糖胺聚糖(GAG)含量随年龄增加,二者均与力学特性改变相关。组织学染色进一步显示外膜内胶原排列更致密、GAG存在增加,与力学和生化结果一致。机械加载下的多光子成像为了解外膜中层特异性胶原重组提供了线索。这些结果共同阐明了人脑动脉结构-功能关系的关键年龄依赖性改变,并为衰老相关脑血管风险增加提供机制基础。意义声明:ECM的年龄相关重塑是组织功能障碍的基本驱动因素,但其对人脑动脉力学的影响仍知之甚少。本研究结合生物力学测试、生化检测、组织学和多光子显微镜,在较宽年龄范围内表征人MCA的结构和功能重塑。研究显示衰老与动脉刚度增加和黏弹性松弛增强相关,并伴随胶原和GAG含量升高。通过将ECM成分和组织方式直接与生物力学功能相联系,本工作为脑血管衰老机制提供新认识。这些发现为理解血管组织重塑建立了重要的结构-功能框架,并对年龄相关血管功能障碍、力学生物学和生物材料研究具有更广泛意义。
Stroke IF 11.1 2026-10-30 PMID: 42960431
Recovery after ischemic stroke is limited by persistent cerebrovascular dysfunction, but the mechanisms regulating vascular repair remain poorly understood. Prnd (Prnd/Doppel) is a prion family protein expressed in the cerebrovascular endothelium during development. We tested the hypothesis that endothelial Prnd promotes vascular repair and functional recovery in the adult brain after stroke. Using middle cerebral artery occlusion in mice, we compared wild-type and Prnd-null mice and evaluated endothelial-specific Prnd overexpression. Functional recovery was assessed by behavioral testing, while infarct volume, brain atrophy, vascular architecture, blood-brain barrier integrity, and macrophage/microglia infiltration were evaluated histologically. Vascular signaling and endothelial cell junctional proteins were examined mechanistically. Acute infarct volumes were comparable between wild-type and Prnd-null mice, indicating that Prnd does not substantially affect initial ischemic injury. During recovery, however, Prnd-null mice exhibited disrupted cerebrovascular architecture, increased blood-brain barrier disruption, greater brain atrophy, and increased macrophage/microglial infiltration. Conversely, endothelial Prnd overexpression improved long-term functional recovery without altering acute infarct size and was associated with enhanced blood-brain barrier integrity and vascular remodeling. Mechanistically, Prnd manipulation was associated with enhanced VEGF-A (vascular endothelial growth factor-A) signaling and increased endothelial cell tight junction protein expression. Prnd is dispensable for acute ischemic injury but promotes cerebrovascular remodeling, blood-brain barrier restoration, and functional recovery after stroke. These findings identify endothelial Prnd as a regulator of poststroke vascular repair and a potential therapeutic target for enhancing long-term recovery.
中文摘要:缺血性卒中后的恢复受持续脑血管功能障碍限制,而血管修复的调控机制仍不清楚。Prnd(Prnd/Doppel)是一种发育期脑血管内皮表达的朊蛋白家族蛋白。研究检验内皮Prnd促进成年脑卒中后血管修复与功能恢复的假说。采用小鼠大脑中动脉闭塞模型,比较野生型与Prnd缺失小鼠,并评估内皮特异性Prnd过表达。功能恢复通过行为学测试评估,梗死体积、脑萎缩、血管结构、血脑屏障完整性和巨噬细胞/小胶质细胞浸润通过组织学评估。机制上检查血管信号和内皮细胞连接蛋白。野生型与Prnd缺失小鼠急性梗死体积相当,提示Prnd对初始缺血性损伤无明显影响。恢复期Prnd缺失小鼠出现脑血管结构破坏、血脑屏障破坏增加、脑萎缩加重和巨噬细胞/小胶质细胞浸润增加。相反,内皮Prnd过表达改善长期功能恢复而不改变急性梗死体积,并与血脑屏障完整性和血管重塑增强相关。机制上,Prnd调控与VEGF-A(血管内皮生长因子-A)信号增强及内皮细胞紧密连接蛋白表达增加相关。Prnd对急性缺血性损伤并非必需,但促进卒中后脑血管重塑、血脑屏障恢复和功能恢复。这些发现表明内皮Prnd是卒中后血管修复的调控因子,也是增强长期恢复的潜在治疗靶点。
Advanced healthcare materials IF 11.0 2026-10-29 PMID: 42958811
Stroke causes substantial reorganization of neural activity and connectivity in the peri-infarct cortex during functional recovery. Tracking these changes at high resolution, however, remains difficult. Mechanical mismatch of conventional rigid neural probes is exacerbated in the fragile peri-infarct region, destabilizing the tissue-electrode interface and limiting long-term recording. Here, we present a fully soft, liquid metal-based multichannel neural interface that enables stable electrophysiological recording in freely moving mice. Using this platform, we performed longitudinal recordings before and after ischemic stroke, enabling within-animal comparisons. We applied complementary analyses of population-level latent dynamics and functional connectivity, capturing network-level coordination and pairwise interactions. Both analyses revealed acute suppression followed by partial recovery without restoration of the pre-stroke state. Instead, neural networks reorganized into a distinct and reproducible functional configuration. These findings establish soft liquid metal neural interfaces combined with population-level analysis as a useful approach for resolving neural reorganization during stroke recovery.
中文摘要:卒中后功能恢复过程中,梗死周围皮层神经活动与连接发生显著重组,但高分辨率追踪这些变化仍困难。传统刚性神经探针的力学失配在脆弱的梗死周围区域更为突出,使组织-电极界面不稳定并限制长期记录。我们提出一种全软液态金属多通道神经接口,可在自由活动小鼠中稳定进行电生理记录。利用该平台,我们在缺血性卒中前后开展纵向记录,实现同一动物内比较。采用群体水平潜在动力学与功能连接的互补分析,捕捉网络层面的协调与成对交互。两类分析均显示急性抑制后部分恢复,但未恢复至卒中前状态;神经网络重组为一种独特且可重复的功能构型。这些结果确立软液态金属神经接口结合群体水平分析作为解析卒中恢复期神经重组的有用方法。
Nature neuroscience IF 20.3 2026-10-28 PMID: 42951997
Brain myeloid cells, including infiltrating monocyte-derived macrophages (MDMs) and microglia, play critical roles in ischemic brain injury, clearing debris and shaping neuroinflammation and neurological outcomes. Yet the underlying mechanisms remain unclear. Here, using single-cell RNA sequencing and fate mapping with an MDM-specific Ms4a3creERT2-Ai14 mouse line, we identified serotonin receptor Htr2b+ MDMs as a crucial cell population involved in resolving neuroinflammation within the ischemic penumbra. Htr2b+ MDMs significantly accumulate in the peri-infarct region and exhibit enhanced phagocytosis and inflammation-resolving gene signatures. Mechanistically, Htr2b activation promotes nuclear translocation of Tfe3, a key lysosomal regulator, enhancing lysosomal biogenesis and supporting phagocytic activity. MDM-specific Htr2b ablation impairs debris clearance, exacerbates neuroinflammation and ischemic injury, whereas pharmacological agonism or Tfe3 activation restores lysosomal biogenesis in brain MDMs and improves post-stroke outcomes. Thus we demonstrate a previously unrecognized Htr2b+ MDM subset that integrates serotonin signaling to license intrinsic phagocytic function, alleviating ischemic brain injury.
中文摘要:脑髓系细胞,包括浸润性单核细胞来源巨噬细胞(MDMs)和小胶质细胞,在缺血性脑损伤中发挥关键作用,负责清除碎片并塑造神经炎症和神经功能结局。然而其潜在机制仍不清楚。利用单细胞RNA测序和MDM特异性Ms4a3creERT2-Ai14小鼠系的命运图谱,识别出5-羟色胺受体Htr2b+ MDMs是参与缺血半暗带内神经炎症消退的关键细胞群。Htr2b+ MDMs显著聚集于梗死周围区域,并表现出增强的吞噬作用和炎症消退基因特征。机制上,Htr2b激活促进关键溶酶体调节因子Tfe3的核转位,增强溶酶体生物发生并支持吞噬活性。MDM特异性Htr2b缺失损害碎片清除,加重神经炎症和缺血性损伤,而药理学激动或Tfe3激活可恢复脑MDMs中的溶酶体生物发生并改善卒中后结局。因此,证明了一个先前未被认识的Htr2b+ MDM亚群,其整合5-羟色胺信号以许可内在吞噬功能,减轻缺血性脑损伤。

3心肌病/心肌炎 (6篇)

临床研究 (5篇)

Molecular biomedicine IF 13.0 2026-10-30 PMID: 42961724
Hypertrophic cardiomyopathy (HCM) exhibits great prognostic heterogeneity, necessitating the identification of high-risk patients for timely treatment. This study aimed to find novel prognostic biomarkers directly from diseased cardiac tissue to improve risk stratification of HCM. We utilized a myocardial transcriptome discovery cohort (n = 246; median follow-up 6.8 years) alongside two independent plasma validation cohorts (Beijing, n = 1,238; follow-up 2.5 years; Xi'an, n = 402; follow-up 4.8 years). The primary and secondary endpoints were cardiovascular death and sudden cardiac death (SCD), respectively. In the discovery cohort, myocardial expression of CECR1 (cat eye syndrome chromosome region, candidate 1, also known as ADA2, Adenosine Deaminase 2) demonstrated the strongest association with cardiovascular death (P = 9.6 × 10-5). Plasma CECR1 levels correlated modestly but significantly with myocardial expression. In the Beijing validation cohort, decreased plasma CECR1 predicted increased risks of cardiovascular death (adjusted hazard ratio (HR) 3.731, P < 0.001) and SCD (adjusted HR 7.398, P < 0.001), with areas under the curves (AUCs) of 0.720 and 0.798, respectively. These findings were replicated in the Xi'an validation cohort. Integrating plasma CECR1 into the HCM Risk-SCD model significantly enhanced its predictive performance, increasing the AUC from 0.723 to 0.845 (P = 0.031) in the Beijing validation cohort and consistently improving it from 0.600 to 0.781 (P = 0.018) in the Xi'an validation cohort. In conclusion, CECR1 represents a novel prognostic biomarker of HCM. Measurement of CECR1 may improve risk stratification by facilitating the identification of individuals at higher risk of cardiovascular mortality. CECR1 assessment may provide additional information for SCD risk evaluation and support clinical decision-making regarding implantable cardioverter-defibrillator therapy.
中文摘要:肥厚型心肌病(HCM)的预后异质性很大,需要识别高风险患者以及时治疗。本研究旨在直接从病变心肌组织中寻找新的预后生物标志物,以改善HCM的风险分层。我们使用了一个心肌转录组发现队列(n=246;中位随访6.8年)以及两个独立的血浆验证队列(北京,n=1238;随访2.5年;西安,n=402;随访4.8年)。主要终点和次要终点分别为心血管死亡和心源性猝死(SCD)。在发现队列中,CECR1(猫眼综合征染色体区域候选基因1,又称ADA2,腺苷脱氨酶2)的心肌表达与心血管死亡的关联最强(P=9.6×10-5)。血浆CECR1水平与心肌表达呈中等程度但显著的关联。在北京验证队列中,血浆CECR1降低预示心血管死亡风险增加(校正风险比HR 3.731,P<0.001)和SCD风险增加(校正HR 7.398,P<0.001),曲线下面积(AUC)分别为0.720和0.798。这些结果在西安验证队列中得到重复。将血浆CECR1纳入HCM Risk-SCD模型显著提高了其预测性能,北京验证队列AUC从0.723升至0.845(P=0.031),西安验证队列AUC从0.600升至0.781(P=0.018)。CECR1是HCM的一种新预后生物标志物。检测CECR1可能通过帮助识别心血管死亡风险较高的个体来改善风险分层。CECR1评估可为SCD风险评估提供额外信息,并支持关于植入式心律转复除颤器治疗的临床决策。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42217207
Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating transthyretin (TTR) by targeting TTR mRNA. We present baseline data from an ongoing trial, CARDIO-TTRansform, evaluating eplontersen in patients with TTR amyloid cardiomyopathy (ATTR-CM) and compare findings across previous ATTR-CM trials. We evaluated 1432 patients enrolled in CARDIO-TTRansform from March 2020 to July 2023 who received ≥1 dose of study intervention (eplontersen or placebo) and had ≥1 post-baseline measurement. Mean (standard deviation) age was 76.4 (7.1) years; 9.4% were female; 88.8% were White. A total of 211 (14.7%) patients had hereditary/variant ATTR-CM (ATTRv-CM); Val122Ile (p.Val142Ile) was the most common genotype (n = 130). Patients spanned New York Heart Association functional classes I (n = 192), II (n = 997), and III (n = 243); 62.6% were National Amyloidosis Centre disease stage 1. Median (interquartile range) N-terminal pro-B-type natriuretic peptide was 2025 (1296-3465) pg/ml; n = 51 measured >8500 pg/ml. Median (interquartile range) high-sensitivity troponin T was 50 (35-69) pg/ml and mean left ventricular ejection fraction was 55.7% (9.7%). At baseline, 57.2% were on TTR stabilizer; 18.4% were on sodium-glucose co-transporter-2 inhibitors. The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of care for ATTR-CM. Overall, blinded baseline data suggest that CARDIO-TTRansform provides a unique opportunity to determine the clinical benefits of eplontersen in a contemporary setting and in clinically relevant subgroups of patients with ATTR-CM. NCT04136171.
中文摘要:Eplontersen 是一种反义寡核苷酸,通过靶向 TTR mRNA 抑制肝脏生成循环中的转甲状腺素蛋白(TTR)。该报告呈现正在进行的 CARDIO-TTRansform 试验的基线数据,该试验评估 eplontersen 对转甲状腺素蛋白淀粉样心肌病(ATTR-CM)患者的作用,并与既往 ATTR-CM 试验进行比较。研究分析 2020 年 3 月至 2023 年 7 月入组 CARDIO-TTRansform 的 1432 例患者,均接受至少 1 剂研究干预(eplontersen 或安慰剂)且至少有 1 次基线后测量。平均年龄 76.4 岁(标准差 7.1);女性占 9.4%;白人占 88.8%。211 例(14.7%)为遗传型/变异型 ATTR-CM(ATTRv-CM),Val122Ile(p.Val142Ile)是最常见基因型(n=130)。患者覆盖纽约心脏协会心功能分级 I 级(n=192)、II 级(n=997)与 III 级(n=243);62.6% 为英国国家淀粉样变性中心疾病 1 期。N 末端 B 型利钠肽原中位数(四分位距)为 2025(1296-3465)pg/ml;51 例测得值高于 8500 pg/ml。高敏肌钙蛋白 T 中位数(四分位距)为 50(35-69)pg/ml,左心室射血分数均值 55.7%(9.7%)。基线时 57.2% 使用 TTR 稳定剂,18.4% 使用钠-葡萄糖共转运蛋白 2 抑制剂。CARDIO-TTRansform 的基线特征与既往 ATTR-CM 试验相符,但该试验纳入的患者疾病严重程度范围较广,并正在接受 ATTR-CM 的当代标准治疗。总体来看,盲态基线数据提示 CARDIO-TTRansform 为在当代背景下以及在有临床意义的 ATTR-CM 患者亚组中确定 eplontersen 的临床获益提供了独特机会。NCT04136171。
European journal of heart failure IF 10.3 2026-10-28 PMID: 41904995
Vutrisiran was shown to maintain overall health status, as measured by the 23-item Kansas City Cardiomyopathy Questionnaire-overall summary score (KCCQ-OSS), in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B. We assessed individual KCCQ components to better contextualize changes in KCCQ-OSS in a manner relevant to patients and clinicians. In this analysis of HELIOS-B, a double-blind, randomized, placebo-controlled trial of vutrisiran in ATTR-CM, we assessed treatment effect on mean score changes from baseline to 30 months for each 23 KCCQ components (scaled from 0 [worst] to 100 [best]) using a multivariable linear regression model. We further assessed overall changes in KCCQ-OSS as a function of age in both treatment groups to estimate the age-equivalent benefit observed. Of 654 participants in HELIOS-B, 486 completed KCCQ assessment both at baseline and 30 months (age: 75 ± 6 years; 93% male; 91% wild-type ATTR; baseline KCCQ-OSS: 74.6 ± 18.9). Vutrisiran, compared with placebo, was associated with more favourable changes in most KCCQ components (median: +3.8, range: -0.9 to +7.6). The greater differences favouring vutrisiran were observed in 'hurrying or jogging', 'walking on level ground,' and 'discouraged/down with heart failure'. Similar or greater benefits with vutrisiran were observed in patients not on tafamidis at baseline. KCCQ-OSS at 30 months was inversely related to age, with vutrisiran shifting the age-KCCQ-OSS relationship by approximately 11 years (95%CI: 3-20 years). In HELIOS-B, vutrisiran was associated with improvement in a wide range of individual KCCQ components, with the greatest benefits observed in physical limitations and quality-of-life domains.
中文摘要:HELIOS-B 研究显示,vutrisiran 可维持转甲状腺素蛋白淀粉样变性伴心肌病(ATTR-CM)患者的总体健康状态,以堪萨斯城心肌病问卷总体总结评分(KCCQ-OSS,23 个条目)衡量。本研究进一步评估 KCCQ 各组成条目,以便从与患者和临床医生相关的角度更好地解释 KCCQ-OSS 的变化。该分析基于 HELIOS-B 试验,这是一项在 ATTR-CM 中评价 vutrisiran 的双盲、随机、安慰剂对照试验;采用多变量线性回归模型评估治疗对 23 个 KCCQ 条目各自从基线至 30 个月平均评分变化的影响(各条目评分范围 0 分[最差]至 100 分[最佳])。另按年龄评估两个治疗组 KCCQ-OSS 的总体变化,以估算观察到的等效年龄获益。HELIOS-B 共纳入 654 例受试者,其中 486 例在基线和 30 个月均完成 KCCQ 评估(年龄 75±6 岁;男性 93%;野生型 ATTR 91%;基线 KCCQ-OSS 74.6±18.9)。与安慰剂相比,vutrisiran 与多数 KCCQ 条目更有利的变化相关(中位数 +3.8,范围 -0.9 至 +7.6)。偏向 vutrisiran 的较大差异见于「匆忙行走或慢跑」、「平地行走」和「因心力衰竭感到气馁/情绪低落」条目。在基线未使用 tafamidis 的患者中,vutrisiran 的获益相似或更大。30 个月时 KCCQ-OSS 与年龄呈负相关,vutrisiran 使年龄与 KCCQ-OSS 的关系约前移 11 年(95%CI:3-20 年)。在 HELIOS-B 中,vutrisiran 与广泛的 KCCQ 各条目改善相关,其中体力受限和生活质量领域的获益最大。
European journal of heart failure IF 10.3 2026-10-28 PMID: 41771146
Acoramidis is an oral transthyretin (TTR) stabilizer that achieves near-complete (≥90%) TTR stabilization. This post-hoc analysis evaluated response categories based on NT-proBNP concentration and 6-minute walk distance (6MWD) changes among participants with transthyretin amyloid cardiomyopathy (ATTR-CM) in the phase 3 ATTRibute-CM trial. Clinically meaningful improvement (CMI) was defined as a decrease from baseline to Month 30 in NT-proBNP of >700 ng/L and >30%, and separately, a 6MWD increase of >35 m. Data from 611 participants were analysed (409: acoramidis; 202: placebo). Median baseline NT-proBNP and 6MWD values were 2273 ng/L and 365 m in the acoramidis group and 2274 ng/L and 352 m in the placebo group, respectively. A significantly higher proportion of participants in the acoramidis group reached CMI in NT-proBNP or 6MWD (22.7%) compared with the placebo group (8.9%; OR 3.0, 95% CI 1.8-5.1; P < .001). Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. These findings suggest that the treatment paradigm of ATTR-CM may evolve from slowing disease progression to achieving improvement.
中文摘要:Acoramidis 是一种口服转甲状腺素蛋白(TTR)稳定剂,可实现接近完全的 TTR 稳定(≥90%)。这项事后分析基于 3 期 ATTRibute-CM 试验中转甲状腺素蛋白淀粉样心肌病(ATTR-CM)受试者,评估以 NT-proBNP 浓度和 6 分钟步行距离(6MWD)变化划分的反应类别。具有临床意义的改善(CMI)定义为从基线至第 30 个月 NT-proBNP 下降 >700 ng/L 且 >30%,以及另行定义 6MWD 增加 >35 m。共分析 611 名受试者(409 例 acoramidis;202 例安慰剂)。Acoramidis 组基线 NT-proBNP 和 6MWD 中位数分别为 2273 ng/L 和 365 m,安慰剂组分别为 2274 ng/L 和 352 m。Acoramidis 组达到 NT-proBNP 或 6MWD 的 CMI 的比例为 22.7%,显著高于安慰剂组的 8.9%(OR 3.0,95% CI 1.8-5.1;P < .001)。Acoramidis 使相当一部分 ATTR-CM 受试者在 NT-proBNP 浓度或 6MWD 上较基线达到 CMI。这些结果提示 ATTR-CM 的治疗范式可能从延缓疾病进展转向实现改善。
Circulation IF 41.3 2026-10-27 PMID: 42741831
Disruption of MYBPC3 precursor mRNA splicing is a frequent genetic cause of hypertrophic cardiomyopathy (HCM). Most often, it reflects changes at canonical sites or the creation of novel splice sites. Prediction tools usually prioritize splice variants with lower efficiency when they are distant from canonical sites. These elusive variants may explain HCM in patients considered genotype-negative after DNA testing. Massively parallel sequencing identified the previously unreported deep-intronic variant MYBPC3 c.2308+227G>A in a cohort of genotype-negative patients with HCM from Salamanca, Spain. SpliceAI predicted a benign effect (Δ score, 0.03). However, its recurrent detection prompted us to conduct extensive analyses to investigate its pathogenicity, including genetic testing, clinical assessment, family studies, splicing assays, and haplotype reconstruction. We identified 35 unrelated HCM probands carrying c.2308+227G>A, plus 46 relatives from 27 families, yielding 81 confirmed carriers. Of these, 56 (69%) met diagnostic criteria for HCM (66% male; mean age, 53±15 years). By age 60 years, cumulative penetrance was estimated to be 81% in women and 96% in men. The combined logarithm of the odds score of 5.51 across 20 informative families provided strong evidence of cosegregation. During follow-up of probands, no significant differences were observed in heart failure, arrhythmic events, atrial fibrillation, or mortality when compared with cohorts carrying other pathogenic MYBPC3 variants. Blood splicing assays, confirmed in cardiac tissue, showed that c.2308+227G>A disrupts splicing by the use of pre-existing cryptic donor (c.2308+299) and acceptor (c.2309-580) splice sites, generating 2 misspliced mRNAs with partial intron retention or cryptic exon inclusion, which encode truncated proteins. These cryptic sites are the leading natural, unannotated missplicing events in intron 23, and some of the most frequent across the whole MYBPC3 precursor mRNA, as revealed by SpliceVault analysis of RNA sequencing databases. This deep-intronic variant does not alter essential splice motifs but promotes the use of pre-existing cryptic sites, likely through gain of splicing regulatory enhancer elements. The identification of a shared haplotype among HCM probands carrying this variant explains its recurrent detection, consistent with an ancient founder effect. MYBPC3 c.2308+227G>A is a pathogenic splice-altering variant that causes HCM by amplifying natural missplicing events. These background splicing errors help explain how this elusive variant disrupts splicing without creating novel essential splice sites, thereby expanding the known mechanisms by which deep-intronic variants alter MYBPC3 splicing and ultimately contribute to HCM pathogenesis. Elusive MYBPC3 splice-altering variants should be considered in HCM patients with an unresolved genetic origin of disease.
中文摘要:MYBPC3 前体 mRNA 剪接异常是肥厚型心肌病(HCM)常见的遗传学病因,多数表现为经典剪接位点的改变或新剪接位点的产生。预测工具通常对远离经典位点的剪接变异给出较低权重,这类难以识别的变异可以解释 DNA 检测后被判为基因型阴性的 HCM 患者。研究对来自西班牙萨拉曼卡的基因型阴性 HCM 患者队列行大规模平行测序,发现此前未报道的深内含子变异 MYBPC3 c.2308+227G>A。SpliceAI 预测其为良性(Δ 评分 0.03)。该变异被反复检出,促使研究开展包括基因检测、临床评估、家系调查、剪接实验与单倍型重建在内的系统分析以判断其致病性。研究共识别 35 例携带 c.2308+227G>A 的无亲缘关系 HCM 先证者,以及来自 27 个家系的 46 名亲属,确认携带者 81 例。其中 56 例(69%)符合 HCM 诊断标准(男性 66%;平均年龄 53±15 岁)。至 60 岁时,累积外显率估计女性为 81%、男性为 96%。20 个信息性家系合并的优势对数(LOD)评分为 5.51,为共分离提供了有力证据。先证者随访期间,与携带其他致病性 MYBPC3 变异的队列相比,心力衰竭、心律失常事件、心房颤动及死亡率均无显著差异。血液剪接实验并在心脏组织中得到确认,显示 c.2308+227G>A 通过启用既有的隐匿供体位点(c.2308+299)和受体位点(c.2309-580)破坏剪接,产生 2 种误剪接 mRNA,分别伴有部分内含子保留或隐匿外显子纳入,编码截短蛋白。SpliceVault 对 RNA 测序数据库的分析显示,这些隐匿位点是第 23 内含子中最主要的天然未注释误剪接事件,也是整个 MYBPC3 前体 mRNA 中最常见者之一。该深内含子变异不改变必需的剪接基序,而是可能通过获得剪接调控增强子元件,促进既有隐匿位点的使用。携带该变异的 HCM 先证者之间存在共享单倍型,解释了其反复检出,符合古老奠基者效应。MYBPC3 c.2308+227G>A 是一种致病性剪接改变变异,通过放大天然误剪接事件导致 HCM。这些背景性剪接错误解释了该难以识别的变异如何在不产生新的必需剪接位点的情况下破坏剪接,从而拓展了深内含子变异改变 MYBPC3 剪接并最终参与 HCM 发病的已知机制。对遗传学病因未明的 HCM 患者,应考虑难以识别的 MYBPC3 剪接改变变异。

基础研究 (1篇)

Nature cardiovascular research IF 12.6 2026-10-29 PMID: 42957901
Arrhythmogenic cardiomyopathy is a heritable cardiac disorder commonly linked to alterations in desmosomal proteins. While desmosomal dysfunction is a recognized pathogenic mechanism, the early molecular remodeling that precedes clinical manifestations remains unclear. Here we used a mouse model with inducible cardiomyocyte-specific knockout of Pkp2 (encoding plakophilin-2) and performed time-resolved mass spectrometry-based proteomics to map disease progression from early PKP2 loss to structural remodeling. Molecular changes preceded phenotypic abnormalities, and spatial asymmetry was evident, with earlier and more pronounced proteome remodeling in the right ventricle despite comparable PKP2 depletion in both ventricles. Downregulation of protein networks spanning desmosomes, sarcomeres and mitochondria suggests their functional coupling, with mitochondrial remodeling emerging as an early and progressively worsening feature. Intervention with honokiol attenuated changes across the major protein networks, highlighting mitochondrial pathways as promising therapeutic targets and honokiol as a potential strategy to delay arrhythmogenic cardiomyopathy progression. Our findings provide critical insights into the concealed stage of disease progression and identify molecular targets for early intervention.
中文摘要:致心律失常性心肌病是一种遗传性心脏疾病,常与桥粒蛋白改变相关。桥粒功能障碍是已知的致病机制,但临床表现出现之前的早期分子重塑仍不清楚。我们使用可诱导心肌细胞特异性敲除Pkp2(编码plakophilin-2)的小鼠模型,开展基于质谱的时间分辨蛋白质组学,以描绘从早期PKP2缺失到结构重塑的疾病进展。分子改变先于表型异常出现,并存在空间不对称性:尽管两个心室的PKP2耗竭程度相当,右心室的蛋白质组重塑出现更早、更明显。桥粒、肌节和线粒体相关蛋白网络的下调提示这些网络之间存在功能耦联,其中线粒体重塑作为早期且进行性加重的特征出现。和厚朴酚干预可减弱主要蛋白网络的变化,突显线粒体通路是有前景的治疗靶点,和厚朴酚则可能成为延缓致心律失常性心肌病进展的策略。这些发现为疾病进展的隐匿阶段提供了关键认识,并确定了早期干预的分子靶点。

4心肌梗死/ACS (5篇)

临床研究 (3篇)

European heart journal IF 45.3 2026-10-29 PMID: 42954950
Suspected myocardial infarction in patients with acute chest pain at rest is one of the most common diagnostic categories leading to emergency hospital admission and emergency department overcrowding worldwide. Efforts are being made to improve the efficiency of currently used triage and diagnostic work-up strategies. Despite major advances in recent years with the use of high-sensitivity cardiac troponin, challenges still exist regarding how to accurately and rapidly rule out or rule in myocardial infarction, as current strategies are relatively slow due to the need for serial troponin measurements. The 2023 European Society of Cardiology (ESC) guidelines recommend a 0 h/1 h or a 0 h/2 h high-sensitivity troponin diagnostic algorithm, instead of the previously suggested 0 h/3 h diagnostic protocol, to reduce the time required to discharge patients with suspected acute coronary syndrome/myocardial infarction. The ESC endorsed algorithms are not without difficulty, and alternative ways of improving triaging have been proposed, particularly a dual biomarker rule-out strategy involving the combined measurement of copeptin and troponin. Supporters of the dual biomarker strategy argue that a timely optimized algorithm can potentially allow the safe rule-out of myocardial infarction earlier than currently used strategies. In the present Great Debate article, two expert teams discuss the 'pros' and 'cons' of implementing single vs dual biomarker strategies for the rule-in and rule-out of myocardial infarction, under the moot topic 'A dual biomarker strategy improves the triage of patients with suspected acute coronary syndrome'. They address in detail many of the controversial issues currently affecting everyday clinical practice and provide insightful comments on how to best triage patients presenting with suspected acute myocardial infarction.
中文摘要:静息状态下急性胸痛患者疑似心肌梗死是全球急诊入院和急诊科拥挤最常见的诊断类别之一。目前正努力提高现有分诊与诊断检查策略的效率。尽管近年来高敏心肌肌钙蛋白的应用取得重要进展,如何准确、快速排除或确诊心肌梗死仍存在挑战,因为当前策略需要连续检测肌钙蛋白,速度相对较慢。2023年欧洲心脏病学会指南推荐0小时/1小时或0小时/2小时高敏肌钙蛋白诊断算法,替代先前建议的0小时/3小时诊断方案,以缩短疑似急性冠脉综合征/心肌梗死患者出院所需时间。欧洲心脏病学会认可的算法并非没有困难,已有替代方式用于改进分诊,尤其是联合检测和肽素与肌钙蛋白的双生物标志物排除策略。支持双生物标志物策略者认为,及时优化的算法可能比当前策略更早安全排除心肌梗死。在本篇辩论文章中,两个专家团队围绕「双生物标志物策略改善疑似急性冠脉综合征患者的分诊」这一议题,讨论实施单一与双生物标志物策略用于心肌梗死确诊和排除的利弊。他们详细讨论当前影响日常临床实践的诸多争议问题,并就如何最佳分诊疑似急性心肌梗死患者提出见解。
European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 41055556
To assess the prognostic value of expiratory carbon monoxide (CO) levels in patients admitted for myocardial infarction (MI). In this prospective study, expiratory CO levels were measured upon admission in consecutive patients hospitalized for MI across 39 centres. The primary outcome was 1-year all-cause death. Secondary outcomes included 1-year major adverse cardiac events (MACEs: cardiovascular death and recurrent MI) and in-hospital major adverse events (MAEs: death, severe ventricular arrhythmia, cardiogenic shock, and the need for mechanical ventilation). The prognostic value of expiratory CO levels was further evaluated using machine learning (ML) analysis. Among 717 patients (64 ± 13 years; 75% males; 33% active smokers; 43% ST-elevation MI), elevated expiratory CO levels (>11 ppm) were found in 79 patients (11%). Patients with elevated CO levels had a higher rate of 1-year all-cause mortality compared with those without (16.5% vs. 5.2%, P < 0.001). Elevated CO levels were independently associated with 1-year all-cause death across various adjustment models: comorbidities [odds ratio (95% confidence interval): 3.6 (1.7-7.5)], clinical parameters of in-hospital severity [4.5 (2.3-8.8)], and respiratory parameters [6.3 (3.1-12.8)]. Elevated CO levels were also independently associated with a significant increase in 1-year MACEs and in-hospital MAEs. Machine learning analysis identified CO level as one of the most important predictors of adverse events, compared with other known prognosticators. This is the first study to demonstrate that elevated expiratory CO levels upon admission are independently associated with an increased risk of 1-year all-cause mortality, 1-year MACEs, and in-hospital MAEs in patients hospitalized for MI.
中文摘要:评估因心肌梗死(MI)入院患者呼气一氧化碳(CO)水平的预后价值。这项前瞻性研究在39个中心连续纳入因MI住院的患者,入院时测定呼气CO水平。主要结局为1年全因死亡。次要结局包括1年主要不良心血管事件(MACE:心血管死亡和再发MI)及院内主要不良事件(MAE:死亡、严重室性心律失常、心源性休克和需要机械通气)。进一步采用机器学习分析评估呼气CO水平的预后价值。717例患者(64 ± 13岁;男性75%;现吸烟者33%;ST段抬高型MI 43%)中,79例(11%)呼气CO水平升高(>11 ppm)。CO水平升高患者1年全因死亡率高于未升高者(16.5% vs. 5.2%,P < 0.001)。在多种校正模型中,CO水平升高与1年全因死亡独立相关:合并症模型比值比(95%置信区间)为3.6(1.7-7.5),院内严重程度临床参数模型为4.5(2.3-8.8),呼吸参数模型为6.3(3.1-12.8)。CO水平升高还与1年MACE及院内MAE显著增加独立相关。机器学习分析显示,与其他已知预后因素相比,CO水平是不良事件最重要的预测因素之一。这是首个研究,表明因MI住院患者入院时呼气CO水平升高与1年全因死亡、1年MACE及院内MAE风险增加独立相关。
European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 40146252
While the association between daily smoking and myocardial infarction (MI) risk is well-established, little is known concerning the relationship between occasional smoking and MI risk. In this Norwegian study, we aimed to investigate the risk of first-time MI among occasional smokers over a 20-year follow-up period. In this prospective cohort study, data on smoking habits and relevant risk factors were collected from 15 617 participants enrolled in the fifth and/or sixth survey of the Tromsø Study. Participants were followed up for the first MI from 2001 to 2021. Smoking, age, marriage/cohabitant status, body mass index, hypertension, cholesterol, alcohol consumption, education, physical activity, and sex were included as covariates in Cox proportional hazard models. At baseline, 9.2% of participants were occasional smokers. Over the follow-up period, 1297 participants experienced their first MI. Adjusted for covariates, we observed a 41% increased MI risk among occasional smokers compared to never smokers [hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.11-1.80]. We noted a dose-response relationship in the hazards of smoking, categorized as never, former, occasional, and daily. Compared with never smokers, the relative risk of MI in occasional smokers was twice as high in women (HR 2.08, 95% CI 1.43-3.04) and 11% higher in men (HR 1.11, 95% CI 0.81-1.52). This study highlights an elevated risk of MI among occasional smokers, with higher relative risk in women. The result emphasizes that there is no safe threshold for smoking, underlining the importance of smoking cessation.
中文摘要:每日吸烟与心肌梗死风险之间的关联已经明确,但偶尔吸烟与心肌梗死风险的关系所知较少。这项挪威研究旨在分析偶尔吸烟者在20年随访期内首次心肌梗死的风险。该前瞻性队列研究纳入特罗姆瑟研究第五次和/或第六次调查的15617名参与者,收集吸烟习惯及相关危险因素数据,并随访2001至2021年首次心肌梗死。Cox比例风险模型纳入吸烟、年龄、婚姻/同居状况、体质指数、高血压、胆固醇、饮酒、教育、体力活动和性别作为协变量。基线时9.2%的参与者为偶尔吸烟者。随访期间1297名参与者发生首次心肌梗死。校正协变量后,偶尔吸烟者相较从不吸烟者的心肌梗死风险增加41%(风险比1.41,95%置信区间1.11-1.80)。吸烟风险呈剂量反应关系,分类为从不吸烟、既往吸烟、偶尔吸烟和每日吸烟。与从不吸烟者相比,偶尔吸烟女性的心肌梗死相对风险为两倍(风险比2.08,95%置信区间1.43-3.04),男性高11%(风险比1.11,95%置信区间0.81-1.52)。该研究显示偶尔吸烟者心肌梗死风险升高,女性的相对风险更高。结果强调吸烟不存在安全阈值,戒烟具有重要意义。

基础研究 (2篇)

Cardiovascular research IF 12.5 2026-10-31 PMID: 42963081
β3 adrenergic receptor (ADRB3) has recently emerged as an important regulator of cardiovascular homeostasis. However, the role of endothelial ADRB3 in cardiac repair after myocardial infarction (MI) remains unclear. As endothelial dysfunction critically drives post-MI remodeling, we hypothesized that ADRB3 preserves endothelial integrity and protects the heart from ischemic injury. Endothelial cell-specific ADRB3 knockout mice and adeno-associated virus serotype 9 (AAV9)-mediated endothelial ADRB3 overexpression mice were subjected to MI. Single-cell RNA sequencing (scRNA-seq) was performed to characterize cellular heterogeneity and endothelial phenotypic changes. scRNA-seq revealed enhanced EndoMT and activated TGFβ signaling in ADRB3-deficient hearts, accompanied by accelerated fibrotic remodeling and exacerbated ischemic injury. In contrast, endothelial ADRB3 overexpression suppressed EndoMT, reduced fibrosis, and improved cardiac function following MI. In vitro, ADRB3 knockdown induced EndoMT and endothelial dysfunction, whereas ADRB3 overexpression attenuated hypoxia-induced mesenchymal activation. Mechanistically, proximity ligation assay, co-immunoprecipitation, and mass spectrometry identified TGFβ receptor 2 (TGFβR2) as an endogenous binding partner of ADRB3. ADRB3 interaction with TGFβR2 prevented SMAD2 recruitment to TGFβR1 and inhibited downstream SMAD2 phosphorylation. Moreover, endothelial-specific TGFβR2 knockdown using AAV9 mitigated cardiac injury in ADRB3-deficient mice following MI. These findings demonstrate that endothelial ADRB3 protects against ischemic heart injury by limiting TGFβR2-SMAD2-dependent EndoMT, highlighting its role as a critical endothelial regulator and a potential therapeutic target for myocardial repair.
中文摘要:β3肾上腺素能受体(ADRB3)近来被视为心血管稳态的重要调节因子。然而,内皮ADRB3在心肌梗死(MI)后心脏修复中的作用仍不清楚。内皮功能障碍是MI后重构的关键驱动因素,因此我们假设ADRB3可维持内皮完整性并保护心脏免受缺血性损伤。研究对血管内皮细胞特异性ADRB3敲除小鼠和腺相关病毒血清型9(AAV9)介导的内皮ADRB3过表达小鼠实施MI。采用单细胞RNA测序(scRNA-seq)刻画细胞异质性和内皮表型变化。scRNA-seq显示,ADRB3缺失心脏中内皮-间质转化(EndoMT)增强、TGFβ信号激活,并伴有纤维化重构加速和缺血性损伤加重。内皮ADRB3过表达则抑制EndoMT、减少纤维化并改善MI后心脏功能。体外实验中,ADRB3敲低诱导EndoMT和内皮功能障碍,而ADRB3过表达减轻缺氧诱导的间质活化。机制上,邻位连接试验、免疫共沉淀和质谱鉴定TGFβ受体2(TGFβR2)为ADRB3的内源性结合伙伴。ADRB3与TGFβR2相互作用阻止SMAD2募集至TGFβR1,并抑制下游SMAD2磷酸化。采用AAV9敲低内皮特异性TGFβR2可减轻ADRB3缺失小鼠MI后的心脏损伤。这些发现表明,内皮ADRB3通过限制TGFβR2-SMAD2依赖的EndoMT防止缺血性心脏损伤,提示其是重要的内皮调节因子和心肌修复的潜在治疗靶点。
Nature cardiovascular research IF 12.6 2026-10-27 PMID: 42946862
Mitofusin (MFN) 1 and MFN2 are large outer mitochondrial membrane GTPases. Dimerization of MFNs on adjacent mitochondria mediates mitochondrial fusion. MFN2, but not MFN1, also resides at the endoplasmic reticulum (ER)/sarcoplasmic reticulum (SR) membrane, and dimerization of MFNs on ER/SR and mitochondria tethers the two organelles. Here we report that cell-permeable peptides that perturb MFN conformations regulate myocardial infarct size by impacting ER/SR-mitochondria interactions and Ca2+ transfer independently of changes in mitochondrial fusion. MFN activators increase ER/SR-mitochondria proximity, promote ER/SR to mitochondria Ca2+ transfer and exacerbate infarct size in mice, with effects dependent on MFN2, but not MFN1, and on mitochondrial calcium uniporter, which transports Ca2+ into the mitochondrial matrix. Conversely, although ER/SR-mitochondria proximity is not affected, MFN inhibitors reduce mitochondrial Ca2+ transfer and infarct size, even when their administration is delayed until reperfusion. These findings demonstrate the feasibility of acutely modulating ER/SR-mitochondria interactions and Ca2+ dynamics and suggest that pharmacological MFN inhibition may provide a new therapeutic strategy to limit cardiac damage during reperfused myocardial infarction.
中文摘要:线粒体融合蛋白(MFN)1和MFN2是位于线粒体外膜的大型GTP酶。相邻线粒体上的MFN二聚化介导线粒体融合。MFN2而非MFN1还定位于内质网(ER)/肌浆网(SR)膜,ER/SR与线粒体上的MFN二聚化将这两种细胞器系连。本研究报告,扰动MFN构象的细胞通透性肽可通过影响ER/SR-线粒体相互作用和Ca2+转移来调节心肌梗死面积,且不依赖线粒体融合的变化。MFN激活剂增加ER/SR-线粒体邻近度,促进ER/SR向线粒体的Ca2+转移,并加重小鼠梗死面积,其效应依赖MFN2而非MFN1,并依赖将Ca2+转运至线粒体基质的线粒体钙单向转运体。相反,虽然ER/SR-线粒体邻近度未受影响,MFN抑制剂仍减少线粒体Ca2+转移和梗死面积,即使给药延迟至再灌注时也是如此。这些发现证明急性调控ER/SR-线粒体相互作用和Ca2+动态具有可行性,并提示药物性MFN抑制可能成为限制再灌注心肌梗死中心肌损伤的新治疗策略。

5高血压 (4篇)

临床研究 (3篇)

JAMA cardiology IF 15.2 2026-10-30 PMID: 42961436
Angiotensinogen (AGT) is the precursor of angiotensin peptides and a key determinant of renin-angiotensin-aldosterone system activity. ART101 is an investigational N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) designed to durably suppress hepatic AGT synthesis. To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of the AGT-targeting GalNAc-siRNA in healthy volunteers and to provide an initial exploratory assessment of blood pressure effects in patients with hypertension. This phase I study was conducted from January 2025 to April 2026 with 24-week follow-up. Part A was a double-blind, placebo-controlled, single ascending-dose trial; part B was an open-label, single-dose study. The study took place at Beijing Friendship Hospital, Capital Medical University, Beijing, China. Part A enrolled 40 healthy adults randomized 6:2 to receive the GalNAc-siRNA (25-600 mg) or placebo; 39 completed the study. Part B enrolled 8 patients with hypertension receiving the GalNAc-siRNA, 600 mg; all completed the study. A single subcutaneous injection of the AGT-targeting GalNAc-siRNA (25, 75, 150, 300, or 600 mg) or placebo in part A; a single open-label subcutaneous injection of GalNAc-siRNA, 600 mg, in part B. The primary outcome was safety and tolerability; secondary outcomes included pharmacokinetics, pharmacodynamics, exploratory blood pressure assessments, and renin-angiotensin-aldosterone system biomarkers. Among 40 healthy volunteers (27 [67.5%] male; mean [SD] age, 40.4 [7.8] years) and 8 patients (6 [75.0%] male; mean [SD] age, 47.3 [10.3] years) with hypertension, the AGT-targeting GalNAc-siRNA was well tolerated. In part A, treatment-emergent adverse events (TEAEs) occurred in 23 of 30 active-treatment participants (76.7%) vs 7 of 10 placebo recipients (70.0%); in part B, 6 of 8 patients (75.0%) had TEAEs. No serious adverse events, injection site reactions, or hyperkalemia were observed; all TEAEs were mild to moderate. Plasma exposure (maximum plasma concentration [Cmax] and area under the plasma concentration-time curve [AUC]) increased with dose over the wide dose range from 25 mg to 600 mg. Mean maximum serum AGT reductions of 93% (at 600 mg) in healthy volunteers and 90% (at 600 mg) in patients with hypertension were observed. At 24 weeks after a single 600-mg dose, the placebo-corrected 24-hour ambulatory systolic blood pressure decreased by 12.9 mm Hg in healthy participants. In this phase I study, no serious treatment-related safety signals were identified. Sustained, dose-dependent AGT reductions and exploratory blood pressure lowering were observed. These findings support further investigation of the AGT-targeting GalNAc-siRNA as a potential long-acting therapeutic for hypertension. China Drug Clinical Registry Identifiers: CTR20250041 (part A) and CTR20253973 (part B).
中文摘要:血管紧张素原(AGT)是血管紧张素肽的前体,也是肾素-血管紧张素-醛固酮系统活性的关键决定因素。ART101是一种在研的N-乙酰半乳糖胺偶联小干扰RNA(GalNAc-siRNA),设计用于持久抑制肝脏AGT合成。本研究评估靶向AGT的GalNAc-siRNA单次递增剂量在健康志愿者中的安全性、耐受性、药代动力学和药效学,并对高血压患者的血压影响进行初步探索性评估。这项I期研究于2025年1月至2026年4月开展,随访24周。A部分为双盲、安慰剂对照、单次递增剂量试验;B部分为开放标签、单次给药研究。研究地点为首都医科大学附属北京友谊医院。A部分纳入40名健康成人,按6:2随机接受GalNAc-siRNA(25-600 mg)或安慰剂,39名完成研究。B部分纳入8名高血压患者,接受GalNAc-siRNA 600 mg,均完成研究。A部分为单次皮下注射靶向AGT的GalNAc-siRNA(25、75、150、300或600 mg)或安慰剂;B部分为单次开放标签皮下注射GalNAc-siRNA 600 mg。主要结局为安全性和耐受性;次要结局包括药代动力学、药效学、探索性血压评估及肾素-血管紧张素-醛固酮系统生物标志物。40名健康志愿者(27名[67.5%]男性;平均[SD]年龄40.4[7.8]岁)和8名高血压患者(6名[75.0%]男性;平均[SD]年龄47.3[10.3]岁)中,靶向AGT的GalNAc-siRNA耐受性良好。A部分中,30名活性治疗参与者有23名(76.7%)发生治疗中出现的不良事件(TEAE),10名安慰剂接受者中有7名(70.0%);B部分8名患者中有6名(75.0%)发生TEAE。未观察到严重不良事件、注射部位反应或高钾血症;所有TEAE均为轻至中度。在25 mg至600 mg的宽剂量范围内,血浆暴露(最大血浆浓度[Cmax]和血浆浓度-时间曲线下面积[AUC])随剂量增加。健康志愿者中血清AGT平均最大降幅为93%(600 mg时),高血压患者中为90%(600 mg时)。单次600 mg给药后24周,健康参与者安慰剂校正的24小时动态收缩压降低12.9 mm Hg。这项I期研究未发现严重治疗相关安全性信号。观察到持续、剂量依赖性的AGT降低和探索性血压下降。这些结果支持进一步研究靶向AGT的GalNAc-siRNA作为高血压潜在长效治疗药物。中国药物临床试验登记与信息公示平台注册号:CTR20250041(A部分)和CTR20253973(B部分)。
Endocrine reviews IF 23.9 2026-10-30 PMID: 42960688
Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in whom the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classical apparent mineralocorticoid excess (NC-AME), defined by partial insufficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), represents a prevalent and underrecognized cause of cortisol-mediated mineralocorticoid receptor overactivation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This Scientific Statement addresses that gap. The panel formally defines NC-AME as a syndrome of partial 11β-HSD2 insufficiency occurring in the absence of biallelic HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The Statement consolidates evidence across three mechanistic domains, genetic and epigenetic dysregulation of HSD11B2, endogenous and exogenous enzyme inhibition, and patient-specific alterations (i.e. age, sex, renal function), and proposes both a structured, an LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
中文摘要:高血压影响全球超过13亿人,是心血管疾病发病和死亡的首位可干预原因。约三分之一高血压患者表现为低肾素表型,该亚组临床异质性强,多数病例的潜在病因仍未明确。非经典表观盐皮质激素过多(NC-AME)由11β-羟类固醇脱氢酶2型(11β-HSD2)部分不足所定义,是皮质醇介导的盐皮质激素受体过度激活的常见但认识不足的原因,迄今缺乏正式临床定义、标准化诊断标准或循证治疗框架。本科学声明填补这一空白。专家组将NC-AME正式定义为不存在双等位基因HSD11B2变异时发生的部分11β-HSD2不足综合征,生化特征为皮质醇/可的松(F/E)比值升高和可的松浓度降低,通常伴血浆肾素低、醛固酮正常至偏低和血压升高。声明整合了三个机制领域的证据,即HSD11B2的遗传和表观遗传失调、内源性和外源性酶抑制以及患者特异性改变(如年龄、性别、肾功能),并提出结构化的基于LC-MS/MS的诊断算法和资源适配的诊断路径。盐皮质激素受体拮抗剂被推荐为机制导向的一线治疗,血压和肾素正常化作为共同主要治疗目标。获得性和可逆性病因单独分类以指导临床管理。声明提出研究议程,以推动阈值标准化、多中心验证,并将NC-AME纳入内分泌学、心脏病学和肾脏病学的高血压指南。
European heart journal IF 45.3 2026-10-28 PMID: 42946534
Despite guideline-directed therapy, many patients with cardio-kidney-metabolic (CKM) disease remain uncontrolled due to therapeutic inertia, adherence barriers, and underrecognized secondary causes. Hypercortisolism, ranging from mild autonomous cortisol secretion (MACS) to overt Cushing syndrome, is an increasingly recognized contributor. MACS is associated with a 2.5-fold higher risk of cardiovascular death and increased prevalence of hypertension, type 2 diabetes mellitus (T2DM), and kidney impairment. Cortisol excess promotes muscle insulin resistance, hepatic gluconeogenesis, β-cell dysfunction, sodium retention, and vascular remodelling, worsening glycaemia and blood pressure, leading to poor CKM outcomes. Recent prospective studies suggest that hypercortisolism is more prevalent than previously suspected in selected CKM phenotypes, including 24% in patients with difficult-to-control T2DM in CATALYST and 27% in patients with resistant hypertension in MOMENTUM. The overnight 1 mg dexamethasone suppression test remains the diagnostic test of choice. Therapeutic strategies include adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies in selected cases, while surgery remains the first-line treatment for surgically remediable disease. This review summarizes the epidemiology and mechanisms linking cortisol excess to CKM dysfunction, and also highlights the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk. This review will serve as a practical guide for cardiologists to manage a potentially reversible contributor to poor CKM control.
中文摘要:尽管接受指南导向治疗,许多心肾代谢(CKM)疾病患者仍控制不佳,原因包括治疗惰性、依从性障碍以及未被充分识别的继发原因。皮质醇增多症,从轻度自主皮质醇分泌(MACS)到显性库欣综合征,是日益被认识的促发因素。MACS与心血管死亡风险升高2.5倍以及高血压、2型糖尿病(T2DM)和肾功能受损患病率增加相关。皮质醇过多促进肌肉胰岛素抵抗、肝脏糖异生、β细胞功能障碍、钠潴留和血管重构,加重血糖和血压异常,导致CKM结局不良。近期前瞻性研究提示,在特定CKM表型中,皮质醇增多症比既往怀疑更常见,包括CATALYST中难以控制的T2DM患者占24%,MOMENTUM中难治性高血压患者占27%。过夜1 mg地塞米松抑制试验仍是首选诊断试验。治疗策略包括肾上腺类固醇生成抑制剂、糖皮质激素受体拮抗剂,以及特定病例中的垂体靶向治疗;对于可通过手术治疗的疾病,手术仍是一线治疗。该综述总结将皮质醇过多与CKM功能障碍联系起来的流行病学和机制,并强调需要临床试验、标准化诊断阈值和检测方法,以将皮质醇靶向治疗纳入管理路径,降低残余CKM风险。该综述将为心脏科医生管理CKM控制不佳的一种潜在可逆因素提供实用指导。

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-10-24 PMID: 42921666
Preclinical studies suggest a pivotal role of adaptive immunity, particularly T cells, in hypertension. However, due to the multifactorial pathogenesis, there is still no definitive evidence for a causal role of T cells in the development of hypertension in humans. We sought to determine whether T cells from patients with treatment-resistant hypertension (TRH) directly modulate blood pressure and vascular function in vivo. Peripheral blood mononuclear cells (PBMCs) from TRH patients and healthy controls (HC) were adoptively transferred into immunodeficient NSG-(KbDb)^null mice. Hypertension was induced by angiotensin II infusion for 14 days and monitored continuously by radiotelemetry. Following T cell engraftment, blood pressure was assessed at baseline and during AngII infusion in both groups of recipient mice. At baseline, systolic blood pressure did not differ between both groups. However, mice receiving TRH-PBMCs developed a significantly higher systolic blood pressure following AngII compared with HC-PBMC recipients. Endothelial dysfunction in isolated perfused kidneys was more pronounced in AngII-challenged TRH-PBMC recipients compared to HC-PBMC recipients. TRH-PBMC recipients displayed elevated effector memory CD4+ T cells and Th17 frequencies in spleen and kidney, along with markedly increased renal expression of human T cell-derived TNF. Overnight incubation of mouse aortic rings with human TNF induced endothelial dysfunction, indicating a causal role of T cell-derived TNF. As a proof of concept, TNF inhibition attenuated AngII-induced hypertension in TRH-PBMC-engrafted mice. T cells from patients with treatment-resistant hypertension promote an exaggerated hypertensive response and endothelial dysfunction in PBMC-engrafted humanized mice, promoted by TNF-mediated mechanisms. These findings provide evidence that T cell-derived TNF may contribute to the pathogenesis of human hypertension.
中文摘要:临床前研究提示适应性免疫尤其T细胞在高血压中起关键作用。然而,由于发病机制涉及多因素,T细胞在人类高血压发生中的因果作用仍缺乏明确证据。我们旨在确定难治性高血压(TRH)患者的T细胞是否在体内直接调节血压和血管功能。将TRH患者和健康对照(HC)的外周血单个核细胞(PBMCs)过继转移至免疫缺陷NSG-(KbDb)^null小鼠。通过输注血管紧张素II 14天诱导高血压,并用无线电遥测连续监测。T细胞植入后,评估两组受体小鼠基线和AngII输注期间的血压。基线时,两组收缩压无差异。然而,接受TRH-PBMCs的小鼠在AngII后收缩压显著高于接受HC-PBMC者。在AngII刺激下,离体灌注肾的内皮功能障碍在接受TRH-PBMC的受体中较接受HC-PBMC者更明显。TRH-PBMC受体脾和肾中效应记忆CD4+ T细胞及Th17频率升高,同时人T细胞来源TNF的肾脏表达明显增加。小鼠主动脉环与人TNF过夜孵育可诱导内皮功能障碍,提示T细胞来源TNF的因果作用。作为概念验证,抑制TNF可减轻TRH-PBMC植入小鼠中AngII诱导的高血压。难治性高血压患者的T细胞在PBMC植入的人源化小鼠中促进过度高血压反应和内皮功能障碍,其由TNF介导机制推动。这些发现提供证据表明T细胞来源TNF可能参与人类高血压的发病机制。

6冠心病/心绞痛 (4篇)

临床研究 (4篇)

JAMA cardiology IF 15.2 2026-10-30 PMID: 42961412
Prior imaging studies (predominantly using intravascular ultrasound) have demonstrated modest plaque regression with lipid-lowering therapy in stable coronary artery disease (CAD). The effect of initiating intensive lipid-lowering therapy on coronary plaque regression across the entire coronary tree in treatment-naive patients remains uncertain. To report the prespecified secondary imaging end points of the FLOWPROMOTE trial by comparing the effects of intensive vs more intensive lipid-lowering therapy on plaque regression in statin-naive patients with stable CAD and to assess the association between achieved low-density lipoprotein cholesterol (LDL-C) levels and plaque regression. FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD, defined by a coronary computed tomography angiography (CTA) stenosis greater than 50% and fractional flow reserve CT less than or equal to 0.80. Coronary CTA was performed at baseline and repeated at 9 and 18 months. Study data were analyzed from February 2025 to January 2026. Patients were randomized to intensive lipid-lowering therapy (atorvastatin 40 mg) or more intensive lipid-lowering therapy (rosuvastatin 40 mg plus ezetimibe 10 mg) for 18 months. Prespecified secondary end points included changes in total plaque volume (TPV), noncalcified plaque volume (NCPV), and calcified plaque volume (CPV) across all coronary vessels at 9 and 18 months compared with baseline. A total of 104 patients (mean [SD] age, 64 [9] years; 82 male [79%]) were included in this analysis, with 52 patients in the intensive group and 52 patients in the more intensive group. LDL-C levels decreased from 119.7 to 69.5 mg/dL (-38%) with intensive therapy and from 127.4 to 42.5 mg/dL (-65%) with more intensive therapy (between-group P < .001). At 18 months, both TPV and NCPV decreased in both groups, with significantly greater regression in the more intensive-therapy group. TPV was reduced by -69.8 mm3 (-21.1%) with more intensive therapy vs -39.0 mm3 (-13.6%) with intensive therapy (between-group difference, -30.9 mm3; 95% CI, -57.2 to -4.5 mm3; P = .02), and NCPV was reduced by -82.3 mm3 (-28.2%) vs -53.5 mm3 (-20.0%), respectively (between-group difference, -28.9 mm3; 95% CI, -53.2 to -4.6 mm3; P = .02). CPV increased similarly in both groups. Regression of TPV occurred in 90% of patients receiving more intensive therapy compared with 76% receiving intensive therapy (47 of 52 [90%] vs 38 of 51 [75%]; P = .05), and regression of NCPV was observed in 98% vs 77% (51 of 52 [98%] vs 39 of 51 [77%]; P =.001). Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV. This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction. ClinicalTrials.gov Identifier: NCT04737408.
中文摘要:既往影像学研究(主要采用血管内超声)显示,稳定性冠心病患者接受降脂治疗可出现轻度斑块逆转。在未接受过他汀治疗的患者中,启动强化降脂治疗对整棵冠状动脉树斑块逆转的影响仍不确定。报告FLOWPROMOTE试验预设的次要影像学终点,比较强化与更强化降脂治疗对稳定性冠心病他汀初治患者斑块逆转的影响,并评估达到的低密度脂蛋白胆固醇(LDL-C)水平与斑块逆转的关系。FLOWPROMOTE是一项多中心随机临床试验,纳入新诊断稳定性冠心病且未接受过他汀治疗的患者,定义为冠状动脉CT血管成像(CTA)狭窄大于50%且CT血流储备分数小于或等于0.80。基线及第9、18个月重复冠状动脉CTA。研究数据于2025年2月至2026年1月分析。患者随机接受强化降脂治疗(阿托伐他汀40 mg)或更强化降脂治疗(瑞舒伐他汀40 mg联合依折麦布10 mg)18个月。预设次要终点包括第9和18个月所有冠状动脉血管的总斑块体积(TPV)、非钙化斑块体积(NCPV)和钙化斑块体积(CPV)较基线的变化。本分析纳入104例患者(平均[SD]年龄64[9]岁;男性82例[79%]),强化组52例,更强化组52例。LDL-C由119.7降至69.5 mg/dL(-38%)与由127.4降至42.5 mg/dL(-65%)(组间P<.001)。18个月时,两组TPV和NCPV均下降,更强化组逆转幅度显著更大。TPV在更强化组减少-69.8 mm³(-21.1%),强化组减少-39.0 mm³(-13.6%)(组间差-30.9 mm³;95% CI -57.2至-4.5 mm³;P=.02),NCPV分别减少-82.3 mm³(-28.2%)与-53.5 mm³(-20.0%)(组间差-28.9 mm³;95% CI -53.2至-4.6 mm³;P=.02)。CPV两组均相似增加。TPV逆转在更强化组占90%,强化组占76%(47/52[90%] vs 38/51[75%];P=.05),NCPV逆转分别为98%与77%(51/52[98%] vs 39/51[77%];P=.001)。达到的LDL-C水平越低,TPV和NCPV逆转幅度越大,呈线性相关。这项FLOWPROMOTE随机临床试验的次要分析显示,在冠心病他汀初治患者中,与强化降脂治疗相比,更强化降脂治疗与冠状动脉总斑块和非钙化斑块负荷逆转幅度显著更大相关。斑块逆转程度与达到的LDL-C水平相关,支持强化降脂可能部分逆转冠状动脉粥样硬化。ClinicalTrials.gov注册号:NCT04737408。
Circulation IF 41.3 2026-10-27 PMID: 42661461
Coronary artery calcification (CAC) progression is a strong predictor of cardiovascular events. We investigated whether supplementation with vitamin K2 and vitamin D3 reduces CAC progression in patients with severe coronary calcification. In this multicenter, double-blind, placebo-controlled randomized trial, 400 participants with a CAC score ≥400 Agatston units (AU) were randomly assigned to vitamin K2 (720 μg/d) plus vitamin D3 (25 μg/d) or placebo for 24 months. Participants were enrolled from February 2023 to February 2024. Noncontrast cardiac computed tomography was performed at baseline, 12 months, and 24 months. The primary end point was change in CAC score at 24 months. Subgroup analyses by sex and baseline CAC subgroups (400-999 and ≥1000 AU) were performed. Change in plaque composition was assessed in a subset with CAC score <1000 AU who underwent coronary computed tomography angiography at baseline and 24 months. A total of 398 participants (30% women; median age, 71 years) were included. Median baseline CAC was 903 AU, and 44% had CAC ≥1000 AU. In the intention-to-treat analysis, the mean CAC increase was 196 AU (95% CI, 178-214) with vitamin K2 and D3 and 248 AU (95% CI, 225-271 AU) with placebo (between-group difference, -52 AU [95% CI, -79 to -24]). The treatment effect was consistent across sex and baseline CAC subgroups. In the 143 participants who underwent coronary computed tomography angiography, there were a similar increase in total plaque volume and no change in noncalcified plaque volume between groups; progression of calcified plaque volume was attenuated in the intervention group (between-group difference, -8 mm3 [95% CI, -13 to -2]). Among patients with severe CAC, supplementation with vitamin K2 and vitamin D3 reduced progression of CAC over 24 months. The reduction in calcification progression was not associated with an increase in noncalcified plaque volume. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05500443.
中文摘要:冠状动脉钙化(CAC)进展是心血管事件的强预测因素。研究维生素K2与维生素D3补充是否减少严重冠状动脉钙化患者的CAC进展。这项多中心、双盲、安慰剂对照随机试验纳入400例CAC评分≥400 Agatston单位(AU)的参与者,随机接受维生素K2(720 μg/d)加维生素D3(25 μg/d)或安慰剂治疗24个月。参与者于2023年2月至2024年2月入组。基线、12个月和24个月进行非增强心脏计算机断层扫描。主要终点为24个月时CAC评分变化。按性别和基线CAC亚组(400-999 AU和≥1000 AU)进行亚组分析。在基线及24个月接受冠状动脉计算机断层扫描血管造影、CAC评分<1000 AU的亚组中评估斑块组成变化。共纳入398例参与者(30%为女性;中位年龄71岁)。基线CAC中位数为903 AU,44%的患者CAC≥1000 AU。在意向治疗分析中,维生素K2加D3组CAC平均增加196 AU(95% CI,178-214),安慰剂组增加248 AU(95% CI,225-271),组间差异为-52 AU(95% CI,-79至-24)。治疗效果在性别和基线CAC亚组间一致。在143例接受冠状动脉计算机断层扫描血管造影的参与者中,两组总斑块体积增加相似,非钙化斑块体积无变化;干预组钙化斑块体积进展减缓(组间差异,-8 mm³ [95% CI,-13至-2])。在严重CAC患者中,补充维生素K2和维生素D3在24个月内减少了CAC进展。钙化进展的减少未伴随非钙化斑块体积增加。网址:https://www.clinicaltrials.gov;唯一标识符:NCT05500443。
European heart journal IF 45.3 2026-10-26 PMID: 42234492
Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13-165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02-1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02-1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38-1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
中文摘要:脂蛋白(a)(Lp(a))被认为是动脉粥样硬化形成的因果性危险因素。已有报告显示,Lp(a)浓度较低的患者某些不良事件(包括糖尿病(DM))的患病率较高。降低Lp(a)的治疗药物正在进行临床测试。因此,较低Lp(a)浓度与安全性结局之间的关联具有临床重要性。FOURIER(Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)试验将27 564例稳定型动脉粥样硬化性心血管疾病(ASCVD)患者随机分配至在他汀治疗背景下的依洛尤单抗组或安慰剂组。研究检查了Lp(a)与所关注现患和新发不良结局风险之间的关系,并校正了相关预测因素。基线时对25 090名参与者评估了Lp(a)(中位数37 nmol/L,四分位距13-165)。Lp(a)浓度与出血性卒中、严重出血、神经认知事件、恶性肿瘤或心房颤动的新发风险之间没有关联,包括Lp(a)水平≤13 nmol/L者。较低的基线Lp(a)水平与基线时现患DM呈反向关联(校正比值比1.03,95%置信区间[CI]1.02-1.04,P<.001;Lp(a)每降低50 nmol/L),也与随访期间发生DM的新发风险呈反向关联(校正风险比[HR]1.05,95%CI 1.02-1.08,P=.002;Lp(a)每降低50 nmol/L),按治疗组分析结果一致。无论基线Lp(a)如何,依洛尤单抗均未增加DM风险,即使在基线Lp(a)最高十分位的参与者中也是如此(校正HR .72,95%CI .38-1.35),依洛尤单抗使这些参与者的Lp(a)中位数降低71 nmol/L。在ASCVD患者中,低Lp(a)浓度与大多数不良安全性结局风险增加无关,但较低Lp(a)与现患和发生DM的风险增加相关。
European heart journal IF 45.3 2026-10-26 PMID: 42177636
Current guidance recommends better LDL-C control in patients with elevated Lp(a) as Lp(a) lowering therapies are unavailable. Whether risks attributable to Lp(a) are mitigated in patients with CAD who achieved LDL-C <55 mg/dL remains unknown. Multicentre retrospective observational study analysed 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of MACE (cardiac-caused death + nonfatal MI + coronary revascularization in non-culprit segments) was compared according to Lp(a) levels (<30, ≥30, and <50 mg/dL and ≥50 mg/dL) and amongst LDL-C strata (<55 mg/dL vs ≥55 mg/dL) 8 weeks after PCI. During the 5.1-year observation amongst patients with LDL-C ≥55mg/dL (n=1069), MACE occurred in 21.3% with risk of MACE increasing with Lp(a) levels (3.9, 7.9, and 11.0 events per 100 person-years for <30, ≥30, and <50 mg/dL and ≥50 mg/dL, log-rank p<0.001). Amongst those with LDL-C <55mg/dL (n=512), the proportion with MACE was lower overall (4.3%, p<0.001). However, elevated Lp(a) levels still identified those at higher risk of MACE (1.4, 4.7, and 7.5 events per 100 person-years in Lp(a) <30, ≥30, and <50 mg/dL and ≥50 mg/dL, p<0.001). Standardized 5-year MACE rate was over twice and five times higher in patients with Lp(a) ≥30 and <50 mg/dL (17.0%: adjusted HR = 3.80, 95% CI = 1.78-8.11, p<0.001) and ≥50 mg/dL (33.4%: adjusted HR = 6.90, 95% CI = 3.53-13.46, p<0.001) compared to Lp(a) <30 mg/dL (5.0%), respectively. The ROC analyses identified Lp(a) ≥28.2 mg/dL as the threshold for MACE (AUC = 0.68, p<0.001). Whilst lower achieved LDL-C attenuates in part the risk from Lp(a), elevated Lp(a) levels still associate with worse cardiovascular outcomes. The Lp(a) threshold amongst Japanese patients with CAD at risk of recurrent events appears lower than in Caucasian populations which merits further evaluation.
中文摘要:现行指南建议Lp(a)升高的患者应更严格控制LDL-C,因为降低Lp(a)的治疗尚不可用。已达到LDL-C<55 mg/dL的冠心病患者中,Lp(a)相关风险是否被削弱仍不清楚。这项多中心回顾性观察研究分析1581例日本冠心病患者[Lp(a)-JAPAN: jRCT1050260016]。研究比较PCI后8周按Lp(a)水平(<30、≥30且<50 mg/dL、≥50 mg/dL)以及按LDL-C分层(<55 mg/dL与≥55 mg/dL)的MACE风险,MACE定义为心源性死亡、非致死性心肌梗死与非罪犯节段冠状动脉血运重建的复合终点。5.1年观察期间,LDL-C≥55 mg/dL患者(n=1069)中MACE发生率为21.3%,MACE风险随Lp(a)水平升高而增加(Lp(a)<30、≥30且<50 mg/dL、≥50 mg/dL分别为每100人年3.9、7.9、11.0次事件,log-rank p<0.001)。LDL-C<55 mg/dL者(n=512)MACE比例总体更低(4.3%,p<0.001),但Lp(a)升高仍可识别出MACE风险更高的人群(Lp(a)<30、≥30且<50 mg/dL、≥50 mg/dL分别为每100人年1.4、4.7、7.5次事件,p<0.001)。与Lp(a)<30 mg/dL者(5.0%)相比,Lp(a)≥30且<50 mg/dL者的标准化5年MACE率高出两倍以上(17.0%:校正HR=3.80,95%CI=1.78-8.11,p<0.001),Lp(a)≥50 mg/dL者高出五倍(33.4%:校正HR=6.90,95%CI=3.53-13.46,p<0.001)。ROC分析确定Lp(a)≥28.2 mg/dL为MACE的阈值(AUC=0.68,p<0.001)。达到更低的LDL-C可部分削弱Lp(a)带来的风险,但Lp(a)升高仍与更差的心血管结局相关。日本冠心病患者中复发事件风险的Lp(a)阈值似乎低于白种人群,值得进一步评估。

7冠心病/PCI (3篇)

临床研究 (3篇)

European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 42105323
Alcohol and its relationship with cardiovascular disease (CVD) remain contentious. Several observational studies have found cardioprotective associations, while Mendelian randomization studies have found null or harmful effects of moderate drinking. Biases, including abstainer misclassification and sick-quitter effects, may obscure true associations. It is widely understood that former drinkers are often sick quitters. However, removal of former drinkers from analyses addresses bias in the abstainer group but fails to account for induced survivorship among current drinkers. This study sought to determine whether adjusting for biases altered the association between alcohol and CVD by comparing conventional models with those using (i) occasional drinkers as the reference group instead of lifetime abstainers and (ii) 'intention-to-treat' reallocation of former drinkers based on past drinking patterns. The Multi-Ethnic Study of Atherosclerosis is a prospective cohort study of 6814 participants aged 45-84 years between 2000 and 2002 without baseline CVD. A total of 6755 participants were included after excluding those with missing data. Alcohol consumption was self-reported and classified as lifetime abstainer, former, or current drinker [occasional (≤1 drink/week), light (2-7 drinks/week), moderate (8-14 drinks/week), heavy (>14 drinks/week)]. Outcomes included coronary artery calcium (CAC; 0, 1-100, 101-300, and >300) and clinical events [myocardial infarction (MI), stroke, cardiovascular mortality, composite major adverse cardiovascular events (MACEs), and heart failure]. Of 6755 participants, 20.6% were lifetime abstainers, 24.1% former drinkers, and 55.3% current drinkers. Adjusting for biases altered the observed relationship between alcohol and CVD, showing increased harm with light drinking, decreased protection with moderate drinking, and a dose-response relationship between alcohol and CAC, particularly CAC >300 in adjusted models. Protective associations between moderate drinking and MI [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.38-1.06] and cardiovascular mortality (HR: 0.81, 95% CI: 0.53-1.25) were attenuated and became non-significant. Light drinking shifted from null to increased risk for MI (HR: 1.46, 95% CI: 1.11-1.92), stroke (HR: 1.54, 95% CI: 1.17-2.03), MACE (HR: 1.33, 95% CI: 1.12-1.57), and heart failure (HR: 1.42, 95% CI: 1.10-1.84). Associations between alcohol and CVD in observational studies are sensitive to methodologic variation. Results from models correcting for abstainer/sick-quitter biases may help explain discrepant results from previous studies.
中文摘要:饮酒与心血管疾病(CVD)的关系仍有争议。多项观察性研究提示饮酒与心血管疾病存在保护性关联,而孟德尔随机化研究显示中度饮酒无效应或有害。戒酒者错分和因病戒酒效应等偏倚可能掩盖真实关联。既往饮酒者常属于因病戒酒者,这一点已被广泛认识。将既往饮酒者从分析中剔除可处理戒酒组偏倚,但未能考虑当前饮酒者中由此产生的生存者效应。本研究通过比较传统模型与以下两类模型,判断校正偏倚后是否会改变饮酒与CVD的关联:第一类以偶尔饮酒者而非终身戒酒者作为参照组;第二类按既往饮酒模式对既往饮酒者进行「意向治疗」式重新分配。多族裔动脉粥样硬化研究是一项前瞻性队列研究,纳入2000至2002年间45至84岁、基线无CVD的6814名参与者。排除数据缺失者后共纳入6755名参与者。饮酒情况为自我报告,分为终身戒酒者、既往饮酒者和当前饮酒者,当前饮酒者又分为偶尔饮酒(每周≤1杯)、轻度饮酒(每周2至7杯)、中度饮酒(每周8至14杯)和重度饮酒(每周>14杯)。结局包括冠状动脉钙化(CAC;0、1至100、101至300和>300)以及临床事件,包括心肌梗死(MI)、卒中、心血管死亡、复合主要不良心血管事件(MACE)和心力衰竭。6755名参与者中,20.6%为终身戒酒者,24.1%为既往饮酒者,55.3%为当前饮酒者。校正偏倚改变了观察到的饮酒与CVD关系,显示轻度饮酒危害增加、中度饮酒保护作用减弱,并在校正模型中呈现饮酒与CAC的剂量反应关系,尤其是CAC>300。中度饮酒与MI(风险比HR:0.64,95%置信区间CI:0.38至1.06)和心血管死亡(HR:0.81,95%CI:0.53至1.25)的保护性关联减弱且不再显著。轻度饮酒与MI(HR:1.46,95%CI:1.11至1.92)、卒中(HR:1.54,95%CI:1.17至2.03)、MACE(HR:1.33,95%CI:1.12至1.57)和心力衰竭(HR:1.42,95%CI:1.10至1.84)的关联由无关联转为风险增加。观察性研究中饮酒与CVD的关联对方法学差异敏感。校正戒酒者/因病戒酒者偏倚的模型结果可能有助于解释既往研究结果的不一致。
Circulation IF 41.3 2026-10-26 PMID: 42929153
Improving cardiovascular health in women is an urgent public health priority given the persistent and pervasive gaps in awareness, prevention, and management of cardiovascular disease in this population. Advances in scientific understanding have led to increased recognition of female-specific considerations in cardiovascular disease, which informed the development of the Female Life Stage construct by the American Heart Association in collaboration with the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine. This construct integrates assessment of hormonal, psychosocial, and cardiovascular health across life stages. However, gaps remain in operationalizing this construct and optimizing the delivery of patient-centered, interdisciplinary care among women. Over the past several decades, women's cardiovascular centers have emerged as leaders, expanded rapidly, and elevated the recognition of cardiovascular diseases that exclusively, disproportionately, or differently affect women (eg, myocardial infarction with nonobstructive coronary arteries, spontaneous coronary artery dissection, Takotsubo syndrome). In this science advisory, we describe the current landscape of women's cardiovascular centers and propose a national infrastructure to support the expansion of dedicated Comprehensive Centers of Excellence for Women's Cardiovascular Care. These centers are conceptualized as interdisciplinary care models comprising 4 defining pillars: interdisciplinary clinical care, education and training, research, and community engagement. By establishing integrated pathways that span clinical disciplines, these centers can reduce fragmentation, enhance earlier risk identification, and expand opportunities to increase representation of women in clinical research. In doing so, they offer a bold opportunity for a scalable and equitable model to improve cardiovascular health for all women.
中文摘要:改善女性心血管健康是紧迫的公共卫生优先事项,因为该人群在心血管病的认知、预防和管理方面长期存在普遍缺口。科学认识的进步使女性特有的心血管病考量得到更多识别,美国心脏协会与美国儿科学会、美国妇产科医师学会、母胎医学会合作提出的女性生命阶段构念即以此为基础。该构念整合了不同生命阶段激素、心理社会和心血管健康的评估。但在将该构念付诸实施、优化以患者为中心的多学科照护方面仍存在缺口。过去数十年,女性心血管中心逐渐成为引领者,快速扩展,并提升了对仅影响女性、不成比例影响女性或以不同方式影响女性的心血管病的认识,例如非阻塞性冠状动脉心肌梗死、自发性冠状动脉夹层、Takotsubo综合征。本科学建议描述女性心血管中心的现状,并提出支持扩展专门女性心血管照护卓越综合中心的国家基础设施。这些中心被设想为多学科照护模式,包含4个界定支柱:多学科临床照护、教育与培训、研究、社区参与。通过建立跨临床学科的整合路径,这些中心可减少碎片化、促进更早识别风险,并扩大增加女性在临床研究中代表性的机会。由此,它们为改善所有女性心血管健康提供了可扩展且公平的模式的重要机遇。
EBioMedicine IF 11.2 2026-10-24 PMID: 42925816
Obesity involves complex changes in energy metabolism and increased cardiovascular disease (CVD) risk independently of low-density lipoprotein cholesterol (LDL-C). Diets high or low in carbohydrates or fats can be effective for reversing obesity, but their distinct effects on metabolic health and detailed lipid profiles may differentially impact overall CVD risk, particularly with large differences in saturated fatty acid (SFA) intake. In a 2-year randomised controlled trial, 193 males and females with obesity were assigned to 1) an acellular carbohydrate-based diet (A-HCLF, comparator arm), 2) a cellular carbohydrate-based diet (C-HCLF), or 3) a low-carbohydrate high-fat (LCHF) diet (75 energy percent fat, thereof 30 SFAs). As secondary outcomes of the trial, plasma lipids and lipoprotein particle subfractions were quantified by nuclear magnetic resonance spectroscopy assay, and coronary artery calcium score by CT imaging. Data were analysed by constrained linear mixed-effects modelling. Attrition was 74 (39%), 114 (59%), 128 (67%), 135 (70%), and 162 (84%) at 3, 6, 9, 12 and 24 months, respectively. Self-reported adherence ranged from 63 to 85% up to 12 months and 40-60% for the last 12 months. During the first 9-12 months, the LCHF group showed significantly greater reductions than the A-HCLF comparator and C-HCLF diets in very low-density lipoprotein particles (VLDLs), triacylglycerols (TAGs), remnant cholesterol, and the TAG/high-density lipoprotein cholesterol (HDL-C) ratio, alongside increases in HDL-C, total apolipoprotein A1 (apoA1), apoA1 in large HDL particles, LDL-C (attributed to large LDL particles), and the LDL-C/apolipoprotein B ratio. At 24 months, there were still greater reductions on the LCHF compared to the A-HCLF diet for TAGs, VLDL particles, remnant cholesterol, and the TAG/HDL-C ratio, as well as a greater increase in large LDL particles. In adults with obesity, an LCHF diet rich in SFA markedly lowered TAG-rich remnants and raised HDL-C and apoA1 compared to higher-carbohydrate diets, while shifting LDL toward larger particles without significantly increasing apoB or small LDLs-a pattern that may indicate greater lipid turnover. This work was supported by the Trond Mohn Research Foundation, Bergen (Norway), the University of Bergen (Norway), Kostfonden, Stockholm (Sweden), and the Norwegian Health Association.
中文摘要:肥胖涉及能量代谢的复杂改变,并可在低密度脂蛋白胆固醇(LDL-C)之外独立增加心血管疾病(CVD)风险。高或低碳水化合物饮食、高或低脂肪饮食均可有效逆转肥胖,但它们对代谢健康和详细脂质谱的不同影响可能以不同方式影响总体CVD风险,尤其在饱和脂肪酸(SFA)摄入差异很大时。在一项为期2年的随机对照试验中,193名肥胖男性和女性被分配到1)非细胞性碳水化合物饮食(A-HCLF,对照臂),2)细胞性碳水化合物饮食(C-HCLF),或3)低碳水化合物高脂肪(LCHF)饮食(脂肪占75%能量,其中SFA占30%能量)。作为该试验的次要结局,采用核磁共振波谱法测定血浆脂质和脂蛋白颗粒亚组分,采用CT成像测定冠状动脉钙化评分。数据采用约束线性混合效应模型分析。3、6、9、12和24个月时失访分别为74例(39%)、114例(59%)、128例(67%)、135例(70%)和162例(84%)。自我报告的依从性在12个月内为63%至85%,最后12个月为40%至60%。在前9至12个月,LCHF组在极低密度脂蛋白颗粒(VLDL)、三酰甘油(TAG)、残余胆固醇和TAG/高密度脂蛋白胆固醇(HDL-C)比值方面的下降显著大于A-HCLF对照组和C-HCLF饮食,同时HDL-C、总载脂蛋白A1(apoA1)、大HDL颗粒中的apoA1、LDL-C(归因于大LDL颗粒)以及LDL-C/载脂蛋白B比值升高。24个月时,与A-HCLF饮食相比,LCHF饮食在TAG、VLDL颗粒、残余胆固醇和TAG/HDL-C比值方面仍有更大降幅,并且大LDL颗粒有更大增加。在肥胖成人中,富含SFA的LCHF饮食与较高碳水化合物饮食相比明显降低富含TAG的残余物,并升高HDL-C和apoA1,同时使LDL向较大颗粒转移,而未显著增加apoB或小LDL颗粒,这一模式可能提示脂质周转增加。该工作由挪威卑尔根Trond Mohn研究基金会、挪威卑尔根大学、瑞典斯德哥尔摩Kostfonden和挪威健康协会资助。

8卒中/脑血管 (3篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 40795405
Chronic opioid exposure (COE) is linked to adverse health outcomes, but its relationship with cardiovascular disease (CVD) remains unclear. This systematic review and meta-analysis aimed to summarize published evidence on CVD risk associated with COE, including prescription opioids, opium use, and opioid use disorder (OUD). Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and International Prospective Register of Systematic Reviews registration (CRD42024573206), we searched multiple databases for relevant human studies reporting associations between COE and CVD. Random-effects meta-analysis estimated pooled odds ratios (ORs) with 95% confidence intervals. Subgroup analyses and meta-regression explored associations by COE type, CVD outcome, and potential moderators. Risk of bias was assessed using Risk Of Bias In Non-randomized Studies - of Exposures. Seventeen studies (1 676 000 participants) met inclusion criteria, with 13 studies contributing 22 effect sizes to meta-analysis. Chronic opioid exposure was associated with increased CVD risk (pooled OR, 1.74; 95% CI, 1.12-2.70), though substantial heterogeneity was observed. Cerebrovascular accidents (OR, 1.84; 95% CI, 1.45-2.35) and ischaemic heart disease (OR, 1.51; 95% CI, 1.40-1.63) showed the strongest associations. Opium use had a significant association with CVD, whilst findings for OUD and prescription opioids were less consistent. Meta-regression identified study design as a key moderator. Chronic opioid exposure is associated with increased risk of CVD, particularly cerebrovascular accidents and ischaemic heart disease. Given the global opioid and CVD burden, targeted interventions and integrated care approaches are needed. Findings are limited by heterogeneity and risk of bias in published studies. Further high-quality research should explore pathophysiological mechanisms, causality, dose-response relationships, and the potential reversibility of CVD risk following opioid cessation.
中文摘要:慢性阿片类暴露(COE)与不良健康结局相关,其与心血管疾病(CVD)的关系仍不明确。该系统评价与荟萃分析旨在汇总已发表证据,评估COE相关的心血管疾病风险,涵盖处方阿片类药物、鸦片使用及阿片使用障碍(OUD)。研究遵循PRISMA指南并完成PROSPERO注册(CRD42024573206),检索多个数据库中报告COE与CVD关联的人群研究。采用随机效应模型荟萃分析计算合并比值比(OR)及95%置信区间,并通过亚组分析和荟萃回归探讨COE类型、CVD结局及潜在调节因素的作用。偏倚风险采用非随机干预研究暴露偏倚风险评估工具(ROBINS-E)评价。17项研究(1 676 000名参与者)符合纳入标准,其中13项研究提供22个效应量进入荟萃分析。慢性阿片类暴露与CVD风险升高相关(合并OR 1.74;95% CI 1.12-2.70),但异质性较大。脑血管意外(OR 1.84;95% CI 1.45-2.35)与缺血性心脏病(OR 1.51;95% CI 1.40-1.63)的关联最强。鸦片使用与CVD存在显著关联,OUD与处方阿片类药物的结果一致性较差。荟萃回归显示研究设计是重要调节因素。慢性阿片类暴露与CVD风险升高相关,以脑血管意外和缺血性心脏病尤为明显。鉴于全球阿片类药物与CVD的双重负担,需要针对性干预与整合照护策略。已发表研究的异质性与偏倚风险限制了结论强度。后续高质量研究应探讨病理生理机制、因果关系、剂量反应关系以及停用阿片类药物后CVD风险是否可逆。

基础研究 (2篇)

Advanced drug delivery reviews IF 21.0 2026-10-26 PMID: 42933662
Nanoparticles (NPs) have emerged as versatile platforms for drug delivery in cardiovascular diseases (CVDs), demonstrating robust efficacy in preclinical models by stabilizing atherosclerotic plaques, promoting safe and efficient thrombolysis, and mitigating ischemia-reperfusion injury. These advances highlight the maturation of cardiovascular nanomedicine; however, translation to clinical practice remains limited. This gap between laboratory success and clinical adoption reflects broader challenges in nanomedicine design, including suboptimal delivery to diseased tissues, limited efficacy of single therapeutic payload-based strategies in addressing the multifaceted inflammatory pathways driving CVDs, NPs' immunogenicity, and scale-up feasibility. Addressing these barriers is particularly critical in CVDs, where therapeutic success depends on precise engagement with multiple molecular and cellular drivers of disease. This review discusses the evolving landscape of cardiovascular nanomedicine, focusing on four aspects. First, we highlight advances in NPs bioengineering strategies, such as refined targeting moieties, optimized physicochemical properties, and responsiveness to endogenous and external stimuli that enhance organ- and cell-specific delivery in atherosclerosis, myocardial infarction, and stroke. Second, we discuss analytical innovations that improve characterization and control of NPs' biodistribution, enabling more rational targeting. Third, we evaluate therapeutic payloads, emphasizing how RNA-based and immunomodulatory agents represent a meaningful step toward clinical translation. Fourth, we outline approaches to addressing persistent challenges in safety and scalable manufacturing. Together, these developments establish a foundation for translating NP design principles into practical cardiovascular therapies. With continued progress in targeted delivery, clinical safety, and production scalability, cardiovascular nanomedicine is increasingly well-positioned to translate preclinical advances to transformative patient outcomes.
中文摘要:纳米颗粒已成为心血管疾病药物递送的多功能平台,在临床前模型中显示出强大效力,可稳定动脉粥样硬化斑块、促进安全高效的血栓溶解、减轻缺血再灌注损伤。这些进展表明心血管纳米医学趋于成熟,但向临床实践的转化仍有限。实验室成功与临床采用之间的落差反映出纳米医学设计中的普遍难题:向病变组织的递送不理想、单一治疗载荷策略难以应对驱动心血管疾病的多重炎症通路、纳米颗粒的免疫原性,以及规模化生产的可行性。在心血管疾病中解决这些障碍尤为关键,因为治疗成功取决于对多种分子与细胞致病驱动因素的精准干预。本综述讨论心血管纳米医学不断演变的格局,聚焦四个方面。第一,概述纳米颗粒生物工程策略的进展,如精细化的靶向配体、优化的理化性质以及对内源性和外源性刺激的响应性,这些策略增强了在动脉粥样硬化、心肌梗死和卒中中的器官与细胞特异性递送。第二,讨论分析方法的创新,改善了纳米颗粒体内分布的表征与控制,使靶向设计更趋合理。第三,评估治疗载荷,强调基于RNA的制剂与免疫调节制剂是迈向临床转化的实质性一步。第四,概述应对安全性与可规模化生产方面长期挑战的途径。这些进展共同为将纳米颗粒设计原则转化为实用的心血管疗法奠定基础。随着靶向递送、临床安全性和生产规模化的持续进步,心血管纳米医学正日益具备将临床前进展转化为改变患者结局的能力。
Molecular biomedicine IF 13.0 2026-10-24 PMID: 42920026
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death that is driven by lipid peroxidation. In the past decade, it has emerged as a core pathogenic mechanism in a wide range of human diseases, such as neurodegenerative disorders, cardiovascular disease, cancer, and notably, reproductive dysfunction. This review provides a comprehensive overview of the molecular mechanisms underlying ferroptosis with a specific focus on the System Xc⁻-GSH-GPX4 axis, iron metabolism, lipid peroxidation, and the regulatory roles of key modulators such as Nrf2, ACSL4, and CISD2. This review also explores the physiological roles of ferroptosis in development, tissue homeostasis, and immune regulation, as well as its pathological contributions to obesity, diabetes mellitus, atherosclerosis, neurodegeneration, stroke, cancer, infectious diseases, and reproductive disorders. A substantial part of this review discusses the role of ferroptosis in the pathogenesis of reproductive disorders, such as male reproductive pathologies, including varicocele, testicular ischemia-reperfusion, cryptorchidism, oligospermia, erectile dysfunction, and testicular cancer, and female pathologies like primary ovarian insufficiency, polycystic ovary syndrome, endometriosis, ovarian cancer, and pre-eclampsia. Moreover, the interplay between ferroptosis and immune dysfunction in reproductive tract infections was highlighted. Furthermore, we evaluated current biomarkers, emerging therapeutic strategies, and key translational challenges, highlighting the promise of ferroptosis-modulating agents for novel diagnostic and therapeutic interventions in reproductive medicine and beyond.
中文摘要:铁死亡是一种依赖铁、非凋亡性的调节性细胞死亡形式,由脂质过氧化驱动。过去十年间,它已成为多种人类疾病的核心致病机制,涉及神经退行性疾病、心血管疾病、肿瘤,以及生殖功能障碍。本综述系统梳理铁死亡的分子机制,重点聚焦 System Xc⁻-GSH-GPX4 轴、铁代谢、脂质过氧化,以及 Nrf2、ACSL4、CISD2 等关键调控因子的调节作用。同时讨论铁死亡在发育、组织稳态与免疫调节中的生理作用,及其在肥胖、糖尿病、动脉粥样硬化、神经退行性变、卒中、肿瘤、感染性疾病和生殖障碍中的病理贡献。相当篇幅用于阐述铁死亡在生殖障碍发病中的作用,男性方面包括精索静脉曲张、睾丸缺血再灌注、隐睾、少精症、勃起功能障碍和睾丸癌,女性方面包括原发性卵巢功能不全、多囊卵巢综合征、子宫内膜异位症、卵巢癌和子痫前期。此外,还强调了铁死亡与免疫失调在生殖道感染中的相互作用。最后评估了现有生物标志物、新兴治疗策略和关键转化难题,指出铁死亡调控药物在生殖医学及其他领域作为新型诊断与治疗手段的前景。

9心房颤动 (2篇)

临床研究 (1篇)

Stroke IF 11.1 2026-10-29 PMID: 42953941
Patients with atrial fibrillation (AF) and prior ischemic stroke represent a high-risk population facing competing risks of recurrent thromboembolism and hemorrhagic complications. Although direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists for stroke prevention in AF, no randomized controlled clinical trial has directly compared individual DOACs to each other in this population. We conducted a systematic review and frequentist random-effects network meta-analysis of randomized-controlled clinical trials enrolling patients with AF and prior ischemic stroke or transient ischemic attack. MEDLINE, Scopus, and ClinicalTrials.gov were searched from inception until May 2026. The primary outcome was any stroke. Secondary outcomes included ischemic stroke, hemorrhagic stroke, major bleeding, intracranial hemorrhage (ICH), cardiovascular mortality, and all-cause mortality. Treatment effects were expressed as risk ratios (RR) with 95% CIs. The evidence network comprised 6 trials (18 395 patients) in a star-shaped structure. Each DOAC was informed by a single warfarin-controlled trial, and 2 trials used aspirin as the comparator. All between-DOAC comparisons were indirect. In the network meta-analysis, compared with warfarin, apixaban was the only agent to significantly reduce both any stroke (RR, 0.72 [95% CI, 0.53-0.97]) and major bleeding (RR, 0.73 [95% CI, 0.54-0.99]). Dabigatran, apixaban, and edoxaban each significantly reduced hemorrhagic stroke and ICH versus warfarin, whereas rivaroxaban did not reach significance for any bleeding outcome. Edoxaban was the only agent associated with significantly lower cardiovascular (RR, 0.79 [95% CI, 0.65-0.97]) and all-cause mortality (RR, 0.84 [95% CI, 0.72-0.99]). Based on indirect comparisons only, no differences between individual DOACs were observed. In patients with AF and prior ischemic stroke, individual DOACs reduced intracranial and systemic bleeding relative to warfarin, although not uniformly across agents. Apixaban alone significantly reduced both any stroke and major bleeding versus warfarin, but differences between individual DOACs could not be established given the small number of trials. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261404062.
中文摘要:合并心房颤动(AF)且有既往缺血性卒中的患者属于高危人群,同时面临复发性血栓栓塞和出血并发症的竞争风险。尽管指南推荐直接口服抗凝药(DOAC)优于维生素K拮抗剂用于AF卒中预防,但尚无随机对照临床试验在该人群中直接比较不同DOAC。我们开展了一项系统评价和频率学随机效应网络荟萃分析,纳入AF且有既往缺血性卒中或短暂性脑缺血发作患者的随机对照临床试验。检索MEDLINE、Scopus和ClinicalTrials.gov,时间自建库至2026年5月。主要结局为任何卒中。次要结局包括缺血性卒中、出血性卒中、大出血、颅内出血(ICH)、心血管死亡和全因死亡。治疗效应以风险比(RR)及95% CI表示。证据网络包含6项试验(18 395例患者),呈星状结构。每种DOAC仅由一项华法林对照试验提供证据,2项试验使用阿司匹林作为对照。所有DOAC之间的比较均为间接比较。在网络荟萃分析中,与华法林相比,阿哌沙班是唯一显著降低任何卒中(RR 0.72 [95% CI 0.53-0.97])和大出血(RR 0.73 [95% CI 0.54-0.99])的药物。达比加群、阿哌沙班和艾多沙班均显著降低出血性卒中和ICH相对于华法林的风险,而利伐沙班在任何出血结局上均未达到显著。艾多沙班是唯一与显著较低心血管死亡(RR 0.79 [95% CI 0.65-0.97])和全因死亡(RR 0.84 [95% CI 0.72-0.99])相关的药物。仅基于间接比较,未观察到各DOAC之间的差异。在AF且有既往缺血性卒中的患者中,各DOAC相对于华法林降低了颅内和全身性出血,但并非所有药物均一致。仅阿哌沙班相对于华法林显著降低任何卒中和大出血,但鉴于试验数量较少,无法确定各DOAC之间的差异。URL: https://www.crd.york.ac.uk/PROSPERO/;唯一标识符:CRD420261404062。

基础研究 (1篇)

Nature cardiovascular research IF 12.6 2026-10-30 PMID: 42963405
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p-CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p-CTR axis as a potential therapeutic target in AF.
中文摘要:心房颤动(房颤)是最常见的持续性心律失常,心房纤维化作为一种结构重构促进其发生,目前缺乏有效治疗。miR-31-5p是一种与衰老相关、在心房富集的microRNA,与房颤有关,但其在心房纤维化中的作用尚不清楚。持续性房颤患者的心房成纤维细胞中miR-31-5p表达升高,降钙素受体(CTR,由CALCR编码)表达降低。miR-31-5p直接抑制CTR并促进成纤维细胞的促纤维化反应,抑制miR-31-5p可恢复CTR表达。小鼠成纤维细胞特异性过表达miR-31会降低心房CTR表达、增加心房纤维化并提高心律失常易感性。使用锁核酸靶位点阻断剂选择性破坏miR-31-5p与CALCR的结合,可恢复心房CTR表达、阻止纤维化进展并降低心律失常负荷。在已形成心房重构的小鼠中,该策略促进纤维化消退,表明miR-31-5p-CTR轴是房颤的潜在治疗靶点。

10肺动脉高压 (2篇)

临床研究 (1篇)

JAMA cardiology IF 15.2 2026-10-30 PMID: 42961442
Pulmonary hypertension (PH), a progressive and life-threatening condition with rising prevalence among older adults, frequently coexists with systemic hypertension, the prognostic impact of which is poorly understood. To evaluate the association between systemic hypertension and survival in patients with PH. This multicenter cohort study analyzed data from the Pulmonary Vascular Research Institute GoDeep meta-registry, integrating global retrospective and prospective PH cohorts (n = 3238 in Europe, n = 3014 in North America, n = 96 in Africa, n = 802 in Asia, and n = 851 in Oceania). Survival was assessed using multivariable Cox proportional hazards models and adjusted for key confounders, with sensitivity analyses to validate robustness. Independent external validation was performed in a cohort in the UK. A total of 12 771 patients with incident PH (median [IQR] age, 65 [53-73] years; 7372 [58%] female) were diagnosed via right heart catheterization and comprehensive clinical data, encompassing PH groups 1-5 and all age categories. The study spans diagnosis decades from 1980 to 2020. Data were analyzed from February 2025 until September 2026. Center-reported diagnosis of systemic hypertension, baseline systolic systemic arterial pressure (sSAP), and heart rate as well as longitudinal sSAP and heart rate trajectories. All-cause mortality, adjusted for confounding variables, including age, PH group, antihypertensive and PH-specific medications, and cardiac index. Higher baseline sSAP and preexisting systemic hypertension were independently associated with improved survival. Patients with hypertension exhibited a 26% reduced mortality hazard (hazard ratio [HR], 0.74; 95% CI, 0.68-0.79) compared to their counterparts without hypertension. Survival benefits correlated positively with increasing sSAP (80-180 mm Hg), remained consistent across PH groups and age groups, and were independent of antihypertensive and PH-specific medications. Elevated heart rate was associated with higher mortality. sSAP increments correlated with improved cardiac index and tricuspid annular plane systolic excursion. Decreased sSAP and higher heart rate during follow-up correlated with higher mortality. External validation in a separate UK cohort confirmed these findings. In this global PH cohort, higher sSAP was associated with enhanced survival, while a higher baseline heart rate and declining systemic blood pressure during follow-up were significantly associated with increased mortality risk.
中文摘要:肺动脉高压(PH)是一种进展性、危及生命的疾病,在老年人中患病率上升,且常与系统性高血压并存,后者对预后的影响尚不清楚。为评估系统性高血压与PH患者生存之间的关系,这项多中心队列研究分析了肺血管研究所GoDeep meta-registry的数据,整合了全球回顾性和前瞻性PH队列(欧洲n=3238,北美n=3014,非洲n=96,亚洲n=802,大洋洲n=851)。生存采用多变量Cox比例风险模型评估,并校正关键混杂因素,同时进行敏感性分析以验证稳健性;另在英国一个队列中开展独立外部验证。共纳入12771例新发PH患者(中位[IQR]年龄65[53-73]岁;7372例[58%]女性),均经右心导管检查诊断并有完整临床资料,涵盖PH第1-5组及所有年龄类别。研究覆盖1980年至2020年的诊断年代。数据分析时间为2025年2月至2026年9月。暴露包括中心报告的系统性高血压诊断、基线收缩期体循环动脉压(sSAP)、心率以及纵向sSAP和心率轨迹。结局为全因死亡,并校正年龄、PH组别、降压药和PH特异性药物及心脏指数等混杂变量。较高的基线sSAP和既存系统性高血压与更好的生存独立相关。与无高血压者相比,高血压患者的死亡风险降低26%(风险比[HR] 0.74;95%CI 0.68-0.79)。生存获益随sSAP升高(80-180 mmHg)呈正相关,在不同PH组和年龄组中保持一致,且独立于降压药和PH特异性药物。心率升高与更高死亡率相关。sSAP升高与心脏指数和三尖瓣环收缩期位移改善相关。随访期间sSAP下降和心率升高与更高死亡率相关。英国独立队列的外部验证确认了这些发现。在这个全球PH队列中,较高的sSAP与生存改善相关,而较高的基线心率和随访期间系统性血压下降与死亡风险增加显著相关。

基础研究 (1篇)

American journal of respiratory and critical care medicine IF 21.7 2026-10-26 PMID: 42934119
Immune dysregulation is a pivotal driver of pulmonary hypertension (PH) pathogenesis, yet therapeutic targeting of inflammation has yielded limited clinical success. Although cytosolic RNA-binding proteins are known to regulate immune responses in PH, the specific role of the nuclear m⁶A reader YTHDC1 remains undefined. To elucidate the function of macrophage YTHDC1 in orchestrating inflammatory vascular remodeling during PH. Expression profiles of YTHDC1 and TP53-induced glycolysis and apoptosis regulator (TIGAR) were evaluated in human and rodent PH specimens. The mechanistic and therapeutic roles of this axis were assessed using myeloid-specific knockout mice and pharmacological inhibitors (YL-5092, 5Z-7-oxozeaenol) across hypoxia-, SU5416/hypoxia-, and monocrotaline-induced PH models. In patients with idiopathic or connective tissue disease-associated PAH, YTHDC1 and TIGAR expression levels were elevated in pulmonary and circulating macrophages, correlating with disease severity. In murine models, myeloid-specific deletion of Ythdc1 or Tigar conferred profound protection against hypoxia- and SU5416/hypoxia-induced PH. Mechanistically, hypoxia upregulated Ythdc1, which directly bound and stabilized Tigar mRNA. The subsequent accumulation of Tigar protein operated non-enzymatically via a specific domain (residues 152-161) to interact with Tak1, thereby activating the NF-κB cascade, augmenting pro-inflammatory cytokine release, and driving pulmonary artery smooth muscle cell proliferation. Pharmacological inhibition of YTHDC1 (YL-5092) or disruption of the TIGAR-TAK1 interaction (5Z-7-oxozeaenol) effectively attenuated vascular inflammation and mitigated PH progression in diverse rodent models. The macrophage YTHDC1/TIGAR/NF-κB signaling axis acts as a critical determinant of inflammation and vascular remodeling in PH, representing a potential biomarker and therapeutic target for this disease.
中文摘要:免疫失调是肺动脉高压(PH)发病的关键驱动因素,但针对炎症的治疗在临床上收效有限。已知胞质RNA结合蛋白参与调控PH的免疫反应,核内m⁶A阅读蛋白YTHDC1的具体作用尚未明确。为阐明巨噬细胞YTHDC1在PH炎症性血管重构中的功能,研究在人与啮齿类PH标本中检测了YTHDC1与TP53诱导的糖酵解和凋亡调节因子(TIGAR)的表达,并利用髓系特异性敲除小鼠与药物抑制剂(YL-5092、5Z-7-oxozeaenol)在缺氧、SU5416/缺氧及野百合碱诱导的PH模型中评价该信号轴的作用与治疗潜力。在特发性或结缔组织病相关PAH患者中,肺内及循环巨噬细胞的YTHDC1与TIGAR表达升高,并与疾病严重程度相关。小鼠模型中,髓系特异性敲除Ythdc1或Tigar对缺氧及SU5416/缺氧诱导的PH提供显著保护。机制上,缺氧上调Ythdc1,后者直接结合并稳定Tigar mRNA;Tigar蛋白积累后以非酶方式通过特定结构域(第152-161位残基)与Tak1相互作用,激活NF-κB级联,增加促炎细胞因子释放,并推动肺动脉平滑肌细胞增殖。药物抑制YTHDC1(YL-5092)或阻断TIGAR-TAK1相互作用(5Z-7-oxozeaenol)可有效减轻多种啮齿类模型的血管炎症并延缓PH进展。巨噬细胞YTHDC1/TIGAR/NF-κB信号轴是PH炎症与血管重构的关键决定因素,可作为该病的潜在生物标志物与治疗靶点。

11心脏瓣膜病/TAVR (1篇)

临床研究 (1篇)

Progress in cardiovascular diseases IF 10.6 2026-10-30 PMID: 42962742
Pre-procedural nutritional status has been proposed as a prognostic marker in transcatheter aortic valve replacement (TAVR), although most studies rely on isolated nutrition scores. This study examined how multiple serum-based nutritional scores influence post-TAVR survival. Consecutive patients undergoing TAVR between December 2021 and December 2023 were retrospectively analyzed. Eight serum biomarker-based scores were calculated for each patient (GNRI, PNI, CONUT, PALBI, TCBI, PACI, AGR, ALBI). Associations with overall survival were assessed with Kaplan-Meier curves and adjusted multivariable Cox regression. Principal component analysis (PCA) evaluated relationships among scores. A total of 459 patients were included (mean age 81.7 ± 7.1 years, 45.8% female, median STS 2.8 [1.8-4.4]). The eight scores frequently classified the same patients into different risk strata. Significant survival differences were observed for all scores' most severe stratification except CONUT (p = 0.083) and PNI (p = 0.133). In adjusted Cox models, most scores showed a statistically significant association with overall mortality, except for GNRI (p = 0.237), PALBI (p = 0.378) and TCBI (p = 0.125). PCA demonstrated substantial collinearity among several scores and highlighted a dominant first principal component (PC), PC1 = 54%, without improved discrimination compared to STS score. In the adjusted Cox model, PC1 was also significantly associated with overall mortality (p < 0.001). Despite capturing overlapping biological domains, serum-based nutritional scores inconsistently classify TAVR patients. PCA suggests that a single underlying biomarker dimension explains most of the variability among scores, highlighting overlap and inconsistency across them and supporting the need for a more integrated approach to nutritional assessment rather than single metrics.
中文摘要:术前营养状态被认为是经导管主动脉瓣置换术(TAVR)的预后标志物,但多数研究依赖单一营养评分。本研究考察多种基于血清的生物标志物营养评分如何影响TAVR术后生存。回顾性分析2021年12月至2023年12月连续接受TAVR的患者。为每例患者计算8种基于血清生物标志物的评分(GNRI、PNI、CONUT、PALBI、TCBI、PACI、AGR、ALBI)。采用Kaplan-Meier曲线和校正多变量Cox回归评估与总生存的关联。主成分分析(PCA)评估评分间关系。共纳入459例患者(平均年龄81.7±7.1岁,女性45.8%,STS中位数2.8[1.8-4.4])。八种评分常将同一患者分入不同风险分层。除CONUT(p=0.083)和PNI(p=0.133)外,各评分最严重分层均观察到显著生存差异。校正Cox模型中,除GNRI(p=0.237)、PALBI(p=0.378)和TCBI(p=0.125)外,多数评分与总死亡率呈统计学显著关联。PCA显示若干评分间存在明显共线性,并突出一个主导的第一主成分(PC),PC1=54%,但与STS评分相比未改善区分能力。在校正Cox模型中,PC1也与总死亡率显著相关(p<0.001)。尽管基于血清的营养评分捕捉到重叠的生物学维度,其对TAVR患者的分层并不一致。PCA提示单一潜在生物标志物维度可解释评分间大部分变异,凸显评分间的重叠与不一致,支持需要更整合的营养评估方法而非单一指标。

12心脏瓣膜病 (1篇)

基础研究 (1篇)

Molecular biomedicine IF 13.0 2026-10-28 PMID: 42955596
Aortic stenosis (AS) is increasingly prevalent in ageing populations, yet no pharmacological therapy has been shown to modify its progression to heart failure (HF). Sodium glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in HF, but their effects in pressure overload-induced cardiac remodeling remain unclear. Here, we show that rats with long-term AS develop HF features, left ventricular dilation, and systolic and diastolic dysfunction, accompanied by increased oxidative stress, impaired antioxidant defenses, myocardial fibrosis, and transcriptional remodeling. Empagliflozin (10 mg/kg/day for 8 weeks) attenuated cardiac dysfunction and reduced HF features. At molecular level, empagliflozin prevented increase in lipid peroxidation, and decreased interstitial collagen deposition, while increasing glutathione peroxidase and matrix metalloproteinase-2 activity. Transcriptomic analysis identified 1,078 differentially expressed genes and revealed enrichment of pathways associated with extracellular matrix organization and signal transduction in AS. Empagliflozin predominantly regulated genes involved in cardiac contraction, mitochondrial membrane organization, apoptosis, and cell survival. Profibrotic and remodeling-associated genes were upregulated in AS, while empagliflozin induced a distinct transcriptional program associated with improved myocardial homeostasis. AS was associated with reduced activity of energy metabolism enzymes, which was not restored by empagliflozin. Collectively, these findings identify oxidative stress, extracellular matrix remodeling, and transcriptional reprogramming as mechanisms underlying cardiac dysfunction in AS. Empagliflozin mitigates cardiac remodeling and HF progression and modulates fibrosis and gene networks regulating cardiac function. These data highlight SGLT2 inhibition as a potential therapeutic strategy in pressure overload-induced heart failure.
中文摘要:主动脉狭窄(AS)在老龄人群中日益常见,但尚无药物疗法被证明可改变其向心力衰竭(HF)的进展。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂可改善HF结局,但其在压力负荷诱导的心脏重构中的作用仍不清楚。在长期AS大鼠中,可见HF特征、左心室扩张及收缩和舒张功能障碍,并伴有氧化应激增加、抗氧化防御受损、心肌纤维化和转录重构。恩格列净(10 mg/kg/天,8周)减轻心脏功能障碍并减少HF特征。在分子层面,恩格列净阻止脂质过氧化升高,减少间质胶原沉积,同时增加谷胱甘肽过氧化物酶和基质金属蛋白酶-2活性。转录组分析识别出1,078个差异表达基因,并显示AS中与细胞外基质组织和信号转导相关的通路富集。恩格列净主要调控参与心脏收缩、线粒体膜组织、凋亡和细胞存活的基因。AS中促纤维化和重构相关基因上调,而恩格列净诱导了与改善心肌稳态相关的独特转录程序。AS与能量代谢酶活性降低相关,恩格列净未恢复该活性。这些发现将氧化应激、细胞外基质重构和转录重编程确定为AS中心脏功能障碍的机制。恩格列净减轻心脏重构和HF进展,并调节纤维化及调控心脏功能的基因网络。这些数据提示SGLT2抑制是压力负荷诱导心力衰竭的潜在治疗策略。

13心肌梗死 (1篇)

基础研究 (1篇)

Cell stem cell IF 23.3 2026-10-28 PMID: 42950822
Whether epicardium-derived cells (EPDCs) can differentiate into endothelial cells after myocardial infarction (MI) remains unclear. Considering the heart's electrical dependence, we asked if restoring electrical conduction could direct this potential. Using cardiac patches with tunable electroconductivity and genetic fate-mapping approaches in mice, we found that patches matching native myocardial electroconductivity (10-4-10-3 S/cm) specifically promoted proliferation and endothelial differentiation of WT1+ EPDCs, rescuing cardiac function. Single-cell transcriptomic sequencing revealed that electroconductive patches drove WT1+ EPDCs into a distinct WT1+TRPC3+CD93+ transitional state. These cells differentiated into endothelial cells via TRPC3-Ca2+ signaling and integrated into functional vessels. Inhibiting TRPC3 blocked differentiation and reduced infarct vascularization. Thus, improving electrical conduction unlocks and directs the endothelial differentiation of WT1+ EPDCs, offering a strategy for post-MI repair.
中文摘要:心肌梗死后心外膜来源细胞(EPDCs)能否分化为内皮细胞仍不清楚。考虑到心脏对电活动的依赖,我们提出恢复电传导是否可引导这一潜能。利用电导率可调的心脏补片和小鼠遗传命运图谱方法,我们发现与天然心肌电导率(10⁻⁴–10⁻³ S/cm)匹配的补片特异性促进WT1+ EPDCs增殖和内皮分化,并改善心功能。单细胞转录组测序显示,导电补片驱动WT1+ EPDCs进入一种独特的WT1+TRPC3+CD93+过渡状态。这些细胞通过TRPC3-Ca2+信号分化为内皮细胞,并整合进功能性血管。抑制TRPC3阻断分化并减少梗死区血管化。因此,改善电传导可解锁并引导WT1+ EPDCs的内皮分化,为梗死后修复提供策略。

14急性肾损伤 (1篇)

临床研究 (1篇)

Science translational medicine IF 15.6 2026-10-28 PMID: 42950015
Acute kidney injury (AKI) affects ∼20% of hospitalized patients and is traditionally viewed as a transient complication of acute illness. Evidence suggests that AKI can initiate long-term renal and cardiovascular disease, even when kidney function appears to recover. Survivors of AKI face increased risks of CKD, heart failure, myocardial infarction, and premature mortality, yet post-AKI care remains poorly defined. We synthesize emerging mechanistic and clinical evidence linking AKI to systemic cardiorenal disease and discuss how biomarkers, imaging, and clinical risk prediction may enable identification of high-risk patients and support translational strategies to prevent progression to chronic disease.
中文摘要:急性肾损伤(AKI)影响约20%的住院患者,传统上被视为急性疾病的短暂并发症。证据提示,即使肾功能看似恢复,AKI仍可启动长期肾脏和心血管疾病。AKI幸存者面临慢性肾脏病、心力衰竭、心肌梗死和过早死亡的风险增加,但AKI后的照护仍缺乏明确规范。我们综合了将AKI与全身性心肾疾病联系起来的新兴机制和临床证据,并讨论生物标志物、影像学和临床风险预测如何识别高风险患者,并支持阻止进展为慢性疾病的转化策略。

15先天性心脏病 (1篇)

基础研究 (1篇)

Circulation research IF 18.0 2026-10-28 PMID: 42948879
Haploinsufficiency of the RNA splicing regulator RBFOX2 has been linked to congenital heart disease, including hypoplastic left heart syndrome, yet its pathogenic mechanisms remain unresolved. Human induced pluripotent stem cells heterozygous or null for RBFOX2 were created and their cardiomyocyte (CM) derivatives were characterized in monolayer culture and engineered heart tissues. In addition to cellular phenotyping, molecular profiling by RNA sequencing and enhanced crosslinking and immunoprecipitation sequencing was performed to detect changes in gene expression, exon usage, and RBFOX2 (RNA-binding fox-1 homolog 2) binding. These data sets were integrated to identify RBFOX2-bound RNAs with altered expression and splicing and to compare them with publicly available data sets from progressive CM differentiation time points. Rescue experiments were performed in induced pluripotent stem cell-derived CMs, engineered heart tissues, and zebrafish. We demonstrate that RBFOX2 is essential for CM differentiation by driving transcriptome maturation through gene expression- and alternative splicing-based isoform switching in transcripts primarily encoding sarcomere, cytoskeletal, and focal adhesion components, including the critical Z-disc factor ACTN2 (alpha-actinin-2). We further find that threshold levels of RBFOX2 facilitate autoregulatory splicing of mutually exclusive exons, generating early and late RBFOX2 isoforms with distinct functions. In heterozygous CMs, this threshold is not reached, resulting in isoform imbalance and production of an aberrant transcript, which further reduces functional RBFOX2 levels to well below 50% of wild-type. Finally, we demonstrate that ACTN2 overexpression rescues heterozygous, but not null, phenotypes, suggesting that ACTN2 activates an RBFOX2-dependent feedback loop that promotes transcriptome maturation. Our data demonstrate that reduced RBFOX2 dosage and impaired autoregulation stall CM differentiation by inhibiting transcriptome maturation, contributing to congenital heart disease pathogenesis and potentially increasing heart failure susceptibility following surgical intervention.
中文摘要:RBFOX2单倍剂量不足与先天性心脏病(包括左心发育不良综合征)相关,但其致病机制尚未明确。研究构建了RBFOX2杂合或完全缺失的人诱导多能干细胞,并在单层培养和工程化心脏组织中表征其心肌细胞(CM)衍生细胞。除细胞表型分析外,还通过RNA测序和增强型交联免疫沉淀测序进行分子谱分析,以检测基因表达、外显子使用和RBFOX2结合的变化。整合这些数据集,识别表达和剪接发生改变且被RBFOX2结合的RNA,并与公开的CM逐步分化时间点数据集比较。在诱导多能干细胞来源CM、工程化心脏组织和斑马鱼中开展回补实验。研究显示,RBFOX2通过基于基因表达和可变剪接的异构体转换驱动转录组成熟,从而对CM分化至关重要;这些转录本主要编码肌节、细胞骨架和黏着斑组分,包括关键Z盘因子ACTN2(α-辅肌动蛋白2)。进一步发现,RBFOX2的阈值水平促进互斥外显子的自调控剪接,产生功能不同的早期和晚期RBFOX2异构体。在杂合CM中未达到该阈值,导致异构体失衡并产生异常转录本,使功能性RBFOX2水平进一步降至远低于野生型的50%。最后,ACTN2过表达可挽救杂合而非完全缺失表型,提示ACTN2激活RBFOX2依赖的反馈环路以促进转录组成熟。数据表明,RBFOX2剂量降低和自调控受损通过抑制转录组成熟使CM分化停滞,参与先天性心脏病发病机制,并可能增加外科干预后心力衰竭易感性。

16心脏纤维化 (1篇)

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-10-28 PMID: 42946663
Plasminogen activator inhibitor-1 (PAI-1) regulates plasmin-mediated proteolysis, thereby influencing vascular stability and tissue remodeling. Angiotensin II (AngII) induces an increase in PAI-1 during the development of ascending thoracic aortic aneurysm (ATAA). The initial purpose of this study was to determine whether deletion of PAI-1 influenced development of ATAA. Subsequently, this study aimed to define the early pathological events preceding cardiac fibrosis in PAI-1 deficiency and the structural domain responsible for its protective effect. AngII was infused for 4 weeks in whole-body PAI-1 deficient (PAI-1-/-) mice and their wild-type littermates (PAI-1+/+) to examine the role of PAI-1 in ATAA. PAI-1 deficiency did not alter AngII-induced aortopathy but revealed a striking cardiac phenotype characterized by replacement fibrosis predominantly within the epicardium and posterior septum. Ferric iron, indicative of prior hemorrhage, was coincident with fibrosis. Similar phenotypes were observed in PAI-1-/- mice infused with norepinephrine for 4 weeks. To define the pathological events preceding cardiac fibrosis, either AngII or norepinephrine was infused for 1 week in PAI-1+/+ or -/- mice. Both infusions induced extensive epicardial hemorrhage and posterior septal fibrosis in PAI-1-/- mice. To explore the initiation of cardiac pathology, AngII was infused for approximately 1 day. PAI-1-/- mice developed diffuse hemorrhage and cardiomyocyte injury localized to the posterior septum, pathologic changes that preceded overt fibrosis. Finally, to determine the protective domain of PAI-1, saline or AngII was administered to mice harboring loss-of-function point mutations in the protease inhibitory (PAI-1Ala/Ala) or somatomedin B-binding domains (PAI-1AK/AK). Compared to saline infusion, 1 week of AngII induced hemorrhage and heterogeneous fibrosis in PAI-1Ala/Ala, but not PAI-1AK/AK mice. These findings support that, under hemodynamic stress, PAI-1 deficiency promotes early cardiac hemorrhage and cardiomyocyte injury that lead to fibrosis. Mutational studies implicate dysregulated plasmin generation as an initiator of cardiac injury and fibrosis.
中文摘要:纤溶酶原激活物抑制剂-1(PAI-1)调控纤溶酶介导的蛋白水解,从而影响血管稳定性和组织重塑。血管紧张素II(AngII)在升主动脉胸段动脉瘤(ATAA)形成过程中诱导PAI-1升高。本研究最初旨在确定PAI-1缺失是否影响ATAA发生。随后,研究旨在明确PAI-1缺陷时心脏纤维化之前的早期病理事件,以及其保护作用对应的结构域。对全身PAI-1缺陷(PAI-1-/-)小鼠及其野生型同窝(PAI-1+/+)小鼠输注AngII 4周,以考察PAI-1在ATAA中的作用。PAI-1缺陷未改变AngII诱导的主动脉病变,却显示出显著的心脏表型,以主要位于心外膜和后间隔的替代性纤维化为特征。提示既往出血的铁离子与纤维化同时存在。对PAI-1-/-小鼠输注去甲肾上腺素4周也观察到相似表型。为明确心脏纤维化之前的病理事件,对PAI-1+/+或-/-小鼠输注AngII或去甲肾上腺素1周。两种输注均在PAI-1-/-小鼠中引起广泛心外膜出血和后间隔纤维化。为探索心脏病理的起始,输注AngII约1天。PAI-1-/-小鼠出现局限于后间隔的弥漫性出血和心肌细胞损伤,这些病理改变早于明显纤维化。最后,为确定PAI-1的保护结构域,对携带蛋白酶抑制结构域(PAI-1Ala/Ala)或生长调节素B结合结构域(PAI-1AK/AK)功能丧失点突变的小鼠给予生理盐水或AngII。与生理盐水输注相比,AngII输注1周在PAI-1Ala/Ala小鼠中诱导出血和异质性纤维化,但在PAI-1AK/AK小鼠中未诱导。这些发现支持在血流动力学应激下,PAI-1缺陷促进早期心脏出血和心肌细胞损伤,进而导致纤维化。突变研究提示纤溶酶生成失调是心脏损伤和纤维化的启动因素。

17肥厚型心肌病 (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-28 PMID: 42544039
Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) led to significant improvements in patient-reported outcomes (PROs) in the pivotal SEQUOIA-HCM trial over 24 weeks, but its longer-term impact has not been described. The aim of this study was to describe the long-term effects of aficamten across multiple PROs in FOREST-HCM, an open-label extension study. Participants with oHCM completing an aficamten trial were offered enrolment in FOREST-HCM. The Kansas City Cardiomyopathy Questionnaire (KCCQ), Seattle Angina Questionnaire 7-item, EuroQol Five-Dimensional Questionnaire index, and visual analogue scale were administered at baseline and at weeks 12, 24, 36, and 48. Associations among PROs and clinical markers of oHCM severity were assessed with Spearman correlation coefficients. A total of 172 participants (mean age 60.4 [SD ± 13.1] years; 45.3% female) completed ≥48 weeks of follow-up as of 31 August 2024, and were included. Significant improvements in all PROs were observed by week 12 and sustained through week 48. At 48 weeks, mean Kansas City Cardiomyopathy Questionnaire-Overall Summary Score improved by 18.8 (16.9-20.6) points, (P < .001), with the largest gains in the KCCQ Quality of Life domain (25.8 points [23.2-28.5; P < .001]). Seattle Angina Questionnaire 7-item -Summary Scores increased by 17.2 (15.1-19.4; P < .001), and EuroQol Five-Dimensional Questionnaire index and visual analogue scale scores improved by 0.11 and 12.7 points, respectively (P < .001). Improvements in PROs were significantly correlated with important clinical measures of oHCM. Aficamten resulted in sustained improvements across multiple health status dimensions, which also correlated with clinical markers of oHCM severity. NCT04848506.
中文摘要:在oHCM患者中,aficamten治疗在关键SEQUOIA-HCM试验的24周内显著改善患者报告结局(PROs),但其长期影响尚未描述。本研究旨在描述FOREST-HCM这一开放标签扩展研究中aficamten对多项PROs的长期影响。完成aficamten试验的oHCM参与者被邀请入组FOREST-HCM。在基线及第12、24、36、48周完成堪萨斯城心肌病问卷(KCCQ)、西雅图心绞痛问卷7条目、EuroQol五维问卷指数和视觉模拟量表。采用Spearman相关系数评估PROs与oHCM严重程度临床标志物之间的关联。截至2024年8月31日,共172名参与者(平均年龄60.4岁[SD ±13.1];45.3%女性)完成≥48周随访并纳入分析。至第12周观察到所有PROs显著改善,并持续至第48周。第48周时,KCCQ总体汇总评分平均改善18.8(16.9-20.6)分(P < .001),KCCQ生活质量领域改善最大(25.8分[23.2-28.5;P < .001])。西雅图心绞痛问卷7条目汇总评分增加17.2(15.1-19.4;P < .001),EuroQol五维问卷指数和视觉模拟量表评分分别改善0.11分和12.7分(P < .001)。PROs改善与oHCM的重要临床指标显著相关。Aficamten在多个健康状态维度带来持续改善,并与oHCM严重程度的临床标志物相关。NCT04848506。

18心衰合并房颤 (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-28 PMID: 42531097
The CASTLE-HTx trial (NCT04649801) showed that the combination of catheter ablation and guideline-directed medical therapy (GDMT) was associated with a lower likelihood of a composite of death from any cause, implantation of a left-ventricular assist device (LVAD), or heart transplantation (HTx) in patients with end-stage heart failure (HF) and atrial fibrillation (AF). This is an ancillary analysis with the generalized pairwise comparison methodology of the main outcomes of CASTLE-HTx. In CASTLE-HTX, 194 patients were randomized to catheter ablation and GDMT (n = 97) or medical therapy alone (n = 97). The first hierarchical outcome was a composite of (1) death from any cause, (2) urgent HTx, (3) implantation of an LVAD, and (4) frequency of hospitalizations for worsening HF. Secondary analysis also included AF burden and left-ventricular ejection fraction improvement. Treatment effects are reported as net treatment benefit (NTB) and win odds, with corresponding confidence intervals (CIs). Patients randomized to ablation had more wins with respect to death from any cause (28.4%/12.4%), HTx (4.3%/2.1%), LVAD implantation (4.2%/0.6%), and hospitalizations for worsening HF (24.8%/11.3%). 61.6% of pairs favoured ablation, 26.4% medical therapy, and 12.0% were tied. This resulted in a restricted NTB at 3 years of 35.3% (95% CI, 19.8-49.0, P < .001) favouring ablation (win odds: 2.09; 95% CI, 1.49-2.92). In the secondary analysis, 67.0% of pairs favoured ablation against 28.6% of pairs favouring medical therapy. The restricted NTB was 38.4% (95% CI, 22.8-52.0, P < .001) in favour of ablation (win odds: 2.25; 95% CI, 1.59-3.17). This pairwise analysis of CASTLE-HTx confirms the clinical benefits of early catheter ablation in addition to GDMT among AF patients in end-stage HF. The treatment benefit was primarily driven by mortality and HF hospitalizations.
中文摘要:CASTLE-HTx试验(NCT04649801)显示,在终末期心力衰竭(HF)合并心房颤动(AF)患者中,导管消融联合指南导向药物治疗(GDMT)与全因死亡、植入左心室辅助装置(LVAD)或心脏移植(HTx)复合结局的发生可能性降低相关。这是一项采用广义成对比较方法对CASTLE-HTx主要结局进行的辅助分析。CASTLE-HTx中,194例患者随机接受导管消融联合GDMT(n=97)或单纯药物治疗(n=97)。第一层级结局为复合结局:(1)全因死亡,(2)紧急HTx,(3)植入LVAD,(4)因心衰恶化住院的频率。次要分析还包括AF负荷和左心室射血分数改善。治疗效果以净治疗获益(NTB)和胜率比(win odds)报告,并给出相应置信区间(CI)。随机接受消融的患者在全因死亡(28.4%/12.4%)、HTx(4.3%/2.1%)、LVAD植入(4.2%/0.6%)和心衰恶化住院(24.8%/11.3%)方面获得更多胜出。61.6%的配对倾向于消融,26.4%倾向于药物治疗,12.0%为平局。由此得到3年时限制性NTB为35.3%(95% CI,19.8-49.0,P < .001),倾向于消融(胜率比:2.09;95% CI,1.49-2.92)。在次要分析中,67.0%的配对倾向于消融,28.6%的配对倾向于药物治疗。限制性NTB为38.4%(95% CI,22.8-52.0,P < .001),支持消融(胜率比:2.25;95% CI,1.59-3.17)。这项针对CASTLE-HTx的成对分析证实,在终末期HF的AF患者中,早期导管消融联合GDMT具有临床获益。治疗获益主要由死亡率和心衰住院驱动。

19三尖瓣反流 (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-28 PMID: 42454550
Tricuspid regurgitation (TR) rarely exists as an isolated condition and is most frequently secondary due to heart failure (HF), or atrial fibrillation, with prevalent extracardiac comorbidities. Morphological assessment of the anatomy and severity of TR, together with evaluation of symptoms, currently drives interventional approaches, yet a more holistic integration of causal and contributing comorbid conditions might further improve outcomes. The present review explores such a pathophysiology-driven holistic approach to interpret functional changes and symptomatic burden in patients with TR. It focuses on acknowledging the dynamic nature of TR, but most importantly, the bidirectional crosstalk between TR and HF, as well as other organ systems that might drive symptoms and prognosis, but also TR progression. Assessment of TR is ideally performed after optimizing the treatment of interfering comorbidities and correcting volume overload to isolate the true effects of the TR itself. Invasive haemodynamic assessment, portal vein Doppler, and liver stiffness measurements may offer useful information in clinical decision-making. When TR is identified as the primary driver of disease, or if it is strongly interacting with concomitant diseases, more aggressive therapeutic approaches may be pursued. In contrast, when it is more a consequence of the underlying HF, the right expectations in terms of symptomatic improvement and prognosis should be set. This framework may help to identify patients who are the most likely to benefit from TR interventions, while acknowledging the complexity of their clinical picture in the context of HF.
中文摘要:三尖瓣反流(TR)很少作为孤立疾病存在,多数为继发性,由心力衰竭(HF)或心房颤动引起,并常伴心外共病。TR的解剖形态与严重程度评估以及症状评价目前驱动介入治疗选择,但更整体地整合病因与促发共病可能进一步改善结局。一种以病理生理为驱动的整体评估方法可用于解释TR患者的功能变化与症状负担,重点在于认识TR的动态性,更重要的是TR与HF以及其他器官系统之间的双向交互,这些交互可能驱动症状与预后,也可能推动TR进展。TR评估最好在优化干扰性共病治疗并纠正容量负荷过重之后进行,以分离TR本身的真实影响。有创血流动力学评估、门静脉多普勒与肝硬度测量可在临床决策中提供有用信息。当TR被确定为疾病的主要驱动因素,或与合并疾病强烈交互时,可采取更积极的治疗策略。相反,当TR更多是基础HF的结果时,应对症状改善与预后设定合理预期。该框架可能有助于识别最可能从TR干预中获益的患者,同时承认其在HF背景下临床情况的复杂性。

20心脏移植 (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-28 PMID: 42085519
Heart transplantation (HT) remains the reference therapy for selected eligible patients with advanced heart failure (HF), recent developments in drug and device therapies notwithstanding. The majority of heart transplants are performed in Europe and the USA. However, the rate of heart transplants varies greatly among European countries, ranging from <1 to >10 per million population per annum. Due to donor organ shortage, durable mechanical circulatory support (MCS) became a practical solution for many advanced HF patients, either as a bridge to transplant or as destination therapy. The aim of the present consensus document is to provide a perspective on important issues regarding HT, in particular patient selection, pre-transplant work-up, matching of donor heart and recipient, strategies of bridging patients to transplant with temporary or durable MCS, as well as how to increase the donor organ pool. Furthermore, surgical techniques and complications are discussed, as well as immediate post-transplant, and long-term management including the main aspects of long-term follow up such as rejection surveillance, personalized immunosuppression and managing comorbidities. Cellular and antibody mediated rejection, early cardiac allograft failure, and indications for retransplantation are described. An emphasis is given on the most important post-HT complications, such as cardiac allograft vasculopathy, infections and malignancies. Finally, the need for tailored physical rehabilitation and psychosocial support, and impact of post-transplant status on reproductive health are discussed.
中文摘要:心脏移植(HT)仍是部分符合条件的晚期心力衰竭(HF)患者的参照治疗,尽管药物和器械治疗近期已有进展。大多数心脏移植在欧洲和美国实施。然而,欧洲各国的心脏移植率差异很大,范围为每年每百万人口<1例至>10例。由于供体器官短缺,耐久性机械循环支持(MCS)已成为许多晚期HF患者的实用解决方案,既可作为移植桥接,也可作为终点治疗。本共识文件旨在提供关于HT重要问题的视角,尤其是患者选择、移植前评估、供体心脏与受体的匹配、以临时或耐久性MCS桥接患者至移植的策略,以及如何扩大供体器官池。文中还讨论了手术技术和并发症,以及移植后即刻管理和长期管理,包括长期随访的主要方面,如排斥监测、个体化免疫抑制和合并症管理。文中描述了细胞介导和抗体介导的排斥反应、早期心脏移植物衰竭以及再移植的适应证。重点讨论了HT后最重要的并发症,如心脏移植物血管病变、感染和恶性肿瘤。文末还讨论了定制化身体康复和心理社会支持的必要性,以及移植后状态对生殖健康的影响。

21心脏骤停/猝死 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 40879661
Smoking is a risk factor for cardiovascular events. Regarding the different aetiology of sudden cardiac arrest (SCA) in younger individuals compared with the elderly, we investigated the linkage between smoking and the risk of SCA in young-aged adults. In this retrospective analysis, an observational longitudinal cohort was obtained from the national health screening database in South Korea. Adults aged between 20 and 39 years who underwent health screening from 2009 to 2012 were included. Smoking status was categorized as non-smokers, ex-smokers, and current smokers. The burden of smoking was classified as mild (<10 pack-years), moderate (<20 pack-years), and heavy smokers (≥20 pack-years). The primary outcome was the occurrence of SCA during follow-up. Among 6 293 672 individuals, the mean age was 30.8 years, and the median follow-up duration was 9.7 years. Comorbidities such as hypertension, diabetes mellitus, or dyslipidaemia were rare. Non-smokers were most prevalent (55.2%), followed by current smokers (34.8%) and ex-smokers (10.1%). The incidence of SCA increased from non-smokers (0.06 per 1000 person-years), ex-smokers (0.08), to current smokers (0.14). Current smokers showed increased risk of SCA compared with non-smokers (adjusted hazard ratio 1.69, 95% confidence interval 1.57-1.81, P < 0.001). The risk of SCA was not increased in ex-smokers (0.96, 0.86-1.07, P = 0.420). Higher smoking burden was associated with accelerated risk of SCA (adjusted hazard ratio in heavy smokers 2.15, 1.90-2.43, P < 0.001). In young-aged adults, current smoking was associated with significantly increased risk of SCA in long-term follow-up. The risk of SCA showed a dose-dependent association with cumulative burden of lifetime cigarette exposure.
中文摘要:吸烟是心血管事件的风险因素。年轻人心源性猝死的病因与老年人不同,本研究考察吸烟与年轻成人心脏骤停风险之间的关联。这项回顾性分析采用韩国国家健康筛查数据库构建观察性纵向队列,纳入2009年至2012年接受健康筛查的20至39岁成人。吸烟状态分为不吸烟、既往吸烟和当前吸烟。吸烟负荷分为轻度(<10包年)、中度(<20包年)和重度(≥20包年)。主要结局为随访期间发生心脏骤停。在6 293 672名个体中,平均年龄30.8岁,中位随访时间9.7年。高血压、糖尿病或血脂异常等合并症少见。不吸烟者最多(55.2%),其次为当前吸烟者(34.8%)和既往吸烟者(10.1%)。心脏骤停发生率从不吸烟者(每1000人年0.06)、既往吸烟者(0.08)到当前吸烟者(0.14)逐渐升高。与不吸烟者相比,当前吸烟者心脏骤停风险增加(校正风险比1.69,95%置信区间1.57-1.81,P<0.001)。既往吸烟者的心脏骤停风险未增加(0.96,0.86-1.07,P=0.420)。吸烟负荷越高,心脏骤停风险增加越明显(重度吸烟者校正风险比2.15,1.90-2.43,P<0.001)。在年轻成人中,当前吸烟与长期随访期间心脏骤停风险显著增加相关。心脏骤停风险与终生累计香烟暴露量呈剂量依赖性关联。

22冠心病 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-28 PMID: 40250842
There is a variety of smoking habits trajectories in patients with established stable coronary artery disease (CAD), with unclear consequences on cardiovascular (CV) events. We aimed to clarify the impact of smoking cessation and reduction on long-term cardiovascular outcomes in stable CAD patients, evaluating whether quitting at any stage still provides significant benefits and to what extent. The CLARIFY registry included 32 378 outpatients with stable CAD. Smoking history and status were recorded annually during the 5-year follow-up. In active smokers, we studied the effect of smoking cessation or reduction. In former smokers, we analysed the timing of smoking cessation relative to CAD diagnosis and residual CV risk based on years of abstinence. The primary outcome was a composite of CV death and MI. At inclusion, 46.2% of patients were former smokers and 12.5% current smokers. Amongst active smokers, smoking cessation in the stable phase of the disease was associated with improved outcomes, irrespective of timing (aHR 0.56, 95% CI: 0.42-0.76, P < 0.001). However, smoking quantity reduction was not associated with improved CV outcomes. Among former smokers, 55.7% had quit within a year of CAD diagnosis. Each additional year of smoking post-CAD diagnosis increased CV risk. Former smokers never returned to the CV risk level of never smokers, regardless of years of abstinence. In stable CAD patients, smoking cessation is associated with significantly better CV outcomes and survival, irrespective of the timing of cessation, and should therefore always be a priority. Smoking reduction was not associated with improved CV outcomes. Most former smokers quit within a year of CAD diagnosis, and CV risk increases with each subsequent year of active smoking. In a cohort of over 32 000 patients with stable coronary artery disease (CAD) with a 5-year follow-up, the evolution of smoking habits revealed that:Quitting smoking at any point-even years after diagnosis-is associated with a 50% reduction in the risk of subsequent cardiovascular events and death. However, only 12% of active smokers quit each year on average. Conversely, reducing the number of cigarettes without fully quitting is not associated with a lower risk of adverse cardiovascular events.Most former smokers quit within a year of their CAD diagnosis, with cardiovascular risk increasing for each additional year of continued smoking afterward. Finally, former smokers never returned to the cardiovascular risk level of never smokers, regardless of years of abstinence.
中文摘要:已确诊稳定型冠心病患者的吸烟习惯轨迹多种多样,其对心血管事件的影响尚不清楚。本研究旨在阐明戒烟和减烟对稳定型冠心病患者长期心血管结局的影响,评估在任何阶段戒烟是否仍能带来显著获益以及获益程度。CLARIFY注册研究纳入32378例稳定型冠心病门诊患者,随访5年期间每年记录吸烟史和吸烟状态。在现吸烟者中,研究戒烟或减烟的效果;在既往吸烟者中,分析戒烟时间相对于冠心病诊断的时机,以及基于戒烟年数的残余心血管风险。主要结局为心血管死亡和心肌梗死的复合终点。入组时46.2%为既往吸烟者,12.5%为现吸烟者。在现吸烟者中,疾病稳定期戒烟与结局改善相关,且与戒烟时机无关(aHR 0.56,95% CI 0.42-0.76,P<0.001)。减少吸烟量未与心血管结局改善相关。既往吸烟者中55.7%在冠心病诊断后1年内戒烟。冠心病诊断后每多吸烟1年,心血管风险增加。无论戒烟年数如何,既往吸烟者的心血管风险从未恢复到从不吸烟者水平。在稳定型冠心病患者中,戒烟与显著更好的心血管结局和生存相关,且与戒烟时机无关,因此应始终作为优先事项。减少吸烟量未与心血管结局改善相关。多数既往吸烟者在冠心病诊断后1年内戒烟,此后每继续吸烟1年,心血管风险增加。在超过32000例稳定型冠心病患者、随访5年的队列中,吸烟习惯演变显示:在任何时点戒烟,即使是在诊断多年后戒烟,均与后续心血管事件和死亡风险降低约50%相关;现吸烟者平均每年仅12%戒烟。相反,减少每日吸烟支数但未完全戒烟,与不良心血管事件风险降低无关。多数既往吸烟者在冠心病诊断后1年内戒烟,此后每继续吸烟1年心血管风险增加。无论戒烟年数如何,既往吸烟者的心血管风险从未恢复到从不吸烟者水平。

23子痫前期 (1篇)

基础研究 (1篇)

Circulation research IF 18.0 2026-10-27 PMID: 42935477
Maternal microvascular dysfunction is a hallmark of the hypertensive pregnancy disorder preeclampsia, but the mechanism(s) have not been fully defined. Within vascular smooth muscle cells, the principal pressure-induced vasodilatory pathway depends on localized Ca2+-release events from the sarcoplasmic reticulum ryanodine receptors (Ca2+ sparks), which stimulate BKCa (large-conductance Ca2+-activated potassium channels) to cause spontaneous transient outward currents and vasorelaxation. Here, the Ca2+ sparks-BKCa axis is assessed in preeclampsia for the first time. Pressurized omental resistance arteries from normotensive pregnant women and women with preeclampsia were imaged by high-speed spinning-disk laser confocal microscopy to assess Ca2+ sparks (20-110 mm Hg) and caffeine-evoked Ca2+ release (10 mmol/L; 80 mm Hg). Electrophysiology was used to assess spontaneous transient outward currents (-60 to 0 mV) and BKCa currents (-100 to +100 mV) in isolated vascular smooth muscle cells. A liquid chromatography-selected reaction monitoring-tandem mass spectrometry assay measured SERCA2 (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-2) and unphosphorylated/phosphorylated proteoforms of regulatory PLN (phospholamban). Vasoactive effects of the BKCa-dependent vasorelaxant HBD2 (human β-defensin-2; 0.01-10 nmol/L) were assessed by wire myography. In microvascular arteries from women with preeclampsia, there was reduced Ca2+ spark frequency (P=1.1×10-10) and spontaneous transient outward current frequency (P=0.023). There was also reduced sarcoplasmic reticulum Ca2+ release in response to caffeine (P=0.0013), reduced sarcoplasmic reticulum refilling (P=2.0×10-4), and decreased ratio of SERCA2 to inhibitory unphosphorylated PLN (P=0.030), implicating increased SERCA2 inhibition. HBD2 (0.01-10 nmol/L) caused BKCa-dependent relaxation (P=4.6×10-10) of omental arteries without affecting Ca2+ spark frequency. In microvascular arteries from women with preeclampsia, there is a striking reduction in Ca2+ spark frequency and spontaneous transient outward currents, likely secondary to increased inhibition of SERCA2 by unphosphorylated PLN and reduced sarcoplasmic reticulum Ca2+ load. These defects may provide novel therapeutic targets to restore physiological control of the vasculature. BKCa-mediated relaxation by HBD2 was independent of Ca2+ sparks, supporting vasodilatory strategies bypassing disrupted microvascular mechanisms in preeclampsia.
中文摘要:母体微血管功能障碍是妊娠期高血压疾病子痫前期的标志性改变,其机制尚未完全明确。血管平滑肌细胞中,压力诱导的主要舒血管通路依赖肌浆网雷诺丁受体产生的局部Ca²⁺释放事件(钙火花),钙火花激活大电导Ca²⁺激活钾通道(BKCa),引起自发性瞬时外向电流和血管舒张。在子痫前期中首次评估钙火花–BKCa轴。取正常血压孕妇和子痫前期孕妇的网膜抵抗动脉,加压后以高速转盘激光共聚焦显微镜成像,评估钙火花(20–110 mmHg)和咖啡因诱发的Ca²⁺释放(10 mmol/L;80 mmHg)。采用电生理方法在分离的血管平滑肌细胞中评估自发性瞬时外向电流(−60至0 mV)和BKCa电流(−100至+100 mV)。用液相色谱-选择反应监测-串联质谱法测定SERCA2以及调节蛋白PLN(受磷蛋白)的去磷酸化/磷酸化蛋白形式。用线肌张力描记法评估BKCa依赖性舒血管物质HBD2(人β防御素-2;0.01–10 nmol/L)的血管活性作用。子痫前期孕妇的微血管动脉中,钙火花频率降低(P=1.1×10⁻¹⁰),自发性瞬时外向电流频率降低(P=0.023)。咖啡因引起的肌浆网Ca²⁺释放减少(P=0.0013),肌浆网再充盈减少(P=2.0×10⁻⁴),SERCA2与抑制性去磷酸化PLN的比值下降(P=0.030),提示SERCA2抑制增强。HBD2(0.01–10 nmol/L)引起网膜动脉BKCa依赖性舒张(P=4.6×10⁻¹⁰),但不影响钙火花频率。子痫前期孕妇的微血管动脉中,钙火花频率和自发性瞬时外向电流显著减少,可能继发于去磷酸化PLN对SERCA2抑制增强和肌浆网Ca²⁺负荷降低。这些缺陷可能提供新的治疗靶点,以恢复血管的生理性调控。HBD2经BKCa介导的舒张不依赖钙火花,支持在子痫前期中采用绕过受损微血管机制的舒血管策略。

24高胆固醇血症 (1篇)

基础研究 (1篇)

Circulation IF 41.3 2026-10-27 PMID: 42677454
Inherited variants in the LDL (low-density lipoprotein) receptor (LDLR) gene are the most common cause of familial hypercholesterolemia, significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt lipid-lowering therapy and cascade testing of at-risk relatives; however, most LDLR variants observed in the population have uncertain or absent clinical classifications, leaving many patients without actionable information. We developed the first activity-normalized prime editing screening pipeline to measure the impact of 5184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Each prime editing guide RNA is paired with a genotypic outcome reporter to correct for variable editing efficiency, overcoming a key limitation of previous pooled genome editing screens. A statistical framework further improves variant effect estimates by jointly analyzing all missense variants at each amino acid position. We show that prime editing of the reporter construct correlates with endogenous variant installation frequency, validating the activity normalization approach. The resulting scores capture a continuous spectrum of functional effects, robustly separate pathogenic versus benign ClinVar variants, and show concordance with LDL-C levels in UK Biobank participants. We calibrate functional evidence strengths to the American College of Medical Genetics and Genomics/AMP variant interpretation framework, enabling integration into a clinical variant classification workflow. By combining functional, computational, population, and contextual evidence, 322 of 434 LDLR variants currently classified as variants of uncertain significance, conflicting, or absent from ClinVar appear to meet evidence thresholds for reclassification and can be prioritized for expert review, substantially expanding the pool of actionable variant classifications. The screen also reveals a cluster of gain-of-function variants in LDLR class A repeat 5, at least some of which enhance LDL-C uptake through increased apolipoprotein B interaction, with implications for therapeutic genome editing. Last, prime editing uniquely detects splice-altering coding variants missed by cDNA-based screens and pathogenicity predictors, revealing an advantage of endogenous variant installation. Altogether, activity-normalized prime editing provides a scalable framework for LDLR variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.
中文摘要:LDL(低密度脂蛋白)受体(LDLR)基因的遗传变异是家族性高胆固醇血症最常见的原因,会显著增加冠状动脉疾病风险。及早识别致病性LDLR变异可促成及时降脂治疗并对高危亲属进行级联检测;但人群中观察到的大多数LDLR变异缺乏临床分类或分类不确定,使许多患者得不到可操作信息。我们建立了首个活性归一化的先导编辑筛选流程,用于测量5184个LDLR编码变异对LDL-胆固醇(LDL-C)摄取的影响。每个先导编辑向导RNA与一个基因型结果报告基因配对,以校正编辑效率差异,克服了既往混合基因组编辑筛选的一个关键局限。一个统计框架通过联合分析每个氨基酸位点的所有错义变异,进一步改善变异效应估计。我们显示报告构建体的先导编辑与内源变异安装频率相关,验证了活性归一化方法。所得评分覆盖连续的功能效应谱,能稳健区分ClinVar中的致病性变异与良性变异,并与UK Biobank参与者的LDL-C水平一致。我们将功能证据强度校准到美国医学遗传学与基因组学学会/AMP变异解读框架,使其能够整合进临床变异分类流程。结合功能、计算、人群和背景证据,目前被归类为意义未明变异、分类冲突或未收录于ClinVar的434个LDLR变异中,有322个似乎达到重新分类的证据阈值,可优先进行专家审核,从而大幅扩展可操作的变异分类集合。该筛选还揭示了LDLR A类重复5中的一组功能获得性变异,其中至少部分通过增强与载脂蛋白B的相互作用而提高LDL-C摄取,这对治疗性基因组编辑具有意义。先导编辑还能独特地检测基于cDNA的筛选和致病性预测工具遗漏的改变剪接的编码变异,显示出内源变异安装的优势。活性归一化的先导编辑由此为LDLR变异分类提供了可扩展框架,能大幅提高具有遗传诊断证据的变异比例,并揭示具有治疗相关性的新生物学。

25心血管病 (1篇)

临床研究 (1篇)

Cardiovascular diabetology IF 15.6 2026-10-26 PMID: 42947108
Natriuretic peptides (NPs) and copeptin are established cardiovascular biomarkers which can partly affect human metabolism. However, impact of human metabolism on their postprandial regulation in high-risk patients remains insufficiently understood. We aimed to characterize meal-induced changes in MR-proANP, NT-proBNP, and copeptin and to assess how these dynamics relate to acute cardiovascular (CV) events, type 2 diabetes (T2D) and insulin resistance (IR). Within the BeLOVE cohort, a subset of 373 participants with acute coronary syndrome, stroke or very high chronic CV risk underwent standardized study-specific mixed-meal testing approximately 3 months after the acute event or 1 month after enrollment for the chronic high-risk group. Fasting and 120-min postprandial concentrations of MR-proANP, NT-proBNP, copeptin, insulin and glucose were assessed. Structural equation models were used to evaluate direct and indirect associations of acute CV events, T2D, and IR (HOMA-IR) with fasting levels and postprandial changes, adjusted for age, sex and BMI. MR-proANP showed the most pronounced meal-induced suppression. NT-proBNP demonstrated only minor and inconsistent postprandial changes. For all peptides, fasting concentrations were the main determinant of their postprandial changes. A recent acute CV event was associated with higher fasting NP levels (MR-proANP: standardized β = 0.22 [0.09; 0.34]; NT-proBNP: β = 0.28 [0.15; 0.41]), but not substantially with their postprandial changes after accounting for their baseline levels. T2D showed no consistent association with fasting or postprandial NP responses. In contrast, higher HOMA-IR was associated with lower fasting MR-proANP (β=-0.19 [-0.30; -0.07]) and a stronger postprandial decline (β=-0.18 [-0.33; -0.04]). Similarly, higher HOMA-IR was linked to lower fasting NT-proBNP (β=-0.15 [-0.28; -0.03]) but showed no clear association to its postprandial change. Copeptin dynamics were largely independent of acute CV disease and metabolic status. In patients after a recent ACS or stroke, postprandial MR-proANP dynamics are linked to insulin resistance, rather than diabetes status. In contrast, the limited postprandial variability of NT-proBNP and the largely fasting-related changes of copeptin make these markers less suited for capturing short-term metabolic responses. Together, these findings highlight the value of postprandial phenotyping for understanding cardiometabolic regulation and support further evaluation of MR-proANP as a potential biomarker in future prospective studies with cardiovascular outcomes across subjects with and without acute CV event. The study protocol was approved by the institutional ethics committee (EA1/066/17) and registered in the German Clinical Trials Register (DRKS00016852).
中文摘要:钠尿肽(NPs)和和肽素是已确立的心血管生物标志物,可部分影响人体代谢。但高危患者中人体代谢对其餐后调节的影响仍认识不足。研究旨在描述MR-proANP、NT-proBNP和和肽素餐后变化特征,并评估这些动态变化与急性心血管事件、2型糖尿病(T2D)及胰岛素抵抗(IR)的关系。在BeLOVE队列中,373名参与者的亚组(包括急性冠脉综合征、卒中或慢性心血管极高危者)在急性事件后约3个月或慢性高危组入组后1个月接受标准化的研究专用混合餐试验。检测空腹及餐后120分钟MR-proANP、NT-proBNP、和肽素、胰岛素和葡萄糖浓度。采用结构方程模型评估急性心血管事件、T2D和IR(HOMA-IR)与空腹水平及餐后变化之间的直接和间接关联,并校正年龄、性别和BMI。MR-proANP显示最明显的餐后抑制。NT-proBNP仅显示轻微且不一致的餐后变化。对所有肽类,空腹浓度是其餐后变化的主要决定因素。近期急性心血管事件与较高的空腹NP水平相关(MR-proANP:标准化β=0.22 [0.09; 0.34];NT-proBNP:β=0.28 [0.15; 0.41]),但在考虑基线水平后与其餐后变化无实质性关联。T2D与空腹或餐后NP反应无一致关联。相反,较高的HOMA-IR与较低的空腹MR-proANP相关(β=-0.19 [-0.30; -0.07]),并与更明显的餐后下降相关(β=-0.18 [-0.33; -0.04])。同样,较高的HOMA-IR与较低的空腹NT-proBNP相关(β=-0.15 [-0.28; -0.03]),但与其餐后变化无明确关联。和肽素动态在很大程度上独立于急性心血管疾病和代谢状态。近期ACS或卒中患者中,餐后MR-proANP动态与胰岛素抵抗相关,而非糖尿病状态。相比之下,NT-proBNP餐后变异性有限,和肽素变化主要与空腹状态相关,使这些标志物较不适合捕捉短期代谢反应。这些发现凸显餐后表型分析对理解心血管代谢调节的价值,并支持在未来前瞻性研究中进一步评估MR-proANP作为潜在生物标志物,研究应纳入有和无急性心血管事件的受试者并观察心血管结局。研究方案获机构伦理委员会批准(EA1/066/17),并在德国临床试验注册中心注册(DRKS00016852)。

26颈动脉斑块 (1篇)

临床研究 (1篇)

Cardiovascular research IF 12.5 2026-10-26 PMID: 42929042
Carotid atherosclerotic plaque instability is a major cause of ischemic stroke. While current clinical guidelines for carotid endarterectomy rely primarily on stenosis severity and patient symptomatology, unstable plaques can cause strokes even with low to moderate stenosis, suggesting that factors beyond plaque stenosis may drive its instability. This study aimed to characterize the cellular and spatial features of plaque instability at both single-cell and subcellular resolution. single-cell RNA sequencing (scRNA-seq) was performed on carotid endarterectomy samples from patients with clinically and histologically classified stable or unstable plaques, consisting of more than 53,000 cells. Vascular smooth muscle cells (VSMCs), macrophages, and T-lymphocytes accounted for ∼85% of plaque-resident cells, with unstable plaques showing increased abundance of inflammatory synthetic VSMCs, GZMK+ cytotoxic T-lymphocytes, and antigen-presenting macrophages. In contrast, stable plaques were enriched in contractile and fibroblast-like VSMCs, alongside MRC1+ resident-like macrophages. To then spatially map these populations, CosMx™ high-plex spatial transcriptomics was integrated utilizing the unprecedented whole-transcriptome (∼18,934 targets) Human Discovery RNA panel. This revealed a distinct spatially disorganized plaque architecture in unstable plaques, characterized by infiltration of inflammatory synthetic VSMCs and effector T-lymphocytes distributed across both the fibrotic cap and lipid core, alongside distinct multicellular microenvironments enriched for adaptive immune engagement. This was in contrast to stable plaques, which exhibited more structured, macrophage-dominant spatial microenvironments and neighborhoods. We lastly profiled ∼90,000 paired peripheral blood mononuclear cells (PBMCs) to assess the plaque macroenvironment. PBMCs surrounding unstable plaques displayed exclusive enrichment of CD14+CD16+ intermediate monocytes and effector T-lymphocytes, which were depleted surrounding stable plaques. Ligand-receptor interaction analyses within CCL and CXCL-mediated pathways revealed enhanced immune-stromal signaling between PBMC-derived monocytes and plaque-resident VSMCs in the unstable plaque group, with coordinated chemokine-driven interactions indicating a shift toward VSMC- and T-lymphocyte mediated recruitment of circulating immune cells. These results demonstrate that carotid plaque instability is driven by spatially coordinated expansion of inflammatory VSMCs and effector immune cells within the plaque and from the circulation, with a shift from predominantly innate immune-dominant characteristics in stable plaques toward adaptive immune-enriched responses in unstable conditions. This integrated single-cell and spatial transcriptomic approach refines an integrated immune-stromal framework linking local plaque remodeling with systemic immune activation, highlighting key tissue-resident and circulating contributors to instability and establishing a foundation for mechanism-informed diagnostics and targeted therapeutic strategies beyond stenosis severity.
中文摘要:颈动脉粥样硬化斑块不稳定性是缺血性卒中的重要原因。当前颈动脉内膜切除术的临床指南主要依据狭窄程度和患者症状,但不稳定斑块在轻中度狭窄时也可导致卒中,提示狭窄程度以外的因素可能驱动斑块不稳定。本研究旨在单细胞和亚细胞分辨率上刻画斑块不稳定性的细胞与空间特征。对临床和组织学分类为稳定或不稳定斑块的颈动脉内膜切除术样本进行单细胞RNA测序,共包含超过53,000个细胞。血管平滑肌细胞、巨噬细胞和T淋巴细胞约占斑块驻留细胞的85%,不稳定斑块中炎症性合成型血管平滑肌细胞、GZMK+细胞毒性T淋巴细胞和抗原呈递巨噬细胞增多。稳定斑块则富集收缩型和成纤维细胞样血管平滑肌细胞,以及MRC1+驻留样巨噬细胞。为空间定位这些细胞群,整合CosMx™高多重空间转录组技术,采用覆盖约18,934个靶标的全转录组Human Discovery RNA检测面板。结果显示不稳定斑块具有明显的空间结构紊乱,表现为炎症性合成型血管平滑肌细胞和效应T淋巴细胞浸润并分布于纤维帽和脂质核心,同时存在富集适应性免疫参与的多细胞微环境。稳定斑块则呈现更有结构的、以巨噬细胞为主的空间微环境和邻域。我们还检测了约90,000个配对外周血单个核细胞,以评估斑块宏观环境。不稳定斑块周围外周血单个核细胞中CD14+CD16+中间型单核细胞和效应T淋巴细胞特异性富集,而这些细胞在稳定斑块周围减少。CCL和CXCL介导通路中的配体-受体互作分析显示,不稳定斑块组外周血单个核细胞来源单核细胞与斑块驻留血管平滑肌细胞之间的免疫-基质信号增强,趋化因子驱动的协同互作提示招募循环免疫细胞的方式向血管平滑肌细胞和T淋巴细胞介导偏移。这些结果说明颈动脉斑块不稳定性由斑块内及循环来源的炎症性血管平滑肌细胞和效应免疫细胞的空间协同扩增驱动,稳定斑块以固有免疫为主的特征在不稳定状态下转向适应性免疫富集的反应。整合单细胞与空间转录组的方法完善了一个连接局部斑块重塑与全身免疫激活的免疫-基质框架,突出组织驻留和循环来源的关键促不稳定因素,并为超越狭窄程度的机制导向诊断和靶向治疗策略奠定基础。

27心律失常(非房颤) (1篇)

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-10-26 PMID: 42929040
Dysregulation of NOR-1 has been reported in cardiovascular diseases associated with altered calcium handling. We therefore investigated how NOR-1 affects calcium homeostasis and arrhythmogenesis to identify the underlying mechanisms. We assessed the expression of NOR-1 and calcium regulatory proteins in myocardial samples from humans and mice that overexpress human NOR-1 in the heart (TgNOR-1). Gene promoter activity was determined by transient co-transfection assays. Calcium imaging, patch-clamp recordings and immunofluorescent labeling was performed in mouse cardiomyocytes. Experimental data were used for mathematical modeling. Arrhythmias were induced in vivo by an epinephrine/caffeine challenge. In human cardiac samples, mRNA levels of genes coding for SERCA2a, CASQ2, TN-C1 and PLB correlated with those of NOR-1, while TgNOR-1 mice exhibited higher cardiac levels of these calcium regulatory proteins than wild-type animals (WT). NOR-1 increased luciferase activity driven by the proximal promoter of both human and mouse genes. Calcium transients were smaller in TgNOR-1 cardiomyocytes while L-type calcium current and SR calcium content were unchanged. Mathematical modeling revealed that more calcium binds to CASQ2 and is released from the SR in TgNOR-1 cardiomyocytes, but the resulting calcium transient is smaller because more calcium is buffered by TN-C1. Furthermore, NOR-1 transgenesis increased the level of reactive oxygen species and CAMKII oxidation, as well as RyR2 phosphorylation at Ser-2814, which led to a higher incidence of calcium waves and afterdepolarizations in resting TgNOR-1 cardiomyocytes. In electrically paced myocytes, NOR-1 transgenesis promoted extra-transients at low frequencies and calcium alternans at high frequencies. Importantly, these derangements in intracellular calcium handling concurred with a dramatic increase in epinephrine/caffeine-induced bidirectional ventricular tachycardia in TgNOR-1 mice. Moreover, the antioxidant N-acetylcysteine and the CAMKII inhibitor KN-93 attenuated arrythmia in TgNOR-1 mice and arrhythmogenic calcium release in isolated myocytes. Our findings highlight NOR-1 as an upstream regulator of CAMKII-oxidation underlying arrhythmia induced by defective calcium homeostasis, pointing to therapies targeting CAMKII as a means to attenuate arrhythmia triggered by pathological upregulation of NOR-1.
中文摘要:NOR-1失调已在钙处理异常相关心血管疾病中有报道。为明确潜在机制,研究NOR-1如何影响钙稳态与心律失常发生。检测人及心脏过表达人NOR-1小鼠(TgNOR-1)心肌样本中NOR-1和钙调节蛋白的表达。通过瞬时共转染实验测定基因启动子活性。在小鼠心肌细胞中进行钙成像、膜片钳记录和免疫荧光标记。实验数据用于数学建模。通过肾上腺素/咖啡因激发在体内诱发心律失常。人心脏样本中,编码SERCA2a、CASQ2、TN-C1和PLB的基因mRNA水平与NOR-1相应水平相关;TgNOR-1小鼠心脏中这些钙调节蛋白水平高于野生型(WT)。NOR-1提高人和小鼠基因近端启动子驱动的荧光素酶活性。TgNOR-1心肌细胞钙瞬变幅度较小,而L型钙电流和肌浆网钙含量未变。数学建模显示TgNOR-1心肌细胞中更多钙与CASQ2结合并从肌浆网释放,但由于更多钙被TN-C1缓冲,最终钙瞬变较小。NOR-1转基因还增加活性氧水平、CAMKII氧化以及RyR2 Ser-2814位点磷酸化,导致静息TgNOR-1心肌细胞中钙波和后除极发生率升高。在电刺激起搏心肌细胞中,NOR-1转基因促进低频下的额外钙瞬变和高频下的钙交替。这些细胞内钙处理异常与TgNOR-1小鼠中肾上腺素/咖啡因诱发的双向室性心动过速显著增加同时出现。抗氧化剂N-乙酰半胱氨酸和CAMKII抑制剂KN-93减轻TgNOR-1小鼠心律失常及分离心肌细胞中的致心律失常性钙释放。研究结果提示NOR-1是CAMKII氧化的上游调控因子,参与钙稳态缺陷所致心律失常,提示靶向CAMKII可减轻NOR-1病理性上调触发的心律失常。